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“I think I can affirm that in scientific research 
neither intelligence grade nor the capacity to do 
and to bring to the  end  the assignment undertaken 
 are essential factors for success and personal satisfaction. 
In both cases total dedication and to close your eyes  
in front of difficulties mostly count: in this way we can face 
problems that others, more incisive and sharp, 
 would not face.” 
 
 
 
 
 
 
 
“Credo di poter affermare che nella ricerca scientifica 
 né il grado di intelligenza né la capacità di eseguire 
 e portare a termine il compito intrapreso siano fattori essenziali 
 per la riuscita e per la soddisfazione personale. 
 Nell'uno e nell'altro contano maggiormente la totale dedizione 
 e il chiudere gli occhi davanti alle difficoltà: 
 in tal modo possiamo affrontare i problemi che altri, 
 più critici e più acuti, non affronterebbero.” 
 
 
Rita Levi Montalcini 
 
Index 
3 
 
INDEX 
ABSTRACT (English) ............................................................................... 5 
ABSTRACT (Italian)……………………………………………………..7 
INTRODUCTION ………………………………………………………..9 
CHAPTER 1 
STEROLS from THEONELLA SWINHOEI ......................................... 23 
CHAPTER 2 
PXR AGONISTS ...................................................................................... 28 
  2.1 Total synthesis of solomonsterol A ................................................ 32 
      2.1.1 Pharmacological evaluation  ....................................................... 34 
      2.2 Modifications in the side chain of SA ............................................ 40 
      2.2.1 Discovery of cholestan disulfate ................................................. 43 
      2.2.2 Docking studies ........................................................................... 48 
      2.3 Total synthesis of solomonsterol B ................................................ 52 
      2.3.1 Pharmacological evaluation ........................................................ 55 
CHAPTER 3 
DUAL PXR/FXR LIGANDS ................................................................... 58 
3.1 Structural determination of compounds 40-46 ............................. 59 
   3.2 Structural determination of compounds 47-49 .............................. 64 
   3.2.1 Pharmacological evaluation. ...................................................... .68 
   3.2.2 Docking studies .......................................................................... 70 
   3.3 Analysis of the third specimen of Theonella swhinoei .................. 74 
   3.3.1 Structural determination of compounds 50-55 ........................... 75 
   3.3.2 Pharmacological evaluation ........................................................ 81 
Index 
4 
 
3.3.3 Docking studies ............................................................................. 86 
CHAPTER 4 
FXR MODULATORS ............................................................................. 90 
 4.1 Isolation and structural determination of conicasterol E ................ 92 
    4.2 New synthetic strategy of 6-ECDCA  ............................................. 94 
    4.2.1 Pharmacological evaluation .......................................................... 96 
    4.2.2 Docking studies ............................................................................ 98 
    4.3 Theonellasterol, a new lead in cholestasis ..................................... 100 
    4.4 Preliminary studies of SAR on theonellasterol ............................. 106 
    4.4.1 Pharmacological evaluation in vitro ........................................... 110 
    4.4.2 Docking studies .......................................................................... 112 
CHAPTER 5 
STEREOCHEMICAL STUDIES of PERTHAMIDE C .................... 116 
 5.1 Application of quantitative QM-J method .................................... 117 
 5.2 Stereoselective synthesis of AHMHA .......................................... 118 
CONCLUSIONS .................................................................................... 124 
EXPERIMENTAL SECTION 
 I.   General experimental procedures  ....................................................... 127 
 II.  Experimental section of PXR agonists .......................................... 129 
     III. Experimental section of dual PXR/FXR ligands ........................... 177 
 IV. Experimental section of FXR modulators.…………………….... 208 
 V.  Experimental section of stereochemical studies of perthamide C..230 
REFERENCES ...................................................................................... 247 
ACKNOWLEDGEMENTS .................................................................. 258 
Abstract 
5 
 
ABSTRACT 
 
Natural products have historically been a rich source of  lead compounds in drug 
discovery. The biochemical investigation of marine organisms, through the deep 
collaboration between chemists and pharmacologists, focused on searching of new 
biologically active compounds, is a central issue of this kind of studies.  
My research work, described in this PhD thesis, has been developed in this 
research area and was addressed to the identification of new ligands of nuclear 
receptors, discovering potent and selective modulators of farnesoid-X-receptor 
(FXR) and pregnane-X-receptor (PXR), regulators of various processes including 
reproduction, development, and metabolism of xeno- and endobiotics. 
First, analysis of the polar extract of the sponge Theonella swinhoei afforded two 
new sulfated sterols, solomonsterols (SA and SB), the first example of  marine 
PXR agonists. Both have been synthesized and characterized in animal models of 
inflammation. Administration of synthetic solomonsterol A effectively protects 
against development of clinical signs and symptoms of colitis; therefore SA holds 
promise in the treatment of inflammatory bowel deseases (IBDs).  
To overcome a limitation of SA in clinical settings, a small library of SA 
derivatives has been designed and prepared. Indeed, SA could be absorbed from 
the GIT causing severe systemic side effects resulting from the activation of PXR 
in the liver. This study disclosed cholestan disulfate (Coldisolf) as a new, 
simplified agonist of PXR, currently in pharmacological evaluation on animal 
models of liver fibrosis induced by HIV infection. 
Simultaneously, a wide family of 4-methylene steroids were isolated from the 
apolar extracts of  Theonella swinhoei. These marine steroids are endowed with a 
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potent agonistic activity on PXR while antagonize the effects of natural ligands 
for FXR. 
Among this rich family, we have identified theonellasterol as the first example of 
a sponge derived highly selective FXR antagonist demonstrating its 
pharmacological potential in the treatment of cholestasis. Using this compound as 
a novel FXR antagonist hit, we have prepared a series of semi-synthetic 
derivatives in order to gain insights into the structural requirements for exhibiting 
antagonistic activity. These molecules could be used for the pharmacological 
treatment of cholestasis but also in chemotherapy of carcinoma characterized by 
over-expression of FXR.  
In summary, Nature continues to be one of the best sources not only of potential 
chemotherapeutic agents but also of lead compounds that could represent an 
inspiration for the discovery of new therapeutic strategies.  
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ABSTRACT (Italian) 
Le sostanze naturali sono da sempre un’ispirazione per la scoperta di nuove 
strategie terapeutiche. Lo studio chimico di organismi marini in combinazione con 
la valutazione della loro attività biologica costituisce il fulcro della Chimica delle 
Sostanze Naturali. In tale ambito, l’attività di ricerca condotta durante il corso di 
Dottorato, i cui risultati sono riportati nella seguente tesi, è stata focalizzata 
principalmente sull’identificazione di ligandi di recettori nucleari metabolici, 
individuando potenti e selettivi modulatori del recettore dei farnesoidi (FXR) e del 
recettore dei pregnani (PXR), regolatori di processi di detossificazione di 
metaboliti endogeni (acidi biliari) e/o esogeni. 
 In particolare, dall’estratto polare della spugna Theonella swinhoei sono stati 
isolati due nuovi steroli solfatati, i solomonsteroli (SA e SB), il primo esempio di 
agonisti di PXR a struttura steroidica dal mare. Per entrambe le molecole si è 
proceduto alla sintesi totale in larga scala e al conseguente approfondimento 
farmacologico in modelli animali di infiammazione. Il SA si è rivelato efficace 
nel prevenire i sintomi associati alla colite nonché nel migliorare i segni clinici e 
si propone quindi come nuovo lead per il trattamento delle IBDs (Inflammatory 
Bowel Diseases).  
Dalla scoperta dei solomonsteroli, si è poi passati alla progettazione e sintesi di 
derivati ad azione colon-specifica cercando di superare i limiti del lead naturale 
ampiamente assorbito a livello intestinale e quindi potenzialmente tossico per 
effetto su PXR epatico. Questo lavoro ha portato all’identificazione di una nuova 
molecola il colestan disolfato (Coldisolf), di facile sintesi e al momento in fase di 
sperimentazione farmacologica sulla fibrosi epatica indotta da infezione da HIV.  
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Parallelamente dagli estratti apolari della spugna Theonella swinhoei è stata, 
invece, isolata un’ampia famiglia di 4-metilensteroli con un range di attività che 
spazia dall’agonismo su PXR all’antagonismo su FXR passando per la 
modulazione duale. Tra queste molecole, il theonellasterolo, rappresenta il primo 
esempio di antagonista selettivo di FXR di origine naturale e quindi promettente 
lead per il trattamento farmacologico della colestasi. 
 Usando questa molecola come nuovo hit, si è proceduto alla progettazione e 
sintesi di una nutrita serie di derivati, che sottoposti ad una robusta 
sperimentazione farmacologica in vitro, hanno contribuito a delineare la prima 
SAR su questo nuovo chemotipo di antagonista e soprattutto a tracciare le linee 
guida per l’ottenimento di molecole a potenziale uso per il trattamento della 
colestasi e la chemioterapia di carcinomi caratterizzati da over-espressione di 
FXR.  
In conclusione, la Natura è, e continua ad essere, la maggiore fonte di ispirazione 
di nuovi lead da utilizzare per la progettazione di nuovi farmaci.  
Dunque, la chimica delle sostanze naturali offre ancora entusiasmanti prospettive. 
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INTRODUCTION 
Today about 40% of modern pharmaceuticals are derived from biological sources.
1,2 This simply observation can give an idea of the incredible biomedical potential 
represented by the chemical analysis of the biodiversity of natural organisms.3,4 
Secondary metabolites contained in these organisms are the result of millions of 
years of evolution and natural selection: even a single species constitutes a library 
of metabolites that is validated for the bioactivity. As the results of enzymatic 
reactions, natural products have an intrinsic capacity to recognize and bind 
macromolecules, perturb their activity, and modulate biological processes. 
Besides their potential use as pharmaceutical drugs, natural products have and will 
continue to play critical roles as biological probes, to wield temporal control over 
biochemical pathways, and ultimately, to identify novel therapeutic targets.5 
Surely among Nature, plants represent a rich source of novel compounds to be 
used as lead to design new drugs and, notably, several drugs, from aspirin to 
morphine, currently in use for human diseases, have this origin. Particularly rich 
is also the marine environment. Ocean cover seventy percent of the surface of the 
planet and represents a wealthy source of plants, animals and micro-organisms 
which, due to their adaptation to this unique habitat, produces a wide variety of 
secondary metabolites unlike those found in terrestrial species.6 Today, with the 
modern tools of molecular biology and advanced technology, the potential of 
marine environment, with its vast reservoir of original molecules, represents a 
great promise to provide new drugs. Beside in the past century the high-
throughput screening of natural sources has long been recognized as an invaluable 
source of new lead structures, today targeted oriented discovery, focused on the 
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identification of natural products as ligands of specific proteins or enzymes, is 
considered the best rationale approach for the identification of novel therapeutic 
agents from Nature. Indeed natural products are being biosynthesized by their 
hosts to interact with proteins, such as enzymes or receptors, and many human 
protein targets contain structural domains similar to the targets with which small 
ligands (or natural products) have coevolved.  
Nuclear receptors (NRs) represent one of the most important drug targets in terms 
of potential therapeutic application,7 playing a role in every aspect of 
development, physiology and disease in humans. They are ubiquitous in the 
animal kingdom suggesting that they may have played an important role in their 
evolution. NRs have a rich and long-standing history in drug discovery for two 
fundamental reasons. First of all, they have been designed by nature to selectively 
bind small lipofilic molecules, and then they are able to regulate a diverse set of 
biologically important functions. NRs share considerable amino acid sequence 
similarity in two highly conserved domains, the N-terminal DNA-binding domain 
(DBD) and the C-terminal ligand-binding domain (LBD), responsible for binding 
specific DNA sequences and small lipophilic ligands, respectively (Figure 1). 
Upon ligand binding, NR induces conformational changes that lead to the release 
of the co-repressors and recruitment of a co-activators, thus providing a chromatin 
remodeling and subsequent activation of transcriptional machinery.  
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Figure 1. General structure of nuclear receptor 
There are 48 genes in the human genome coding for the NRs superfamily. Most of 
them has been discovered in the last twenty years and several still require a de-
orphanization and a complete and detailed clarification of their physiological role. 
Nevertheless in the last two decades an huge experimentation has been focus on 
the discovery of selective NRs modulators. There are three subfamilies of nuclear 
receptors: NR1, NR2, and NR3. NR3 subfamily, also known as classical 
homodimer steroidal receptors, includes estrogen receptors α and β (ERα and 
ERβ), glucocorticoid receptor (GR), progesterone receptor (PR), androgen 
receptor (AR), and mineralocorticoid receptor (MR). Nuclear receptors of class 1 
and 2, unlike steroidal receptors, function as heterodimers with the retinoid X 
receptor (RXR) (Figure 2). Importantly, these receptors, including the peroxisome 
proliferator-activated receptor (PPAR), liver X receptor (LXR), farnesoid X 
receptor (FXR), vitamin D3 receptor (VDR), retinoic acid receptor (RAR) and 
thyroid hormone receptor (TR), serve as endogenous sensors for fatty acids, 
oxysterols, thyroid hormones and bile acids. These classes also include pregnane 
X receptor (PXR) and constitutive androstane receptor (CAR) for which no 
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physiological ligands have been so far identified. PXR and CAR are defined the 
xenobiotic NRs, master regulators of Phase I and Phase II enzymes and drug 
transporters.8 
 
  
 
 
 
 
 
 
Figure 2. Formation of an heterodimer with  the retinoid X receptor (RXR) 
PXR  is a master gene orchestrating the expression of a wide family of genes 
involved in uptake, metabolism and disposal of a number of endo- and xeno-
biotics, including drugs, bile acids, steroid hormones, environmental toxicants and 
metabolic intermediates in mammalian cells.9 It is almost exclusively expressed in 
the gastrointestinal tract and liver, with lower levels in the kidney and ovary. 
Following ligand binding, PXR forms an heterodimer with RXR that binds to 
specific PXR response elements (PXREs), located in the 5′-flanking region of 
PXR target genes, resulting in their transcriptional activation. Among these, P450 
enzymes (CYP3A, CYP2C, and CYP2B) that promote oxidative (phase I) drug 
metabolism,10,11 phase II-conjugating enzymes that improve solubility of phase I 
metabolites (glutathione S-transferases, sulfotransferases, and UDP-
glucoronosyltransferases)12,13 and xenobiotic transporters (MDR1, MRP2, MRP3, 
and OATP2) mediating excretion of the  above compounds ( Figure 3). In addition 
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to its involvement in detoxification and metabolism of xenobiotics, recent studies 
have indicated that this receptor plays a regulatory role in various physiological 
and pathophysiological processes, such as lipid metabolism,14 glucose 
homeostasis, and inflammatory response.15 To date, several evidences suggest that 
PXR may be an useful target for pharmacological therapies in various conditions, 
including liver disease,16 and inflammatory bowel diseases (IBDs), encompassing 
Crohn’s disease (CD), ulcerative colitis (UC) and liver fibrosis (LF).17 
 
 
 
 
 
 
 
 
Figure 3.  Functions of PXR on hepatic metabolism 
Besides PXR shows the typical NRs organization, X-ray crystallography revealed 
an LBD larger than those of many other nuclear receptors, including the steroidal 
hormone receptor.18 As a consequence, hPXR binds both small and large ligands 
and the number of chemicals that are reported to activate PXR has grown rapidly 
including many drugs currently in use such as statins, the antibiotic rifampicin and 
its semisynthetic derivative rifaximin, antihypertensive drugs nifedipine and 
spironolactone, anticancer compounds, HIV protease inhibitors, calcium channel 
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modulators as well as diverse environmental toxicant, plasticizers and pesticides, 
and agonists of additional nuclear receptors.19  
Rifaximin, (Figure 4) a nonabsorbable structural analog of rifampicin used in the 
treatment of traveler’s diarrhea, IBDs, and hepatic encephalopathy, is a gut-
specific hPXR agonist. When fed to transgeneic mice expressing hPXR, rifaximin 
attenuates inflammation induced by dextran sulfate sodium (DSS) and 
trinitrobenzene sulfonic acid (TNBS), two classical models of IBDs. For a 
molecular point of view, amelioration of IBDs symptoms in hPXR mice by 
rifaximin has been linked to NF-kB and the negative cross-talk PXR-NFkB has 
recently demonstrated.20  
 
 
 
 
 
Figure 4.  Rifaximin 
Pregnenolone-16α-carbonitrile (PCN) (Figure 5) is a potent and specific agonist 
for murine PXR, with no activity for human PXR. It significantly decreased 
CYP7A1 expression, with competition between PXR and PGC-1α for binding to 
HNF4α, thereby blocking PGC-1α-stimulated activation of CYP7A1 by HNF4α.21 
 
 
 
Figure 5. Pregnenolone-16α-carbonitrile (PCN) 
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As concern natural products, hyperforin (Figure 6), the psychoactive constituent 
of the widely used antidepressant herbal H. perforatum, commonly known as St. 
John’s wort, was the first potent agonist of PXR reported from plants.22,23 To date 
hyperforin is one of the most potent activators of human PXR with nanomolar 
EC50 (0.023 µM). Hyperforin competes with 3HSR12813 for binding to human 
PXR and stimulates the interaction between human PXR and the co-activator 
SRC-1. After the discovery of hyperforin, herbal medicines (e.g., Ayurvedic 
medicine and traditional Chinese medicine) have attracted the interest of scientific 
community in order to identify the chemical constituents responsible for 
biological effects of their extracts and various chemicals have been characterized 
as ligands for PXR.24 
 
 
 
 
 
Figure 6.  Hyperforin 
Ginkgolide A (Figure 7) isolated from G. biloba has been identified as a PXR 
activator, increasing the expression of target genes in LS180 human colon 
adenocarcinoma cell (CYP3A4, CYP3A5,and ABCB1) and cultured human 
hepatocytes. Ginkgolide A contributed to the increase in hPXR target genes 
expression (CYP3A4 mRNA and CYP3A-mediated testosterone 6β-
O
O
OH
O
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hydroxylation), moreover in a cell-based reporter gene assay ginkgolide A 
treatment results in increment of SRC-1 recruitment on PXR.25  
 
 
 
 
 
Figure 7.  Ginkgolide A 
It should be noted that all these compounds are PXR agonists whereas to date only 
few PXR antagonists have been described from vegetal sources.26 
Coumestrol (Figure 8), a coumestan phytoestrogen present in soy sprouts and 
alfalfa endowed with estrogen-like structure and actions, has been reported as an 
antagonist of the human nuclear receptor PXR without effects on mouse PXR. In 
primary human hepatocytes, coumestrol suppresses the effects of PXR agonists on 
the expression of CYP3A4 and CYP2B6 as well as inhibits metabolism of 
tribromoethanol in humanized PXR mice and antagonizes the recruitment of  
SRC-1 on PXR.  
 
 
 
Figure 8.  Coumestrol 
The first marine ligand to be described was ecteinascidin 743 (ET-743) (Figure 9), 
isolated from the tunicate Ecteinascidia turbinata. Nanomolar concentrations of 
this potent marine-derived anticancer blocked activation of human PXR by either 
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SR12813, a synthetic agonist, or paclitaxel in cell-based reporter assays.27 ET-743 
also blocked the induction of the PXR target genes CYP3A4 and MDR1 in a 
human intestinal cell lines. 
 
 
 
 
Figure 9.  Ecteinascidin 743 (ET-743) 
Among metabolic NRs, also FXR (Figure 10) has emerged as a valuable 
pharmacological target28,29 in several human deseases for its regulatory function 
on bile acids (BAs), lipid and glucose homeostasis. Activation of FXR, highly 
expressed in the liver, intestine, kidney and adrenals, leads to complex responses, 
the most relevant of which is the inhibition of bile acids synthesis through the 
indirect repression of the expression of cytochrome 7A1 (CYP7A1), the rate 
limiting enzyme of this pathway. It forms part of a complex network 
encompassing PXR and PPARs that regulates the essential steps of bile acid and 
xenobiotic uptake, metabolism and excretion by hepatocytes, cholangiocytes and 
kidney cells.30,31 The FXR gene is conserved from humans to fish32 and, in 
humans and primates, encodes four FXRα isoforms (FXRα1, FXRα2, FXRα3 and 
FXRα4).33 As for other non-steroid hormone NRs, FXRα binds to specific DNA 
response elements as an heterodimer with RXR.34 Upon ligand binding, FXR 
undergoes conformational changes to release co-repressors such as NCor (Nuclear 
Co-repressor) and to recruit co-activators, such as SRC-1 (Steroid Receptor Co-
N
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activator-1), PRMT (Protein Arginine(R) Methyl Transferase-1), CARM 
(Coactivator-Associated Arginine Methyltransferase-1), PGC (PPAR-γ 
Coactivator-1α) and DRIP (vitamin D Receptor-Interacting Protein-205).  The 
mechanisms that regulate recruitment of these co-activators by FXR ligands and 
the relevance of these molecules to the regulation of specific genes by FXR 
ligands is still unknown.  
 
 
 
 
 
 
Figure 10.  Structure of nuclear receptor FXR 
After FXR discovery, specific bile acids (BAs) were identified35,36,37 as 
endogenous ligands (Figure 11). The amphipatic properties of the bile acid 
skeleton displaying a convex hydrophobic face and a concave hydrophilic face are 
essential for their recognition in the FXR-LBD.38 In contrast to other endogenous 
steroids, BAs nucleus adopts a bent shape due to the A/B cis ring juncture that 
forces ring A to lie outside of the plane of the BCD ring system, giving to BAs a 
profile that allows a close fit with respect to the pocket in FXR. Besides the β 
hydrophobic face is common in all BAs, the differences between the primary and 
secondary BAs are in the α face and in their specific pattern of  hydroxylation  at 
the 7 and 12 positions. Chenodeoxycholic acid (CDCA), the most effective 
activator of  FXR, with its two hydroxyl groups at C-3 and C-7 oriented in a cis 
relationship transactivates FXR, whereas ursodeoxycholic acid (UDCA), with its 
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two hydroxyl groups at C-3 and C-7 oriented in a trans relationship does not 
activate this receptor. It creates a more open ligand binding pocket, and this 
arrangement may force a suboptimal orientation of helix 12 and results in partial 
inhibition. 
  
 
  
 
 
 
 
 
Figure 11.  Structures of endogenous BAs as FXR ligands 
Shortly, after FXR de-orphanization by BAs, potent FXR agonists have been 
generated to target liver and metabolic disorders. The most used is the non-
steroidal isoxazole analog GW4064,39 3-(2,6-Dichlorophenyl)-4-(3’-carboxy-2-
chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole (Figure 12), a nanomolar 
nonsteroidal activator of FXR,40 reducing the extent of  hepatic injury when 
administred to rats rendered cholestatic by bile duct ligation or chemical 
intoxication with α-naphthyl-isothiocyanate. Because the clinical utility of 
GW4064  turned  out to be limited  because its short terminal half-life and limited 
oral exposure ( < 10%), several derivatives modified in the stilbene functionality, 
recognized as toxic pharmacophore, have been designed and prepared. So 
obtained the 6-substituted 1-naphthoic acid is a full agonist essentially equipotent 
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to GW 4064. In a rodent model of chemically-induced cholestasis, both 
compounds increased Bsep and SHP and reduced Ntcp, Cyp7A1, alkaline 
phosphatase, alanine amino-transferase, total bile acids and direct bilirubin levels.  
 
  
 
 
Figure 12.  Structures of GW-4064 and 6-substituted 1-naphthoic acid 
In the FXR-LBD the semisynthetic BA, 6-ethyl-CDCA41 (Figure 13) places the 
6α-ethyl group into one and additional  hydrophobic cavity that exists between the 
side chains of Ile359, Phe363, and Tyr366, accounting for its higher affinity. It is 
bound to LBD with ring A directed toward Helix 11 and 12 of the LBD, while the 
carboxylic acid function of the side chain approaches the entry pocket at the back. 
6-ECDCA was found effective in protecting against bile flow impairment induced 
by administration of estrogen E217α, a  model of intrahepatic cholestasis with 
minimal or absent alteration of liver morphology. Similarly to GW4064, 6-
ECDCA increased the liver expression of  Bsep and SHP, while reduced Ntcp and 
Cyp7A1. In aggregate these preclinical observations support the notion that 
administration of potent FXR ligands in a cholestatic setting would induce a 
pattern of genes involved in hepatic detoxification and apical secretion of BA as 
well as inhibition of BAs uptake and BA synthesis.  However, with the except of 
the estrogen model, FXR ligands are only partially effective in reducing 
cholestasis. 
 
O N
O
ClCl
GW-derivativeGW-4064
O N
O
ClCl
Cl
HO2C HO2C
Introduction 
 
21 
 
 
  
 
 
Figure 13.  Structures of 6-ECDCA 
Optimization of a benzopyrane-based combinatorial derived libraries had led to 
the identification of fexaramine,42 3-[3-[(Cyclohexylcarbonyl)-[[4'-
(dimethylamino)-[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-2-propenoic acid 
methyl ester (Figure 14), as a new chemotype of FXR agonist, also endowed with 
nanomolar potency. In vitro assays established that fexaramine and related ligands 
robustly recruit the coactivator SRC-1 to FXR in a manner comparable to that of 
GW4064. 
 
 
   
 
Figure 14.  Structure of Fexaramine 
Despite the good results obtained with FXR agonists, a growing body of evidence 
is emerging about the negative impact of FXR activation on adaptation to 
cholestasis. FXR activation downregulates CYP7A1 inhibiting BAs synthesis 
eventually decreasing BAs pool size, the most important determinant of  BAs 
secretory rate.  In addition FXR activation reduces the expression/activity of those 
basolateral transporters such as MRP4, essential for BAs secretion in the systemic 
circulation. These observations suggest that FXR activation might impair the BAs 
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efflux, one of the key adaptative changes observed in cholestasis and therefore 
FXR antagonists might hold utility in the treatment of this desease. To date only 
few FXR antagonists are known and the main contribute is derived by natural 
compounds. Guggulsterone, isolated from the resin extract of the tree 
Commiphora mukul,43 and Xanthohumol, the principal prenylated chalcone from 
beer hops Humulus lupulus L. 44 (Figure 15) were the first FXR antagonists to be 
reported from “Nature”. However, guggulsterone is a promiscous agent wich 
binds and actives PXR, the glucocorticoid receptor and the progesterone receptor 
at concentrations that are approximately 100-fold lower than that required for 
FXR antagonism. 45,46 
 
 
 
 
 
 
Figure 15.  Structures of natural FXR antagonists. 
In this context, the sea, with its extraordinary variety of organisms, has recently 
emerged as an evaluable source of FXR antagonists. As reported in this 
dissertation, my research work afforded the identification, for the first time, of 
several compounds endowed with promising activity on human NRs 
encompassing the first example of FXR antagonists from the “sea”. 
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CHAPTER 1 
STEROLS from THEONELLA SWINHOEI 
In the last 30 years many sterols with unprecedented structures have been isolated 
from marine sources. Initially carbon skeleton modifications  ranged from C27 to 
C29, with variation occurring exclusively in the side chain at C24.47 After the 
discovery of the C26-sterols, first detected in 1970 from the mollusk Placopecten 
magellanicus48 and later found widespread in marine invertebrates and also in a 
marine phytoplankton,49 a number of  “nonconventional” sterols have been 
reported. Unconventional steroids often co-occur with the conventional ones and 
are sometimes present in small amounts; however, many exceptions are reported 
for sponges producing unusual structures as the predominant steroids rather than 
cholesterol or the conventional 3β-hydroxy sterols.50,51,52 When a sponge contains 
unusual steroids in large quantities, probably they play a functional (rather than 
metabolic) role in maintaining the integrity of membranous structures. It has been 
hypothesized and, to some extent, documented that the uniqueness of sterols in 
cell membranes of sponges is related to other components, particularly the 
phospholipids. These latter are formed by head groups and fatty acids very 
different from those of higher animals; therefore, the structural modifications 
exhibited by the sponge sterols may be a sort of structural adjustments for a better 
fit with other membrane components.53,54,55 The sterols isolated from sponges are 
sometimes very complex mixtures of highly functionalized compounds, many of 
which have no terrestrial counterpart. These include sterols having side chains 
modified by the apparent loss of carbon atoms or by the addition of extra carbon 
atoms at biogenetically unprecedented positions of a normal Cα side chain, as 
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well sterols with unusual nuclei, containing a variety of oxygenated functionalities 
such as polyhydroxy, epoxide, epidioxy, and mono or polyenone systems. A 
plethora of inusual functional groups such as quaternary alkyl groups, 
cyclopropane and cyclopropene rings, allenes, and acetylenes has been found in 
the side chains of marine sterols and in figure 16 are reported the most 
representative but it is not an exhaustive list. 56,57 
 
 
 
 
 
 
Highly functionalized steroids have attracted 
considerable attention because of their biological 
and pharmacological activities. A remarkable 
example is the potent inhibitor of histamine 
release from rat mast cells induced by anti-IgE. 
58,59
 Contignasterol that represents the first marine steroid found to have a cis C/D 
ring junction as well as a cyclic hemiacetal functionality at C-29 of the side-chain. 
 Halistanol sulfate, present in 
Halichondriidae sponges and characterized 
by the 2β,3α,6α-trisulfoxy functionalities 
and alkylation on the side chain, is the first 
Figure 16. Examples of nonconventional side chains of sponge monohydroxysterols. 
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example of sulfated sterol isolated from Porifera, with a potent anti-HIV 
activity.60 Successively, several new sulfate sterols have been reported.  
Other examples of sterols with unconventional nuclei are theonellasterone and  
bistheonellasterone, isolated from an Okinawan collection of Theonella swinhoei; 
bistheonellasterone represents a dimeric steroid biosynthesized from 
theonellasterone through a Diels-Alder cycloaddition with its ∆4-isomer. 
  
 
 
 
 
 
Indeed theonellasterone is the oxidized derivative of theonellasterol, the ideal 
biomarker of sponges of Theonella genus containing the rare 4-methylene steroids 
as exclusive components of the steroidal biogenetic class.  
Theonella genus belongs to order Lithistida, an 
evolutionary ancient lineage that is typically found in 
deeper waters and caves of tropical oceans. Lithistid 
sponges have a structurally massive, rigid or “rock-like” 
morphology and are well known among the scientific community for the 
extraordinary chemio-diversity so far exhibited. Notably over half of the 
compounds reported for litisthid sponges were isolated from Theonella (family 
Theonellidae). Theonella species have been reported to contain a wide variety of 
diverse secondary metabolites with intriguing structures and promising biological 
Theonella swinhoei 
O H
H
H
O
Bistheonellasterone
O
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activities, which have been calculated to represent more than nine biosynthetic 
classes.61 In particular, Theonella swinhoei represents one of the most prolific 
source of innovative and bioactive metabolites, which include complex 
polyketides as swinholide A and 
misakinolide A,62,63 showing  potent 
cytotoxic activity through the distruption of 
functionality of the actine cytoskeleton; 
tetramic acid glycosides as the antifungal 
aurantosides.64,65,66  
The exceptional chemical diversity found 
in the metabolites isolated from Theonella 
sponges may in part be due to the 
biosynthetic capacity of bacteria that they host.67 This hypothesis has been 
convincingly supported in the case of swinholide A, omnamides and theopederins. 
In 2005, Gerwich68 reported the direct isolation of swinholide A and related 
derivatives from two different cyanobacteria, thus unequivocally demonstrating 
that marine cyanobacteria are the real productors of  this class. Moreover, from 
the highly complex metagenome of Theonella swinhoei, the prokaryotic gene 
cluster,69 likely responsible for the biosynthesis of omnamides and theopederins 
has been recently identified.70,71 
In the course of a search for novel metabolites from marine sponges belonging to 
Lithistida order, I had the opportunity to study the sponge Theonella swinhoei. A 
specimen of sponge Theonella swinhoei was collected on the barrier reef of 
Vangunu Island, Solomon Islands, in July 2004. The samples were frozen 
immediately after collection and lyophilized to yield 207 g of dry mass. 
Swinholide A 
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Taxonomic identification was performed by Prof. John Hooper of Queensland 
Museum, Brisbane, Australia, and reference specimens are on file (R3170) at the 
ORSTOM Centre of Noumea. The lyophilized material was extracted with 
methanol and the crude methanolic extract was subjected to a modified Kupchan's 
partitioning procedure (Scheme 1).72 Purification on the apolar extracts afforded 
macrolides and many polyhydroxylated sterols which have been demonstrated 
potent ligands of human nuclear pregnane receptor (PXR) and modulator of 
farnesoid-X-receptor (FXR). On the other hands, polar extract afforded the 
isolation of two new sulfated sterols, solomonsterols A and B, the first example of 
C-24 and C-23 sulfated sterols from a marine source endowed with a PXR 
agonistic activity;73 a large family of cyclical peptides. Perthamides B-K, 
encompassing endowed with a potent anti-inflammatory and immunosuppressive 
activities74 and two minor peptides, solomonamides A and B with an interesting 
anti-inflammatory activity and an unprecedented chemical skeleton.75 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Modified Kupchan’s partitioning methodology applied to the sponge Theonella swinhoei. 
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CHAPTER 2 
PXR AGONISTS 
Sulfated steroids are a family of secondary metabolites often found in sponges and 
echinoderms. They are interesting not only from a structural point of view, but 
also because they often exhibite a variety of biological activities including anti-
viral,76,77 antifungal,78 antifouling,79 and action on specific enzymatic 
targets.80,81,82,83 In a recent work, my group of research worked on the purification 
of the most polar fractions of n-BuOH extract of the sponge  Theonella swinhoei, 
that afforded two new sulfated sterols with a 5-α-cholane and 24-nor-5-α-cholane 
skeleton, named solomonsterols A and B.73 They possess a truncated side chain at 
C24 and C23 respectively, and three sulfoxy groups,  two secondary sulfoxy 
groups, positioned on ring A at C2 and C3 of the steroidal nucleus, and one 
primary sulfoxy group on the side chain at C24 for solomonsterol A and at C23 
for solomonsterol B. The A/B trans ring juncture represented the main structural 
difference respect to BAs with A/B cis ring juncture. (This A/B cis ring juncture 
is fundamental for activation of FXR.) 
 
 
 
 
 
 
Figure 17. Solomonsterols A (1) and B (2) from Theonella swinhoei. 
Despite this difference they have been valuated as potential ligands for nuclear 
receptors. The results of these studies demonstrated that, while solomonsterols A 
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and B did not activate the farnesoid-X-receptor (FXR, data not shown), both 
agents were effective ligands for PXR, an evolutionary conserved nuclear 
receptor. The agonistic behavior of solomosterols toward PXR and PXR regulated 
genes, therefore was assisted by a transactivation in a cell based luciferase assay 
using an human hepatocyte cell line (HepG2 cells). Since PXR functions as an 
heterodimer with the retinoid-X-receptor (RXR), HepG2 cells were transfected 
with a PXR and RXR expressing vectors (pSG5-PXR and pSG5-RXR), with a 
reporter vector containing the PXR target gene promoter (CYP3A4 gene 
promoter) cloned upstream of the luciferase gene (pCYP3A4promoter-TKLuc) 
and with a β-galactosidase expressing vector as internal control of transfection 
efficiency (pCMV-β-gal). As illustrated in Figure 18, solomonsterols were potent 
inducers of PXR transactivation, boosting the receptor activity by 4-5 folds (n=4; 
P<0.05 versus untreated) and were at least as potent as rifaximin, a well 
characterized ligand for the human PXR.84 This activity was then confirmed in a 
RT-PCR assay on PXR target genes; both agents effectively stimulated the 
expression of CYP3A4 and MDR1 in the same cell line (Figure 18; n=4; P<0.05). 
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Figure 18. Panel A. Transactivation of PXR by compounds 1 and 2 in HepG2 cells. Panel B and 
C. Compounds 1 and 2 effectively increased the expression of CYP3A4 and MDR1, two PXR 
regulated genes in HepG2 cells. Expression of target genes was measured by RT-PCR. 
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Considering the well known relationship between PXR and immunity,85 it was 
investigated whether Solomonsterols exert any effect on cells of innate immunity, 
the first line and the most ancient line of defence of mammalians against bacteria 
and viruses.86 For this purpose, RAW264.7 cells, a murine macrophage cell line, 
were incubated with these compounds at the concentration of 10 and 50 µM in the 
presence of bacterial endotoxin (LPS) and expression of mRNA encoding for pro-
inflammator mediators was measured by real-time (RT) polymerase chain reaction 
(PCR). As illustrated in Figure 19, at the concentration of 50 µM solomonsterols 
A and B effectively inhibited induction of the expression of interleukin-(IL)-1β 
mRNA (Figure 19; N=4;P<0.05 versusLPS alone) induced by challenging 
RAW264.7 cells with lipopolysaccharide (LPS), a tool like receptor (TLR)-4 
ligand. By contrast both compounds exerted no effect on expression of tumor 
necrosis factor (TNFα) mRNA (Figure 19, panel B). At the end of the experiment 
cell viability was valued using the trypan blue (a diazo dye used to selectively 
colour dead tissues or cells blue). In fact both compounds had no effect on cell 
viability measured by the trypan blue excluding test (viability was greater than 
95%) excluding that inhibition of IL-1β production was due to a cytotoxic effect. 
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Figure 19. Relative mRNA expression of IL-1β and TNFα in RAW264.7 macrophages treated 
with LPS alone or with LPS in combination with Solomonsterol A and B. 
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Because IL-1β is a key cytokine and high in the hierarchy that drives innate 
immune response, these results highlight the potential for the use of 
solomonsterols in clinical conditions characterized by a dysregulation of innate 
immunity. To have details for what concerns the binding mode of solomonsterols 
A and B to PXR at atomic level, molecular docking studies were performed on 
solomonsterol A with PXR using Autodock Vina 1.0.3 software.87 The docking 
results positioned solomonsterol A within the PXR binding pocket, and among the 
9 docked conformations generated, the lowest binding energy displayed an 
affinity of -10.0 Kcal/mol (Figure 20). In this model, the steroidal nucleus 
establishes hydrophobic interactions with Leu206, Leu209, Val211, Ile236, 
Leu239, Leu240, Met243, Met246, confirming the binding mode already reported 
for a set of analogous compounds.88 Moreover, the sulfate groups exert hydrogen 
bonds with Ser247 (3-O-sulfate), His407 (2-Osulfate), and Lys210 (24-O-sulfate, 
also protruding toward the solvent), providing the complex with an increased 
predicted stability fully compatible with the experimental biological assays. 
 
 
 
 
 
 
 
 
 
Figure 20. Docked model of solomonterol A bound to PXR model (pdb code: 1M13, displayed as 
purple ribbon); solomonsterol A is displayed as sticks coloured by atom type, while HIS407, 
SER247, and LYS210 are depicted as atom type coloured CPK models. 
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In conclusion, solomonsterols A and B are a novel class of PXR agonsts, isolated 
from Theonella swinhoei; such compounds could have a pharmacological 
potential for the treatment of human disorders characterized by dysregulation of 
innate immunity and with inflammation. SA and SB have been isolated in very 
small amounts from the biological source. To a further and detailed 
pharmacological evaluation, total synthesis of the two natural leads was 
accomplished. 
2.1 Total synthesis of solomonsterol A 
Key structural features of  solomonsterol A (1) are the presence of a truncated 
C24 side chain, and three sulfated groups at C2, C3 and C24. We envisaged that 
the commercially available hyodeoxycholic acid (3) could be a suitable starting 
material to set up a robust route to prepare solomonsterol A in large amount.89 
Thus the total synthesis of solomonsterol A (1) started with 3, which was 
methylated with diazomethane and treated with tosyl chloride in pyridine to give 
the corresponding 3,6-ditosylate (5) in nearly quantitative yield (Scheme 2). When 
5 was treated with boiling DMF in the presence of CH3COOK for 1 h, 
simultaneous inversion at the C-3 position and elimination at the C-6 position 
took place to give methyl 3-hydroxy-5-cholen-24-oate (6),90,91 which in turn was 
hydrogenated to give the required A/B trans ring junction in 7.92 The 
simultaneous introduction of the 2β,3α-dihydroxy functionality was achieved by 
the following three-step sequence:93,94 a) elimination at C3-position and 
consequent introduction of ∆-2 double bond; b) epoxidation with m-CPBA; c) 
acid catalyzed ring opening of the epoxide to afford diol 11. β-Elimination and 
epoxydation were found to proceed with excellent regioselectivity and 
stereoselectivity, respectively, as determined by analysis of NMR spectra and 
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comparison of the NMR data of 9 and 10 with previously reported compounds. 
According to the Fürst–Plattner rule,95 epoxide ring opening with sulfuric acid in 
THF provided the desired 2β,3α-diol 11 exclusively. The 1H NMR signals of 2-H 
and 3-H (broad singlet at 3.89 ppm and broad singlet at 3.85 ppm) also confirmed 
the trans-diaxial disposition of the two hydroxy groups in 11. Reduction of methyl 
ester at C24 with LiBH4 afforded triol 12 in 92% yield. Treatment of 12 with 10 
equivalents of triethylammonium–sulfur trioxide complex at 95 ◦C afforded the 
ammonium sulfate salt of solomosterol A, which was transformed via ion 
exchange into the desired target trisodium salt 1 (Scheme 2). The complete match 
of optical rotation, NMR and HRMS data of solomonsterol A with that of the 
natural product secured the identity of the synthetic derivative. This synthesis was 
completed in a total of ten steps starting from commercially available 
hyodeoxycholic acid (3) and had an overall yield of 31%. This route enabled us to 
prepare sufficient quantities of solomonsterol A to be further characterized in 
pharmacological tests. 89 
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Scheme 2. Reagents and conditions: (a) CH2N2, quantitative; (b) p-TsCl, pyridine, quantitative; (c) 
CH3COOK, DMF/H2O 9:1, reflux, 78%; (d) H2 (1 atm), Pd/C, THF/MeOH 1:1, 80%; (e) p-TsCl, 
pyridine; (f) LiBr, LiCO3, DMF, reflux, 83% over two steps; (g) mCPBA, Na2CO3, CH2Cl2/H2O 
1:0.7; (h) H2SO4 1N, THF, 73% over two steps; (i) LiBH4, MeOH/THF, 0 °C, 92%; (l) Et3N.SO3, 
DMF, 95 °C; (m) Amberlite CG-120, sodium form, MeOH, 90% over two steps. 
 
2.1.1 Pharmacological evaluation in vivo 
We have first investigated whether the synthetic solomonsterol A (1) 
transactivates hPXR in PXR transactivation assay.  As illustrated in Figure 21, 
solomonsterol A (1) was equally effective as rifaximin in transactivating the 
hPXR in HepG2 cells.  The relative EC50 was 2.2 ± 0.3 µM for rifaximin and 5.2 
± 0.4 µM for solomonsterol A (n=3). 
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Figure 21. Luciferase reporter assay performed in HepG2 transiently transfected with pSG5-PXR, 
pSG5-RXR, pCMV-βgal, and p(cyp3a4)TKLUC vectors and stimulated 18 h with (A) rifaximin or 
solomonsterol A (0.1, 1 and 10 µM). *P < 0.05 versus not treated (NT )(n = 4). 
 
Colon inflammation that develops in mice administered TNBS 
(trinitrobenzenesulfonic acid) is a model of a Th1-mediated disease with dense 
infiltrations of lymphocytes/macrophages in the lamina propria and thickening of 
the colon wall.96,97 In order to assess whether solomonsterol A would exert 
immune-modulatory activity, TNBS was administered to C57Bl/6 transgenic mice 
expressing the human PXR. In these experiments, mice were treated with 
solomonsterol A and rifaximin for 7 days starting 3 days before intrarectal 
administration of TNBS. 
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Figure 22. Colitis was induced by intrarectal administration of 0.5 mg of TNBS per hPXR mouse, 
and animals were sacrificed 4 days after TNBS administration. Solomonsterol A (1) and rifaximin 
were administered intraperitoneally (I.P.) and orally (per os), respectively, for 3 days before 
TNBS. The severity of TNBS-induced inflammation (A, diarrhea score, B, weight loss, C 
macroscopic colon damage) is modulated by rifaximin and solomonsterol A (1) administration. D 
microscopic colon damage, E histological analysis of colon samples (original magnification 40×, 
H&E staining). TNBS administration causes colon wall thickening and massive inflammatory 
infiltration in the lamina propria. 
 
As shown in Figure 22, administering hPXR transgenic mice with solomonsterol 
A (1) effectively attenuated colitis development as measured by assessing local 
and systemic signs of inflammation. Thus, similarly to rifaximin, treatment with 1 
at the dose of 10 mg/kg protected against the development colitis, as measured by 
diarrhea score and the weight loss (Figure 22A and B, n=6-7; *p<0.05 versus 
naïve; **p<0.05 versus TNBS group) and reduced the macroscopic score of colitis 
as well as the microscopic score (Figure 22C-D, n=6-7; *p<0.05 versus naïve; 
**p<0.05 versus TNBS group). As shown in Figure 22E, histopathological 
samples of colon removed from hPXR transgenic mice administered TNBS had 
an extensive cellular infiltrate, submucosal edema, and large areas of epithelial 
erosions. These changes were robustly attenuated by pre-treatment with 
solomonsterol A (1) or rifaximin.These effects were supported by an attenuation 
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of signs of inflammation-driven immune dysfunction induced by TNBS 
administration. Thus, similarly to rifaximin, solomonsterol A (1) reduced 
neutrophils accumulation in the colonic mucosa as assessed by measuring MPO 
(myeloperoxidase) activity, as well as the expression of a number of signature 
cytokines and chemokines including TNFα (tumor necrosis factor alfa), IFNγ 
(interferon gamma), IL-12p70 (interleukin-12 p70 subunit) and MIP-1α 
(macrophage inflammatory protein-1α) (Figure 23). Of interest, both rifaximin 
and solomonsterol A (1) effectively increased the colon expression of IL-10 
(interleukin-10), a key counter-regulatory cytokine. A similar pattern, thought non 
significant for solomonsterol A (1), was observed for TGFβ (transforming growth 
factory beta) mRNA, a growth factor whose colon expression is linked to 
generation of a subset of regulatory T cells (Treg)98 (Figure 23F and G, n=6-7; 
*p< 0.05 versus naïve; **p<0.05 versus TNBS). 
 
 
 
 
 
 
 
 
Figure 23. MPO (A), TNFα (B), INFγ (C), IL-12 p70 (D), MIP-1α (E), TGF-β1 (F) and IL-10 (G) 
protein levels in colons obtained 5 days after administration of TNBS alone or in combination with 
rifaximin and 1. Treatments inhibit the increase of neutrophil infiltration (MPO levels) and 
proinflammatory factors induced by intrarectal administration of TNBS. Data represent the mean ± 
SE of 6-7 mice per group. (*p< 0.05 vs naïve; **p<0.05 vs TNBS). (H) Effects of rifaximin and 
solomonsterol A in colon mRNA levels of a PXR target gene such as Cyp3A11 (data are mean ± 
SE of 5 animal per group *p< 0.05 solomonsterol A vs rifaximin; **p<0.05 vs TNBS). 
A.                                 B.                           C.                                      D.
E.                                F.                           G.                                   H.
0
10
20
30
40
50
TNBS
naive vehicle 1 rifaximin
*
**
**
M
PO
(m
U
/m
g 
of
pr
ot
e
in
)
0
100
200
300
*
**
**
TN
Fα
(pg
/m
g 
of
pr
ot
ei
n
)
0
100
200
*
** **
IN
Fγ
(pg
/m
g 
of
pr
ot
e
in
)
0
50
100
150
*
**
IL
-
12
 
p7
0
(pg
/m
g 
of
pr
ot
e
in
)
0
250
500
750 *
**
**
M
IP
-
1α
(pg
/m
g 
of
pr
ot
e
in
)
0
10
20
30
*
TG
Fβ
(pg
/m
g 
of
pr
ot
ei
n
)
0
10
20
*
*
IL
-
10
(pg
/m
g 
of
pr
ot
e
in
)
0.0
2.5
7.5
10.0
12.5
15.0
Cy
p3
A1
1
(m
R
NA
le
ve
ls)
**
**
TNBS
naive vehicle 1 rifaximin
TNBS
naive vehicle 1 rifaximin
TNBS
naive vehicle 1 rifaximin
TNBS
naive vehicle 1 rifaximin
TNBS
naive vehicle 1 rifaximin
TNBS
naive vehicle 1 rifaximin
TNBS
naive vehicle 1 rifaximin
M
PO
(m
U
/m
g 
of
pr
ot
e
in
)
TN
Fα
(pg
/m
g 
of
pr
ot
ei
n
)
IN
Fγ
(pg
/m
g 
of
pr
ot
e
in
)
IL
-
12
 
p7
0
(pg
/m
g 
of
pr
ot
e
in
)
M
IP
-
1α
(pg
/m
g 
of
pr
ot
e
in
)
TG
Fβ
(pg
/m
g 
of
pr
ot
ei
n
)
IL
-
10
(pg
/m
g 
of
pr
ot
e
in
)
Cy
p3
A1
1
(m
R
NA
le
ve
ls)
Chapter 2 
38 
 
Finally we found that administering hPXR mice with solomonsterol A (1) 
effectively triggered PXR activation in vivo. Indeed, as shown in Figure 23H, both 
solomonsterol A (1) and rifaximin caused a potent induction in the expression of 
Cyp3A11. In the mice, Cyp3A11 is the orthologue of the human CYP3A4 gene in 
and it is a PXR regulated gene highly expressed in the intestine. These data 
strongly indicated that solomonsterol A and rifaximin are PXR agonists in vivo 
(Figure 23H, n=6-7; *p< 0.05 versus naïve; **p<0.05 versus TNBS). In addition 
we have evaluated the effect of solomonsterol A on NF-κB (nuclear factor-
kappaB) DNA binding  activity in LPS (lipopolysaccharide)-activated monocyte 
cell line. As shown in Figure 24, compared to LPS alone, co-treatment with 
solomonsterol A resulted in robust reduction of LPS induced NF-κB DNA 
binding activity as measured in EMSA assay. These results suggest that 
solomonsterol A inhibits the LPS-induced cytokines and chemokines expression 
by suppressing NF-κB DNA-binding activity. 
 
 
 
 
 
 
Figure 24: Rifaximin and solomonsterol A (1) suppress LPS-induced NF-κB DNA binding 
activity in THP-1 (human acute monocytic leukemia) cells that are a monocyte-like cell line. The 
cells were pre-treated with rifaximin (10 µM) or 1 (10 µM) with vehicle for 3 h and then 
stimulated with LPS (1 µg/mL) for 20 h. (A) DNA binding activity of NF-κB p65 subunit was 
analyzed by EMSA. For the competition assay, a 250-fold excess of unlabeled probe was added 
together with the labelled probe. For the supershift assay, 1 µg of antibody against NF-κB p65 was 
added together with the nuclear extract. Similar results were observed in three independent 
experiments. (B) Desintometric analysis of p65 binding to NF-κB responsive elements shown in 
the left panel. 
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Because these data demonstrate that prophylactic treatment with solomonsterol A 
(1) effectively protects against colitis development, we have investigated whether 
this agent is effective in driving the healing of an established active colitis. For 
this purpose, solomonsterol A was administered in a therapeutic manner in mice 
rendered colitic by TNBS administration. As illustrated in Figure 25, when 
administered to mice on day 1 after TNBS administration, solomonsterol A (1) 
effectively attenuated clinical signs of colitis (Figure 25A and B), including the 
diarrhea score and wasting disease. In addition, solomonsterol A (1) attenuated 
the macroscopic and microscopic scores as well as the MPO activity, a measure of 
neutrophil infiltration into the colonic mucosa (Figure 25C-E). 
 
 
 
 
 
 
 
 
Figure 25. Colitis was induced by intrarectal administration of 0.5 mg of TNBS per mouse, and 
animals were sacrificed 5 days after TNBS administration. Solomonsterol A (1) was administered 
on day 1 after TNBS administration. The severity of TNBS-induced inflammation (A, diarrhea 
score, B, weight loss, C, macroscopic colon damage, D, microscopic score damage and E, MPO 
activity) was reduced by solomonsterol A (1) administration. Body weight is expressed as delta 
percentage versus the weight of mice on the day before TNBS administration. Data represent the 
mean ± SE of 4-6 mice per group (*p< 0.05 vs naïve; **p<0.05 vs TNBS). 
 
In conclusion SA acts as a potent hPXR agonist as demonstrated by the induction 
of a canonical target gene of PXR in colon, such as Cyp3A11 (Figure 23H), 
effectively it protects against development of clinical signs and symptoms of 
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colitis, reduces the generation of TNFα and enhances the expression of TGFβ and 
IL-10, two potent counter-regulatory cytokines in IBD, via inhibition of NF-κB 
activation in a PXR dependent mechanism. 
2.2  Modifications in the side chain of solomonsterol A 
We have identified solomonsterol A (1) as  as a new lead in the treatment of 
IBD.89 However one of the possible limitation to its use in clinical settings is that, 
when administered per os, solomonsterol A could undergo absorption from the 
GIT before reaching the colon causing severe systemic side effects resulting from 
the activation of PXR in the liver. One of the best approaches used for colon 
specific drug delivery is based on the formation of a prodrug through chemical 
modification of the drug structure, usually by the conjugation with a suitable 
carrier, such as amino acids, sugars, glucuronic acid, dextrans or polysaccharides. 
Since the luxuriant microflora presents in the colon, the prodrug undergoes 
enzymatic biotransformation in the colon thus releasing the active drug molecule.  
Another challenging task is the design of a dual-drug able to release in the colon 
two molecules acting in a synergic manner. For example the possible eventual 
chemical linkage of solomonsterol A (1) to 5-ASA (5-aminosalycilic acid), one of 
the oldest anti-inflammatory agents in use for the treatment of IBD, could produce 
a dual-drug with enhanced potency. Upon enzymatic hydrolysis in the colon, this 
kind of molecule could release solomonsterol A and 5-ASA, potent agonists of 
PXR and PPARγ,99 respectively, two nuclear receptors playing a key role in colon 
inflammation diseases. When synthesizing prodrugs, the first step is the 
introduction of a functional group on the drug molecule suitable of conjugation 
with a selected carrier (e.g., an hydroxyl group that could enter into a glycoside 
linkage with various sugars, or alternatively a carboxyl group to form ester e/o 
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amide conjugates with cyclodextrins, amino acids etc). Inspection of chemical 
structure of solomonsterol A (1) revealed that the presence of three sulfate groups 
hampered any further derivatization e/o conjugation. In order to introduce a 
function group suitable for further derivatization, we decided to prepare several 
solomonsterol A (1) derivatives with a modified side chain but preserving the 
steroidal tetracyclic nucleus.100 Our synthetic route started from the advanced 
intermediate 1189 that was sulfated with 10 equivalents of triethylammonium-
sulfur trioxide complex and transformed in the sodium sulfate salt 13 through 
Amberlite CG-120 treatment. The crude product was subsequently hydrolyzed 
with methanolic NaOH (5%) to remove the protecting group at the C-24 methyl 
ester on the side chain affording the desired carboxylic acid functional group. The 
reaction mixture was adjusted to pH 5 with HCl 1N, and loaded onto a C18 
cartridge for the reversed-phase solid extraction. Elution with 30% aqueous 
methanol gave the carboxylic acid 14 as a 2,3,24-trisodium salt in satisfactory 
yield (85% over two steps). Having obtained the carboxyl acid at C24, we decided 
to carry on with the reaction of amidation with glycine ethyl ester, taurine and 5-
ASA. Using the versatile coupling agent, DMT-MM [4-(4,6-dimethoxy-1,3,5-
triazin-2-yl)-4-methylmorpholinium chloride],101 the amidation reaction 
proceeded nearly quantitatively, requiring the activation of the carboxylate 
sodium salt by DMT-MM and triethylamine in DMF at room temperature and 
subsequent condensation of the resulting acyloxytriazine with glycine ethyl ester 
hydrochloride, taurine and 5-ASA affording the amide derivatives 15, 17 and 18 
respectively, as ammonium sulfate salts. Alkaline hydrolisis of ethylester 15 with 
NaOH 5% in MeOH/H2O 1:1 afforded the sodium carboxylate 16. Amide 
derivatives with taurine and 5-ASA were transformed via ion exchange 
Chapter 2 
42 
 
(Amberlite CG-120, sodium form, MeOH) into the desired target trisodium salts 
17 and 18 in nearly quantitative yields (Scheme 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3. a) Et3N.SO3, DMF, 95 °C; b) NaOH 5% in MeOH:H2O 5:1 v/v, 85% over two steps; c) 
DMT-MM, Et3N, GlyOEt, DMF dry; d) NaOH 5% in MeOH:H2O 5:1 v/v, 58% over two steps; e) 
DMT-MM, Et3N, taurine, DMF dry. Then Amberlite CG-120, MeOH, 67%. f) DMT-MM, Et3N, 
5-ASA, DMF dry. Then Amberlite CG-120, MeOH, 72%; g) LiBH4, MeOH, THF, 0 °C, 75%. 
Elution with 30% aqueous methanol gave the carboxylic acid 3 as a 2,3,24-trisodium salt in 
satisfactory yield (85% over two steps). 
 
To prove the ability of these compounds to activate  PXR and eventually PXR 
regulated genes, a luciferase reporter assay on human hepatocyte cell line (HepG2 
cells) transiently transfected with pSG5-PXR, pSG5-RXR, pCMV-βgalactosidase, 
and p(CYP3A4)-TK-Luc vectors (Figure 26), has been performed. Cells were 
then stimulated with rifaximin, SA and with compounds 14-18 at the 
concentration of 10 µM each. As shown in Figure 26A, beside the closely 
structural resemblance with solomonsterol A (1), only carboxylate (14) showed a 
slight activity in transactivating PXR. Besides at first sight this behaviour should 
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be ascribable to a scarce bioavailability, the scarce activity also for the methyl 
ester  13 (Figure 26A) and the complete loss of activity for C-24 alcohol 19 
(Figure 26A), obtained through LiBH4 reduction of 13 (75% yield), pointed 
towards unfavourable pharmacodinamic features. Indeed, although compounds 
14-18 possess a negative charge on their side chains, most likely they are less able 
to form polar interactions with Lys21089 or alternatively with other polar amino 
acids of PXR LBD.   
 
 
 
 
 
 
Figure 26. Luciferase reporter assay. HepG2 cells, a hepatocarcinoma cell line, were transiently  
transfected with pSG5-PXR, pSG5-RXR, pCMV-βgalactosidase and p(CYP3A4)-TK-Luc vectors 
and then stimulated with (A) 10 µM rifaximin or compounds 1, 13, 14, 16, 17, 18, 19, 23, 25 and 
26 for 18 h, or (B) 10 µM rifaximin alone or in combination with 50 µM of compounds 13, 14, 23 
and 25 . N.T., not treated. Rif, rifaximin. *P<0.05 versus cells left untreated. Data are mean± SE 
of three determinations. 
 
2.2.1 Discovery of cholesterol disulfate and pharmacological investigations 
As previously reported, PXR presents a large ligand binding cavity102 allowing the 
accommodation of different kind of molecules and the possible binding modes are 
characterized an adequate balance between hydrogen bond and Van der Waals 
interactions established between a small molecule and the receptor. Therefore the 
lack of a polar interaction should be get over by increasing the contribution of the 
hydrophobic interactions on the side chain, so the derivative 23, 2β,3α-cholestan 
disulfate, has been prepared according the synthetic procedure reported in Scheme 
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Scheme 4. a) H2, Pd/C, THF:MeOH 1:1, room temperature, 90%; b) p-TsCl, pyridine; c) LiBr, 
Li2CO3, DMF, reflux, 87% over two steps; d) m-CPBA, CHCl3 room temperature; e) H2SO4 1N, 
THF, room temperature, 78% over two steps; f) Et3N.SO3, DMF, 95 °C. Then Amberlite CG-120, 
MeOH, 90%.  
 
∆5 cholesterol reduction (H2, Pd/C, THF:MeOH 1:1) followed by tosylation and 
LiBr elimination afforded ∆2-cholestane derivative 20 (78% yield in three steps). 
The introduction of the 2β,3α-dihydroxy functionality was achieved by epoxidation 
with m-CPBA followed by acid catalyzed ring opening on epoxide 21.103 β-
Elimination and epoxidation proceeded with excellent regioselectivity and 
stereoselectivity, providing exclusively the desired 2β,3α-diol 22 in excellent yields 
(78% over two steps). Sulfation of diol 22 followed by Amberlite CG-120 treatment 
and RP-18 chromatography afforded the disodium salt 23 in good yields. As shown 
in Figure 26A, compound 23 with its hydrophobic side chain is able to transactivate 
PXR with a potency comparable with the parent solomonsterol A (1). Having set a 
flexible synthetic strategy, we decided to speculate the pharmacophoric role played 
by the sulfate groups on ring A in the PXR agonistic activity of solomonsterol A (1).  
Tosylation of methyl 3β-hydroxy-5α-cholan-24-oate (7)89 followed by inversion of 
configuration at C-3 with potassium acetate in DMF/H2O and de-acetylation in 
acidic condition (Scheme 5) afforded the 3α-hydroxy derivative 24 (75% over three 
steps). Reduction at C-24, sulfatation/Amberlite ion exchange gave 25 as disodium 
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salt. Methyl 3β-hydroxy-5α-cholan-24-oate (7) was also used as starting material for 
the easy transformation in derivative 26 through LiBH4 reduction of C-24 methyl 
ester and successive sulfation of the alcoholic functions at C-3 and C-24. 
 
 
 
 
 
 
 
Scheme 5. a) p-TsCl, pyridine; b) CH3COOK, DMF:H2O 9:1, reflux; c) p-TsOH, CHCl3:MeOH 5:3, 
75% over three steps; d) LiBH4, MeOH, THF, 0 °C, 85%; e) Et3N.SO3, DMF, 95 °C; then Amberlite 
CG-120, MeOH, 63%; f) LiBH4, MeOH, THF, 0 °C, 72%; g) Et3N.SO3, DMF, 95 °C; then Amberlite 
CG-120, MeOH, 78%. 
 
As indicated in Figure 26A, besides compound 25 induces a slight PXR 
transactivation, the lack of sulfate group at C-2 as well as the inversion of 
configuration at C-3 are responsible of a general loss in the agonistic activity 
towards PXR. To investigate whether these compounds could act as potential 
antagonists of PXR we have carried out a transactivation experiment in HepG2 cells 
stimulated with rifaximin (10 µM) and compounds 13, 14, 23 and 25 at the 
concentration of 50 µM each. As shown in Figure 26B, all compound failed to 
reverse the induction of luciferase caused by rifaximin, indicating that none of these 
solomonsterol A derivatives is a PXR antagonist. To further examine the activity of 
compound 23 as PXR activator and further clarify the behavior of compounds 13, 14 
and 25, we have tested the effects of all members of our series on the expression 
CYP3A4, a canonical PXR target gene (Figure 27 ). Despite compounds 13, 14 and 
25 caused a slight transactivation of PXR, they failed to modulate the expression of 
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CYP3A4 at the concentration of 10 µM. In contrast, confirming data shown in 
Figure 26, compound 23 effectively increased the expression of CYP3A4 (Figure 27) 
in HepG2 cells, with a magnitude similar to that of rifaximin and solomonsterol A 
(1).  
 
 
 
 
 
 
Figure 27. Real-Time PCR of CYP3A4 carried out on cDNA isolated from HepG2 not stimulated 
or primed with 10 µM rifaximin, and compounds 1,13,14,16,17,18,19,23,25 and 26. N.T., not 
treated. Rif, rifaximin. *P<0.05 versus N.T. cells.  
 
To investigate whether compound 23 plays an immunomodulatory activity, the effect 
of 23 in regulating immune response using THP1 cells, a human 
macrophage/monocytic cell line, challenged with lipopolysaccharide (LPS), has been 
evaluated. Previous studies94  have shown that activation of PXR in this setting 
attenuates immune response triggered by LPS. Data shown in Figure 28, demonstrate 
that compound 23 effectively attenuates induction of IL-1β, TNFα and MCP-1 
induced by LPS.  
 
 
 
 
Figure 28. Effect of compound 23 on cytokine release induced by LPS in THP1 cells. 3x106 THP 
were starved for 24 h and then pre-treated with 10 µM of compound 23 for 3 h and then stimulated for 
18 h with LPS 1 µg/mL. Cytokine expression was assessed by RT-PCR. Data shown are mean ± SE of 
9 assays from three different sets of experiments. *P<0.05 versus control cells; ** P<0.05 versus LPS 
alone. 
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Because the above mentioned data indicate that compound 23 effectively modulates 
immune response in human monocytes, additional experiments were carried out to 
investigate the effect of this compound in another model of inflammation-driven 
activation, using hepatic stellate cells (HSCs). HSCs are a liver-resident cell 
population that proliferates in response to liver injury. In response to immune 
activation, HSC undergoes a complex phenotype’s rearrangement characterized by 
resetting expression of nuclear receptors, including PXR, and acquisition of an 
activated, myofibroblast-like phenotype whose main characteristic is the ability to 
express α-smooth muscle actin (αSMA). HSCs are recognized as the main source of 
extracellular matrix production in the fibrotic liver. Previous studies have shown 
that, along with other nuclear receptors, PXR ligands reverse this phenotype and 
reduce α-SMA expression.104,105 For this purpose HSCs were exposed to thrombin, a 
proteinase activated receptor (PAR)-1 agonist alone or in combination with 
compound 23. Previous studies have shown that thrombin drives HSCs trans-
differentiation and its inhibition reverses HSCs from an activated to a quiescent 
phenotype.106 Results shown in Figure 29, demonstrate that not only, similarly to 
solomonsterol A (1), compound 23 effectively reduces basal expression of αSMA, 
but it also attenuates HSCs trans-differentiation (i.e. induction of αSMA expression) 
triggered by thrombin. 
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Figure 29. HSC-T6 cells were starved for 72 h and then stimulated with thrombin, 10 U/mL, in the 
presence of solomonsterol A (1) or compound 23, 10 µM each. αSMA expression was assessed by 
RT-PCR. Data shown are mean ± of three experiments.* P<0.05 versus control cells; ** P<0.05 
thrombin versus control cells; ***P<0.05 versus thrombin alone.  
 
2.2.2 Docking studies 
In order to clarify the different activities of described compounds at a molecular 
level,107 their positioning  in PXR-LBD in comparison with SA was evaluated by 
docking calculations.108 As previously described, the three sulfate groups of 
solomonsterol A (1) act as key points of interactions with polar amino acids in 
LBD (Ser247, His407, Lys210), and contribute to accommodate the steroid 
nucleus in a mostly hydrophobic part of the binding site of PXR. Solomonsterol A 
(1) establishes hydrogen bonds (Figure 30) with Cys284 (2-O-sulfate) and with 
the Lys210 (24-O-sulfate) and electrostatic interactions with the Ser247 (2-O-
sulfate) and His407(3-O-sulfate).89 
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Figure 30. Solomonsterol A (1) (coloured by atom types: C grey, O red, S yellow) in docking with 
PXR-LBD (residues are coloured by atom type: C green, H light grey, O red, N blue). Hydrogen 
bonds are displayed with green spheres. 
 
Compound 23, featuring the C8 aliphatic side chain of cholesterol, is well 
superimposed with the binding pose of 1, and is able to interact with the Ser247, 
Cys284 and the His407 through its two sulfate groups in the ring A (Figure 31). 
Moreover, 23 establishes hydrophobic interactions with almost all the residues 
observed for solomonsterol A (1) (Leu209, Val211, Pro228, Leu239, Met243, 
Phe281, Phe288, Leu411). The presence of an hydrophobic chain allows to gain 
two more Van der Waals interactions (with the Leu209 and Val211) that may 
counter the loss of electrostatic interaction observed for the sulfate group at C24 
of parent solomonsterol A (1). Nevertheless, the weaker nature of these Van der 
Waals interactions could explain the decrease of the activity of 23 on PXR 
(difference of predicted binding energies 1-23=1.05 kcal/mol). 
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Figure 31. Compound 23 (coloured by atom types: C light green, O red, S yellow) in docking with 
PXR-LBD (residues are coloured by atom type: C green, H light grey, O red, N blue). Hydrogen 
bonds are displayed with green spheres. 
 
On the other hand, the absence of the sulfate group at C-2 in the steroid nucleus 
causes the observed decrease of activity, due to an inability to interact 
simultaneously with the three key points of contact previously described. For 
example, compounds 25 and 26 are able to interact with the Lys210 but they fail 
to respect the key interactions involving the internal part of the binding site 
(Figure 32). As concern compound 14, its tetracyclic nucleus is well 
superimposed with 1, but its shorter side chain causes a poor interaction with the 
nitrogen of Lys210. The two oxygens of its terminal carboxylic part are not well 
overlapped with the oxygens of the 24-O-sulfate of the 1, and the different 
arrangement of the side chain causes also a loss of two Van der Waals interactions 
with the Leu239 and Pro227 (Figure 32). The rings A of compounds 13 and 19 are 
in the place occupied by the ring B of 1 and, as a consequence, the 2-O-sulfate 
and/or 3-O-sulfate are in a less deep position (Figure 32). Compounds 16, 17 and 
18 present a longer and more functionalized side chain (Figure 32) compared with 
the previous derivatives, but also in this case the steroid nucleus are placed toward 
the external part of the binding site of PXR (16, 18).  Moreover, compound 17 is 
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unable to bind in the above described fashion and accommodates in a reverse 
orientation (a flipping of ~ 180° along the major axis of the steroid nucleus) of its 
steroid nucleus (Figure 32). The overall result is an inverted disposition of all the 
chemical groups (sulfates/methyl groups, and side chain) in the binding pocket of 
PXR and then a different pattern of interactions.  
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Superimposition between 1 (coloured by atom types: C grey, O red, S yellow) and: a) 
25 (coloured by atom types: C sky-blue, O red, S yellow); b) 26 (coloured by atom types: C 
brown, O red, S yellow); c) 14 (coloured by atom types: C orange, O red, S yellow); d) 13 
(coloured by atom types: C purple, O red, S yellow); e) 19 (coloured by atom types: C turquoise 
green, O red, S yellow); f) 16 (coloured by atom types: C dodger blue, O red, S yellow); g) 17 
(coloured by atom types: C dark green, O red, S yellow); h) 18 (coloured by atom types: C pink, O 
red, S yellow) in PXR-LBD (residues are coloured by atom type: C green, H light grey, O red, N 
blue). 
 
In summary, compound 23 is a robust PXR agonist that modulates immune 
response in human macrophages and liver fibrosis in epatocites. Because its 
simplified structure, compound 23 is a suitable candidate for further development 
in preclinical models of inflammatory diseases and in liver fibrosis induced by 
HIV infection. Further studies aimed to the evaluation of efficacy of 23 in animal 
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models, together with the determination of its chemical-physical proprieties are 
currently in progress. 
2.3 Total synthesis of Solomonsterol B 
Solomonsterol B (2) shares the same tetracyclic nucleus with 1, but differs in the 
length of the side chain. Besides was proved that this modification has no 
influence on the binding within the LBD of PXR,73 and therefore on the ability to 
transactivate PXR, recent reports have demonstrated that in several potential 
drugs the length of the side chain could exert dramatic effects. For example, nor-
ursodeoxycholic acid, the C23 homologue of ursodeoxycholic acid (UDCA), has 
been shown to be more potent that the parent UDCA in pharmacological 
treatments for cholangiopathies and cholestatic liver diseases, demonstrating that 
its therapeutic effects are related to the side chain structure, which strongly 
influences the metabolism and consequently the pharmacokinetic behavior of this 
molecule.109 Unfortunately, any further pharmacological in vivo experimentation 
or evaluation of the pharmacokinetic properties of solomonsterol B (2) was 
hampered by the scarcity of biological material isolated from the marine sponge. 
So we designed and realized the first total synthesis of solomonsterol B (2)110 
starting from commercially available hyodeoxycholic acid (3). The synthetic 
procedure also allowed the preparation of a derivative modified in the side chain, 
and thus a preliminary structure–activity relationship on the interaction between 
solomonsterol B and PXR was established. As depicted in Scheme 6, the key 
steps of our synthetic protocol are the one-carbon degradation at C24 and the 
modification of the functionalities of the A and B rings to establish the desired 
trans junction and the two hydroxyl groups at C2 and C3. Hyodeoxycholic acid 
(HDCA, 3) was protected as performate derivative 27 by Fischer esterification 
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with formic acid, followed by acetic anhydride treatment to shift the equilibrium 
towards the complete formylation of 3.111 Intermediate 27 was subjected to the so-
called second-order “Beckmann rearrangement” by treatment with sodium nitrite 
in a mixture of trifluoroacetic anhydride and trifluoroacetic acid.112 Prolonged 
alkaline hydrolysis of resulting 23- nitrile intermediate 28 gave 24-nor-HDCA 
(29) in an isolated yield of 60% over the three-step sequence. Esterification of the 
carboxylic acid at C23 with methanol and p-toluenesulfonic acid (pTsOH), and 
tosylation of the resulting methyl ester with tosyl chloride in pyridine gave methyl 
3α,6α-ditosyloxy-24-nor-5α-cholan-23-oate (30) in a satisfactory yield (75%, two 
steps). Heating 30 with CH3COOK in refluxing DMF for 1 h resulted in 
simultaneous inversion at C3 and elimination at C6, with the formation of a 
mixture of 31 and its 3-O-acetyl derivative. Hydrolysis with pTsOH gave methyl 
3-hydroxy-5-cholen-24-oate (31),90,91 which in turn was hydrogenated to give 32, 
with the required A/B trans ring junction.92 Tosylation and elimination at C3 
yielded the corresponding ∆2 ester 33 in 81% isolated yield after chromatographic 
purification on silica gel. The introduction of three hydroxyl groups in 34, two on 
ring A in a trans-diaxial disposition and one in the side chain, was obtained by 
epoxidation of double bond, subsequent acid-catalyzed epoxide opening94,95 with 
sulfuric acid in THF, and finally reduction of the methyl ester at C23 with LiBH4 
(56% yield over three steps). Sulfation of triol 34 gave the ammonium sulfate salt 
of solomonsterol B in 72% isolated yield over two steps, and this compound was 
transformed by ion exchange into desired target trisodium salt 2 and purified by 
reversed-phase solid extraction on a C18 cartridge. The complete match of optical 
rotation, NMR spectroscopic data and HRMS data of synthetic solomonsterol B 
(2) with that of the natural product confirmed the identity of the synthetic 
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derivative. This synthesis was completed in a total of 13 steps, starting from 
commercially available hyodeoxycholic acid (3), in an overall yield of 10%. This 
route enabled us to prepare sufficient quantities of solomonsterol B (2) to be 
further characterized in pharmacological tests. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 6. Reagents and conditions. (a) HCOOH, HClO4 50 °C, then (Ac)2O, 97%; (b) 
CF3COOH, (CF3CO)2O, NaNO2, 1 h, 0 °C, then 40 °C for 1.5 h, 80%; (c) 30% KOH, EtOH:H2O 
1:1, reflux, 78%; (d) p-TsOH, MeOH dry, 96%; (e) p-TsCl, pyridine, 78%; (f) CH3COOK, 
DMF/H2O 9:1, reflux; then p-TsOH, CHCl3:MeOH 5:3, 80% over two steps; (g) H2, Pd/C, 
THF/MeOH 1:1, room temperature, 84%; (h) p-TsCl, pyridine; (i) LiBr, Li2CO3, DMF, reflux, 
81% over two steps; (l) m-CPBA, CHCl3. room temperature; (m) H2SO4 1N, THF, room 
temperature, 81% over two steps; (n) LiBH4, MeOH/THF, 0 °C, 69%; (o) Et3N.SO3, DMF, 95 °C. 
Then Amberlite CG-120, MeOH, 72%. 
 
Advanced intermediate 35 was also used as the starting material to obtain alcohol 
37 (Scheme 7), which was judged instrumental to investigate the pharmacophoric 
role played by the side chain sulfate group in the PXR-agonistic activity of 
c
d,e f g
h,i l,m,n
H
COOH
OH
HO
a b
H
COOCH3
OTs
TsO
H
COOH
OCHO
OHCO
COOCH3
HO
COOCH3
H
OH
H
HO
HO
OSO3Na
H
NaO3SO
NaO3SO
3 27 28
29 30
32 33 34
2
31
H
CN
OCHO
OHCO
H
COOH
OH
HO
COOCH3
HO H
o
Chapter 2 
55 
 
solomonsterol B (2). As already discussed for SA, the replacement of the sulfate 
group at C23 of SB with a polar group, such as a hydroxy group as in 37, could 
preserve the key interaction with Lys210, while at the same time introducing a 
functional group suitable for conjugation to a carrier for colon specific drug 
delivery. In fact, a PXR agonist, when administered by mouth in the 
pharmacological treatment of colon diseases (IBD, UC, CD), could undergo 
absorption before reaching the colon, and thus cause severe systemic side-effects 
resulting from the activation of PXR in the liver. Thus, as reported in Scheme 7, 
diol 35 was sulfated with triethylammonium–sulfur-trioxide complex, and 
transformed in sodium sulfate salt 36 by Amberlite treatment and purification on a 
C18 column. LiBH4 reduction gave C23 alcohol 37 in 78% yield from diol 35. 
 
 
 
 
Scheme 7. Reagents and conditions: (a) Et3N·SO3, DMF, 95 °C; then Amberlite CG-120, MeOH; 
(b) LiBH4, MeOH/THF, 0 °C, 78% over two steps. 
 
2.3.1 Pharmacological evaluation  
Synthetic solomonsterol B (2) and alcohol 37 were tested in a luciferase reporter 
assay on a human hepatocyte cell line (HepG2 cells), transiently transfected with 
pSG5-PXR, pSG5-RXR, pCMV-βgalactosidase, and p(CYP3A4)-TKLuc vectors 
(Figure 33).113,114,115 Cells were then stimulated with rifaximin and with 
compounds 2 and 37 at a concentration of 10 µm each. As shown in Figure 33, 
solomonsterol B (2) was able to transactivate PXR with a potency comparable to 
rifaximin, whereas C23 alcohol 37 was inactive, thus demonstrating again the 
a
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pharmacophoric role played by the sulfate group in the side chain of 
solomonsterol B (2). Moreover compounds 2 and 37 were tested in a RT-PCR 
assays on the PXR target genes CYP3A4, CYP3A7, SULT2A1 and MDR1. As 
illustrated in Figure 34, with the exception of CYP3A7, solomonsterol B (2) was 
able to induce CYP3A4, SULT2A1 and MDR1, while, as expected, alcohol 37 
failed to induce these PXR target genes on HepG2 cells. 
 
 
 
 
 
 
Figure 33. Luciferase reporter assay performed in HepG2 transiently transfected with pSG5-PXR, 
pSG5-RXR, pCMV-βgalactosidase, and p(CYP3A4)-TK-Luc vectors, and stimulated for 18 h with 
rifaximin (10 µm), 2 (1 and 10 µm) and 37 (1 and 10 µm). 
 
 
 
 
 
 
 
 
 
Figure 34. Real-time PCR analysis of PXR target genes CYP3A4, CYP3A7, SULT2A1 and 
MDR1 carried out on cDNA isolated from HepG2 not stimulated or primed with 10 µm rifaximin, 
2 and 37. Values are normalized relative to B2M mRNA, and are expressed relative to those of 
untreated cells, which are arbitrarily set to 1. 
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The results of luciferase experiments as well as PCR analysis of canonical PXR 
target genes clearly demonstrated that solomonsterol B (2) is a PXR agonist 
providing also information on the pharmacoforic role of C23 sulfate group.
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CHAPTER 3 
DUAL PXR/FXR LIGANDS 
Steroids bearing a 4-methylene group are relatively rare metabolites in nature. 
They have been exclusively isolated from sponges of the genus Theonella, mainly 
from T. Swinhoei, unaccompanied by conventional steroids and therefore 
proposed as ideal taxonomic markers for sponges of this genus.116 Since the 
isolation, by Djerassi et al., of conicasterol and theonellasterol (Figure 35) from T. 
conica and T. swinhoei,65 respectively, about twenty new 4-methylene-steroids 
were isolated from Theonella sponges.117,118,119,120 Common structural features are 
a 24-methyl and/or 24-ethyl side chain, the presence of oxygenated functions at 
C(3), C(7), or C(15), of a ∆8,14 double bond rarely replaced by a 8(14)-seco-
skeleton. 
 
 
 
 
 
Figure 35. Theonellasterol and conicasterol previously isolated from Theonella species. 
Pursuing our systematic study on the chemical diversity and bioactivity of 
secondary metabolites from marine organisms collected at Solomon Islands, we 
studied the less polar extracts, which resulted in the isolation and identification of 
theonellasterol65 together with ten new polyoxygenated steroids, which we named 
theonellasterols B-H (40-46) and conicasterols B-D (47-49)121 (Figures 36 and 
38). These marine steroids are endowed with potent agonistic activity on the 
human pregnane-X-receptor (PXR) while antagonize the effect of natural ligands 
HO
Theonellasterol (38)
H HO
Conicasterol (39)
H
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for the human farnesoid-X-receptor (FXR). Exploiting these properties, we have 
identified theonellasterol G (45) as the first example of PXR agonist and FXR 
modulator from marine origin, that might have utility in treating liver disorders. 
3.1 Structural determination of theonellasterols B-H  
 
 
 
 
 
 
 
 
 
Figure 36. Theonellasterols from Theonella swinhoei. 
Theonellasterol B (40) was isolated as pale yellow oil. The molecular formula of 
C30H46O was established by HR ESIMS based on the pseudo molecular ion 
[M+Li]+ at m/z 429.3729 (calculated 429.3709), indicating eight degrees of 
unsaturation. The 1H NMR spectrum of 40 (Table 2) showed signals characteristic 
of a 4-methylene-24-ethyl steroidal system: two methyl singlets (δH 0.89 and 
0.98), three methyl doublets (δH 0.90, 0.92 and 1.01), one methyl triplet (δH 0.95), 
two broad singlets at δH 4.77 and 5.33, and one methine proton on an oxygenated 
carbon at δH 3.67. The low-field portion of the 1H NMR spectrum also contained 
signals relative to three olefinic protons at δH 6.10 (1H, br d, J = 5.6 Hz, H-7), δH 
5.85 (1H, br s, H-15) and δH 5.50 (1H, br d, J = 6.5 Hz, H-11). The 13C NMR 
(Table 1) interpreted with the help of the HSQC experiment, evidenced a C30 
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steroidal theonellasterol skeleton with three cross conjugated trisubstituted double 
bonds [UV (MeOH): λmax (log ε) 275 nm (3.62)]. The localisation of the double 
bonds follows from the analysis of COSY and HMBC data. In particular, COSY 
correlations delineated the spin system H-1 through H-7, which included one 
hydroxyl group at C3, the exocyclic double bond at C4 and a double bond at C7 
position. The olefinic proton H-7 at δH 6.10 showed a long range coupling with H-
11 at δH 5.50 that was consistent with a double bond at the C9/C11 position, 
further supported by HMBC cross-peaks from Me-19 to C9 and from H-11 to 
C10. Finally, the last trisubstituted double bond was placed at C14/C15 on the 
basis of diagnostic HMBC cross-peak from Me-18 to C14. The configuration at 
C24 was determined by comparison of 13C-NMR data (Table 1) with the epimeric 
steroidal side chain.122,123 Therefore, theonellasterol B (40) was elucidated as 4-
methylene-24(S)-ethylcholest-7,9(11),14-trien-3β-ol. The molecular formula of 
theonellasterol C (41) was determined to be C30H48O2 by HR ESIMS with 
[M+Li]+ at m/z 447.3834 (calculated 447.3814), possessing seven degrees of 
unsaturation. Analysis of 2D NMR spectra clearly evidenced the same A ring and 
C24-ethyl side chain as in 40.13C NMR data (Table 1) indicated the presence of a 
tetrasubstituted double bond (δC 122.5, s and 138.6, s) and one carbonyl (δC 
214.8). Proton signals due to H2-7 (δH 2.15 and 2.51 ), H2-11 (δH 1.82 and 2.04), 
and H-14 (δH 2.30) showed chemical shifts consistent with allylic hydrogens and a 
double bond at the C8/C9 position that was further supported by an HMBC cross-
peak from Me-19 to C-9. The carbonyl group was placed at C15 on the basis of 
13C chemical shifts of C14 and C16 and of diagnostic HMBC correlations from 
H2-16 and H-14 to C15. Hence, the structure of theonellasterol C (41) was 
determined as 3β-hydroxy-4-methylene-24(S)-ethylcholest-8(9)-en-15-one. The 
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molecular formula of theonellasterol D (42), C31H52O3, indicated one carbon more 
than a conventional theonellasterol-like skeleton. 1H and 13C NMR data (Tables 1 
and 2) evidenced a methoxy group (δH 3.07, δC 51.1), one tetrasubstituted double 
bond (δC 132.2, s and 153.7, s) and one secondary hydroxyl group (δH 4.60, δC 
70.0). The tetrasubstituted double bond was placed at 8(14) position on the basis 
of diagnostic HMBC correlation (Figure 37) from Me-18 to C14 and confirmed 
by the long range correlations H-15 and H2-7 to C8 and C14. Analogously, the 
HMBC correlations Me-19/C9 and OMe/C9 support the localization of the 
methoxy group at C9, whereas the 15-hydroxy function follows from 1H,1H-
COSY correlations. The ROESY correlations H-5α/H-7α, H-7α/OMe, implied 
that the methoxy group at C9 was α-oriented, which was further supported by the 
syn-axial γ-effects exerted by the methoxy substituent on C1, C5 and C7, and by 
the downfield shift of H-5. The strong ROE effect between H-15 and H-17α 
(Figure 37) indicated that the hydroxy group at C15 is in a β-position, as 
confirmed by the chemical shifts of the nuclei of ring D.124 On the basis of 
foregoing analysis the structure of theonellasterol D (42) was determined as 4-
methylene-9α-methoxy-24(S)-ethylcholest-8(14)-en-3β,15β-diol. The molecular 
formula of theonellasterol E (43) was determined as C30H50O3, equivalent to 
theonellasterol D (42) less CH2. Comparison with spectral data of 42, chemical 
shift arguments (Tables 1 and 2), 2D NMR analysis indicated that theonellasterol 
E (43) differs from 40 for a 9α-hydroxy group replacing the 9α-methoxy group, 
disclosing a 4-methylene-24(S)-ethylcholest-8(14)-en-3β,9α,15β-triol structure for 
theonellasterol E (43). As determined by HR ESIMS measurements, 
theonellasterol F (44) is isomeric with 43. From 1D NMR spectra it was possible 
to assign a tetrasubstituted double bond and two oxygen bearing methine groups. 
Chapter 3 
62 
 
The same ∆8,14-15β-hydroxy substructure as in theonellasterols D and E was 
inferred from 2D NMR analysis. COSY correlations delineated the spin system H-
1 through H-7, the 13C chemical shift for C7 (δC 66.7) implied an OH substitution. 
The relative stereochemistry at C7 was deduced from the small vicinal coupling 
constant of H-7, which is consistent with an equatorial disposition for this proton, 
thereby placing the hydroxyl group in an axial α-orientation. This was confirmed 
by the relatively low-field shifts of H-5 and H-9 caused by the 1,3-diaxial 
relationship of these protons to the hydroxy group at C7 (Table 2). Thus, 
theonellasterol F (44) was defined as 4-methylene-24(S)-ethylcholest-8(14)-en-
3β,7α,15β-triol. Theonellasterol G (45) was isolated as an optically active pale 
yellow oil with a molecular formula of C30H50O4. In addition to the signals 
relative to 4-methylene-3β-hydroxy structure, the 13C NMR spectrum of 45 (Table 
1) showed the presence of two quaternary sp2 carbons, (δC 133.6 and 142.5), two 
oxygen-bearing methine carbons (δC 71.2 and 71.3) and one oxygen-bearing 
quaternary carbon (δC 89.7). The HMBC correlation between the angular methyl 
singlet Me-18 and a quaternary oxygenated carbon at δC 89.7 allowed to place an 
hydroxyl group at C14 position, whereas the correlation between the Me-19 and 
the olefinic carbon at δC 142.5 evidenced the presence of a ∆8,9 double bond. 
Moreover, the localization of the secondary alcoholic function at C11 follows 
from the HMBC correlations between H-11 at δH 4.39 and C8, C9 and C13 
(Figure 37) and an hydroxyl group was placed at C-15 by COSY analysis. The 
relative configuration for the steroidal nucleus could be assigned by ROESY 
(Figure 37) and analysis of coupling constant data and on the basis of chemical 
shift considerations. The equatorial disposition of H-11 was evident from the 
small 3JHH vicinal coupling to H2-12, and from the ROESY correlations to axial 
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protons H-1 and H-5. The strong downfield shift exhibited by the H-17 was 
indicative of the α configuration of the 14 hydroxy group, whereas the α 
orientation of 15-OH was assigned on the basis of ROESY correlation between H-
15 and Me-18 (Figure 37) and confirmed by 13C chemical shift pattern of ring D 
nuclei.124 Thus theonellasterol G (45) was defined as 4-methylene-24(S)-
ethylcholest-8(9)-en-3β,11β,14α,15α-tetraol. Theonellasterol H (46) showed the 
same molecular formula C30H50O4 by HR ESIMS as 45. Comparison of 1D NMR 
data of both compounds showed that they differed in ring C (Tables 1 and 2). 
When compared with 45, the chemical shifts of C9, C11 and C14 in 
theonellasterol H (46) were significatively upfield shifted, whereas those of C10, 
C12 and C13 were downfield shifted. These data suggested that the pseudo-axial 
11-OH group in 45 has been replaced by a pseudo-equatorial OH, as confirmed 
from ROESY correlations H-11/Me-19 and H-11/H-1β (Figure 37). As for 45, the 
α orientation of 15-OH and 14-OH was established by ROESY correlation H-
15/Me-18 and on the basis of H-17 resonance, respectively. Therefore 
theonellasterol H (46) was defined as 4-methylene-24(S)-ethylcholest-8(9)-en-
3β,11α,14α,15α-tetraol. 
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Figure 37. Key HMBC (blue arrows) and ROESY (red arrows) correlations for theonellasterols D 
(42), F (44), G (45) and H (46). 
 
3.2 Structural determination of conicasterols B-D 
 
  
 
 
 
Figure 38. Conicasterols from Theonella swinhoei 
Conicasterol B (47) was isolated as an optically active pale yellow oil. The 
molecular formula of C29H44O, equivalent to theonellasterol B (40) less CH2, was 
established by high resolution mass spectrometry. The 1H and 13C NMR spectra of 
47 were very similar to 40 (Tables 1 and 3), with the steroid nucleus being 
identical. The only difference between compounds 40 and 47 appears to be in the 
steroidal side chain, with a methyl group at δH 0.85 (3H, d, J = 7.0 Hz) replacing 
the C24 ethyl group in 40, thus accounting for the difference in molecular formula 
between the two molecules. The stereochemistry of the side chain was determined 
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to be the same of conicasterol by comparison of 1H125 and 13C chemical shifts.122 
Thus, conicasterol B (47) is 4-methylene-24(R)-methylcholest-7,9(11),14-trien-
3β-ol.  Inspection of NMR data of conicasterols C (48) and D (49) (Tables 1 and 
3) clearly evidenced a strong resemblance with theonellasterols D and E, 
respectively. Once again the differences regarded the side chain with a methyl 
group (δH 0.88, 3H, d, J = 6.7 Hz in 48; δH 0.89, 3H, d, J = 6.8 Hz in 49) replacing 
the C24 ethyl group in compounds 42 and 43. HRESIMS analysis gave 
definitively confirmation to the structures reported in Figure 38 as a 4-methylene-
9α-methoxy-24(R)-methylcholest-8(14)-en-3β,15β-diol for conicasterol C (48) 
and a 4-methylene-24(R)-methylcholest-8(14)-en-3β,9α,15β-triol for conicasterol 
D (49). 
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Table 1. 13C NMR Spectroscopic Data (175 and 125 MHz, C6D6) for compounds 40-49.a 
Compounds 
C 
 40   41   42   43   44   45   46   47 48 49 
1 35.4 34.9 29.6 30.1 36.9 34.3 34.6 35.4 29.5 30.0 
2 33.4 32.9 33.3 33.3 33.5 32.9 33.0 33.3 33.3 33.4 
3 73.0 72.9 73.2 73.1 73.2 72.9 72.8 73.1 73.1 73.1 
4 154.0 152.9 154.3 154.2 153.4 152.4 152.7 154.2 154.3 154.1 
5 43.9 46.9 41.6 41.7 43.2 46.4 46.2 44.0 41.6 41.7 
6 26.3 21.3 25.3 24.8 31.6 20.8 20.7 26.2 25.3 24.7 
7 121.1 29.9 27.2 27.1 66.7 25.9 26.9 121.1 27.2 27.2 
8 128.4 122.5 132.2 135.4 136.7 133.6 138.4 128.3 132.1 135.3 
9 142.5 138.6 77.8 74.5 45.6 142.5 141.4 142.7 77.8 74.5 
10 38.5 40.1 45.0 43.7 40.0 37.6 38.7 38.3 45.0 43.8 
11 118.6 21.9 26.5 29.2 20.3 71.2 64.9 118.6 26.5 29.1 
12 42.7 32.3 37.5 34.5 38.1 39.9 45.0 42.7 37.4 34.4 
13 45.6 41.0 43.6 44.2 43.8 45.0 49.8 45.5 43.4 44.2 
14 148.3 65.7 153.7 150.2 151.5 89.7 83.7 148.3 153.7 150.3 
15 118.0 214.8 70.0 69.8 70.2 71.3 71.6 118.1 70.0 69.8 
16 36.2 40.7 39.4 39.4 39.5 40.0 39.6 36.2 39.4 39.4 
17 58.6 42.6 54.3 53.7 53.5 51.8 52.0 58.4 54.2 53.7 
18 18.0 22.6 18.1 18.2 19.9 20.6 19.9 18.0 18.1 18.3 
19 19.8 18.3 17.1 16.9 12.9 18.6 18.0 19.8 17.1 17.0 
20 35.0 35.4 34.6 34.5 34.6 36.9 36.9 34.9 35.0 34.9 
21 19.2 19.3 19.3 19.5 19.4 18.8 18.6 19.3 19.1 19.2 
22 34.3 33.7 34.2 34.3 34.2 34.1 34.1 33.8 33.8 33.8 
23 26.7 27.5 26.8 26.7 26.8 27.4 27.3 30.6 30.6 30.6 
24 46.6 46.3 46.6 46.6 46.7 46.6 46.5 39.2 39.2 39.2 
25 29.3 29.3 29.2 29.4 29.5 29.6 29.3 32.7 32.7 32.7 
26 19.3 19.3 19.3 19.3 19.3 19.4 19.2 18.3 18.5 18.4 
27 19.7 19.7 19.7 19.8 19.6 20.1 19.9 20.3 20.3 20.3 
28 23.5 23.4 23.5 23.5 23.5 23.6 23.4 15.5 15.5 15.6 
29 12.7 12.6 12.6 12.6 12.6 12.7 12.6 104.1 103.5 103.7 
30 104.1 103.3 103.7 103.8 103.3 103.4 103.3    
OMe   51.1      51.0  
a 13C assignments aided by COSY, HSQC and HMBC experiments. 
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Table 2. Selected 1H NMR Spectroscopic Data (700 and 500 MHz, C6D6) for compounds 40-46. 
 
aCoupling costants are in parentheses and given in hertz. 1H assignments aided by COSY experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
H 40 41 42 43 44 45 46 
3 3.67 m 3.71 dd 
(5.4, 11.0) 
3.89 dd 
(5.3, 11.2) 
3.90 m 3.79 m 3.73 dd 
(5.7, 11.0) 
3.79 m 
5 1.95 m 1.74 m 2.89 br d 
(12.4) 
2.78 br d 
(12.3) 
2.42 m 1.85 m 1.78 m 
7 6.10 br d 
(5.6) 
2.15 dd 
(5.6,18.1) 
2.51 m 
2.16 ddd 
(5.3,8.2, 13.6) 
2.52 m 
2.41 m 
2.53 ddd 
(1.8,4.8, 14.5) 
4.63 br t 
(2.9) 
2.02 dd 
(5.7,18.3) 
2.61 m 
2.10 dd 
(5.8,18.
3 
2.47 m 
9 - - - - 2.41 m - - 
11 5.50 br d 
(6.5) 
1.82 m 
2.04 m 
1.60 m 
1.75 m 
1.55 m 
1.81 m 
1.54 m 4.39 br t 
(2.9) 
4.07 d 
(7.9) 
15 5.85 br s - 4.60 br t 
(4.4) 
4.50 br d 
(6.0) 
4.58 br d 
(4.8) 
4.47 dd 
(6.0, 9.6) 
4.19 dd 
(4.9,9.6) 
17 1.73 m 2.00 m 1.64 m 1.62 m 1.64 m 2.40 m 2.35 m 
18 0.98 s 0.81 s 0.73 s 0.73 s 0.79 s 0.43 s 0.49 s 
19 0.89 s 0.82 s 0.72 s 0.71 s 0.59 s 0.59 s 0.66 s 
21 1.01 d 
(6.4) 
0.94 d 
(6.6) 
1.01 d (6.6) 1.04 d 
(6.5) 
1.02 d 
(6.2) 
0.88 d 
(6.4) 
0.90 d 
(6.4) 
26 0.90 d 
(7.0) 
0.84 d 
(6.9) 
0.91 d 
(6.8) 
0.93 d 
(6.9) 
0.93 d 
(6.2) 
0.91 d 
(6.8) 
0.91 d 
(6.8) 
27 0.92 d 
(7.0) 
0.87 d 
(6.9) 
0.93 d 
(6.8) 
0.94 d 
(6.9) 
0.94 d 
(6.2) 
0.94 d 
(6.8) 
0.93 d 
(6.8) 
28 1.22 m  
1.39 m 
1.14 m 
1.33 m 
1.23m 
1.41 m 
1.24 m 
1.42 m 
1.23 m 
1.41 m 
1.22 m 
1.42 m 
1.22 m 
1.42 m 
29 0.95 t 
(7.4) 
0.89 t 
(7.4) 
0.96 t 
(7.4) 
0.96 t 
(7.3) 
0.96 t 
(7.4) 
0.96 t 
(7.3) 
0.97 t 
(7.4) 
30 4.77 br s 
5.33 br s 
4.69 br s  
5.24 br s 
4.75 br s 
5.36 br s 
4.76 br s 
5.36 br s 
4.73 br s 
5.33 br s 
4.67 br s 
5.28 br s 
4.71 br s 
5.30 br s 
OMe   3.07 s     
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Table 3. Selected 1H NMR Spectroscopic Data (700 and 500 MHz, C6D6) for compounds 47-49. 
 
 
 
 
 
 
 
 
 
 
 
 
aCoupling costants are in parentheses and given in hertz. 1H assignments aided by COSY experiments. 
3.2.1 Pharmacological evaluation  
We have investigated whether this family of hydroxylated sterols might act as 
modulators of two well characterized nuclear receptors, the farnesoid-X-receptor 
(FXR) and pregnane-X-receptor (PXR), highly expressed in the mammalian 
livers. For this purpose compounds 40-47 and compound 49 were challenged in a 
reporter gene assay using HepG2 cells, a human hepatoma cell line. As illustrated 
in Figure 39A, all compounds, except theonellasterol G (45), that partially 
activated FXR, failed to activate FXR at the concentrations of 10 µM. By contrast, 
all compounds, with the exception of theonellasterols D (42) and H (46), 
effectively antagonized FXR transactivation induced by CDCA. It is noteworthy 
that theonellasterol G (45) behaves as an antagonist in the presence of CDCA but 
H 47 48 49 
3 3.65 m 3.89 dd 
(5.3, 11.3) 
3.89 m 
5 1.92 m 2.89 br d  
(12.4) 
2.73 br d 
(12.3) 
7 6.08 br d 
(5.6) 
2.15 ddd 
(5.3, 8.2, 13.6) 
2.51 m 
2.42 m 
2.55 ddd 
(1.8, 4.7, 14.6) 
9 - - - 
11 5.49 br d 
(6.5) 
1.60 m 
1.75 m 
1.56 m 
1.83 m 
15 5.84 br s 4.61 br t 
(4.3) 
4.51 br d 
(6.0) 
17 1.73 m 1.65 m 1.62 m 
18 0.97 s 0.73 s 0.73 s 
19 0.87 s 0.72 s 0.70 s 
21 0.97 d  
(6.4) 
0.98 d 
(6.3) 
1.01 d 
(6.6) 
26 0.85 d  
(7.0) 
0.88 d 
(6.5) 
0.89 d 
(6.8) 
27 0.90 d  
(7.0) 
0.93 d 
(6.5) 
0.93 d 
(6.8) 
28 0.85 d 
(7.0) 
0.88 d 
(6.7) 
0.89 d 
(6.8) 
29 4.77 br s  
5.33 br s 
4.74 br s 
5.35 br s 
4.76 br s 
5.36 br s 
OMe  3.07 s  
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is able to partially transactivate FXR, indicating that this agent is an FXR 
modulator. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39. Luciferase reporter assay performed in HepG2 transiently transfected with pSG5-FXR, 
pSG5-RXR, pCMV-βgalactosidase, and p(HSP27)-TK-Luc vectors and stimulated 18 h with (A) 
CDCA (10 µM) and compounds 40-49 (10 µM). (B) CDCA (10 µM) alone or in combination with 
compounds 40-49 (50 µM). *P < 0.05 versus not treated (NT). **P < 0.05 versus CDCA (n = 4). 
 
As shown in Figure 40A, at the concentration of 10 µM, all these compounds 
were PXR agonists. Interestingly, also theonellasterol G (45) acted as a PXR 
ligand, suggesting that this compound might be considered the first FXR 
modulator and PXR ligand so far identified. 
 
 
 
 
 
 
 
 
Figure 40. Luciferase reporter assay performed in HepG2 transiently transfected with pSG5-PXR, 
pSG5-RXR, pCMV-bgal, p(cyp3a4)TKLUC vectors and stimulated 18 hours with (A) rifaximin, 
10 µM, and of compounds 40-47 and compound 49, 10 µM; and (B) rifaximin, 10 µM, alone or in 
combination with compounds 40-47 and compound 49, 50 µM. *P<0.05 versus not treated (NT). 
#P<0.05 versus rifaximin (n=4). 
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Indeed, when incubated with human hepatocytes, theonellasterol G (45) increased 
the expression of OSTα, a well characterized FXR target, along with SULT2A1 
and MDR1, two well characterized PXR responsive genes (Figure 41). Thus, in 
agreement with transactivation experiments, the PCR data demonstrated that 
theonellasterol G (45) is an FXR modulator and PXR agonist.  
 
 
 
  
 
 
 
 
Figure 41. Real-Time PCR analysis of (A) BSEP; (B) OSTα; (C) SULT2A1 and (D) MDR1 
mRNAs expression carried out on cDNA isolated from HepG2 cells not treated (NT) or primed 
with 10 µM CDCA alone or in combination with 50 µM of 45 (A-B) or treated with rifaximin 10 
µM (C-D). *P<0.05 versus not treated. **P<0.05 versus cells treated with CDCA. 
 
3.2.2 Docking studies 
Based on the above mentioned results, we have then analyzed, by means of 
molecular docking calculations, the interactions of polyhydroxylated steroids 40-
47 and 49 with human FXR and PXR, in order to generate a structure-activity 
relationship and obtain informations on their binding mode at atomic level. All the 
calculations were run by Autodock4.2 software.109 As shown in the Figure 42, 
compounds 40-47 and 49 adopt the same positioning in the FXR binding site 
when compared to 6-ECDCA. Even if the junction between A/B rings is trans and 
the OH group at position 3 is in the β position with respect to the co-crystallized 
molecule, for all the complex models relative to compounds 40-47 and 49, the 
fundamental hydrogen bond contacts with the two amino acids of the catalytic 
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triad38 (namely Tyr358 in helix 7, His444 in helix 10/11) are maintained. 
Consequently, it is possible to single out two different docking poses for these 
molecules: a) the first one regards compounds containing the OH group at 
position 3 and/or the OH group at position 15 in a trans relationship (40, 41, 45-
47, Figure 42A); b) the second family includes compounds having the 3- and 15- 
OHs in a relative cis arrangement (42-44, and 49, Figure 42B). Nevertheless for 
all compounds 40-47 and 49, the steroid nucleus is able to accommodate in the 
ligand binding site, establishing hydrophobic interactions with the cavity pocket 
formed between the Helix 2, 3, 5-7, and 10/11 (Figure 42).38 Concerning the 
interactions regarding other positions, the α-OH at position 9 of 43 and 49 forms a 
hydrogen bond with Ser329 (Helix 5) and this interaction is lost when the 
hydroxyl group is replaced by a methoxy group, as in compound 42. Moreover, 
OH groups at 14α and 15α positions (compounds 45 and 46, respectively) are able 
to establish hydrogen bonds with Ser329 (Helix 5), whereas OH group at position 
15β (compounds 42-44, and 49) interacts with Leu284 (Helix 3). The carbonyl 
group at position 15 (compound 41) and the α-OH group at position 7 (compound 
44) do not exert further polar interactions with the FXR ligand binding site. 
 
 
 
 
 
Figure 42. The two different spatial arrangements of polyhydroxylated steroids 40-47 and 49 in 
the binding site of FXR (chain A of crystal structure 1OSV). A) Superposition of 6-ECDCA (light 
blue) with compounds 40 (pink), 41 (red), 45 (yellow), 46 (green), and 47 (white). B) 
Superposition of 6-ECDCA (light blue) with compounds 42 (blue), 43 (purple), 44 (dark red), and 
49 (orange). 
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Regarding the side chain, the presence of a methyl group at position 24 for 45 and 
49 allows stronger interactions with amino acids Met287 (Helix 3), Met262 (Coil 
2), and His291 (Helix 3), present on the external part of the target molecular 
surface, with respect to compounds 40 and 43 bearing an ethyl group with 
different configuration (Figure 43C). As previously reported,126-128 the activation 
of FXR receptor by bile acids and bile acid analogs is affected by simultaneous 
presence of two α-OH at position 3 and 7 and by a good balance between 
hydrophobic and hydrophilic substituents at the α and β face of the nucleus. This 
kind of interactions are missing for our compounds, and in fact all compounds, 
except theonellasterol G (45), failed in the activation of FXR at the concentration 
of 50 µM (see biological section). In particular, as depicted in Figure 43A, the β-
OH group at position 11 of compound 45 is involved in an additional hydrogen 
bond with Leu284 (Helix 3) with respect to its epimer 46 (Figure 43C), where this 
interaction is lost. Moreover, even if also 43 and 49 are able to interact with 
Ser329 (Helix 5) and Leu284 (Helix 3), they present a different spatial 
arrangement (Figures 42 and 43C) with respect to theonellasterol G (45), lacking 
some hydrophobic interactions with the amino acids of FXR ligand binding 
pocket (e.g. Trp466, Ile270, Thr267, Leu345, Figure 43). So, our docking 
calculations point out that the simultaneous interactions129 of 45 with Helix 7 
(Tyr358) and Helix 3 (Leu284) and its optimal hydrophobic contacts with LBD 
compared to compounds 46 (only interacting with Helix 7), and 43 and 49 
respectively (Figures 41 and 42), cause a great difference in activity between these 
sterols, suggesting that a correct orientation of the OH group at position 11 and 
the hydrophobic contacts with the receptor are critical for the FXR modulator 
activity.  
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Figure 43. Three dimensional models of docking pose of 45 (A, yellow), 46 (B, green), 43 (C, 
purple) and 49 (C, orange) with FXR (see text for details). 
 
For what concerns the PXR130 agonist activity, the first observation suggested by 
molecular docking analysis regards the positioning of compounds 40-47 and 49 in 
the PXR-LBD. This region is formed by hydrophobic (Phe251, Phe288, Phe429, 
Cys284, Leu206, Leu209, Leu324, Leu411, Met243, Met243, Met425, Trp299), 
polar and charged (Ser247, Ser208, His407, Asp205, Arg410, Gln285) amino 
acids; particularly crucial is the interaction of our sterols with the Ser247, 
previously reported to be involved in key interactions for the PXR agonist 
activity. In fact, this interaction is associated to the activity modulation observed 
in our series of compounds that is relative to substitution pattern of steroidal 
nucleus. It is noteworthy that 15α-OH, 15β-OH and 15-keto substitutions are all 
possible H-bond acceptor sites interacting with H-bond donor Ser247. The further 
interactions of OH group at position 7 with Ser247 for compound 44, of OH 
group at position 9 with Gln285 for 43, and of OMe group at position 9 with 
Cys284 for 42, may be responsible for the increased activity observed for these 
derivatives (Figure 44). Finally, compounds 47 and 49, featuring a methyl group 
at position 24, are endowed with a weaker agonist activity with respect to 40 and 
43, bearing an ethyl group with different configuration. Even though compounds 
47 and 49 are able to interact by their side-chain with Leu209, our models suggest 
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that their decreased activity is due to lacking interactions with Phe420, Leu411, 
and Phe429 (Figure 44). 
 
 
 
 
 
 
 
Figure 44. Three dimensional model of the most representative polyhydroxylated steroids 42 
(blue), 43 (purple), 44 (dark red), 45 (yellow) and 49 (orange) with the PXR binding pocket. 
 
In summary, a novel class of FXR/PXR modulators of marine origin has been 
discovered. Because PXR is a gene orchestrating the metabolism of xeno- and 
endo-biotics by liver and intestinal epithelial cells,9 and, usually, PXR ligands are 
not ligand for FXR, the discovery of an ancestral dual activator highlights the 
potential for the existence of similar ligands in the mammalian body. From the 
pharmacology point of view, a dual ligand holds potential in the treatment of liver 
disorders characterized by cholestasis and/or impaired metabolism of xenobiotics. 
Of relevance, because both FXR and PXR exert anti-inflammatory effects in the 
intestine, a dual ligand holds potential in the treatment of IBDs. 
3.3 Analysis of the third specimen of Theonella swinhoei 
In a recent report Crews et al.61 pointed on the existence of at least three 
phenotypes of Theonella swinhoei 131, and observed that the morphology of the 
sponge has some influence on the chemical composition. In the course of  my 
PhD experimental work, I have the opportunity of study three Theonella swinhoei 
specimens. Two of them, whose macroscopic morphology could be ascribed to 
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phenotype I, have been subjected by us to extensive chemical investigation, 
previously described, that disclosed those specimens as invaluable sources of new 
secondary metabolites, peptides, macrolides etc. On the other hand, when we 
investigated the apolar extracts, we found, in all three specimens, a great variety 
of polyhydroxysteroids all characterized by a 4-methylene functionality. In 
particular 4-methylene-steroids122,132 from phenotype I specimens mainly 
possessed a 24-ethyl side chain (Figure 36) and have been demonstrated 
modulators of FXR and PXR (see above). The analysis of the apolar extract of the 
third specimen evidenced again the presence of a family of polyhydroxy steroids 
but in this case most of them featuring a 24-methyl side chain (Figure 45, 
conicasterols G-K, 50-54), including known conicasterol (39)65 with its 7- and 15-
hydroxy derivatives (57 and 58),120 dehydroconicasterol (56),117 and the 8-14-
seco, swinhosterol B (59)133 (Figure 46). Trace of a new theonellasterol-like 
derivative, theonellasterol J (55), was also isolated.134  
3.3.1 Structural determination of  4-methylenesterols (phenotype III). 
 
 
 
 
 
 
 
 
 
Figure 45. New 4-methylenesterols isolated from Theonella swinhoei, phenotype III. 
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A molecular formula C29H46O3 was deduced from HR ESIMS (m/z 449.3611 
[M+Li]+) and 13C NMR data for conicasterol G (50). Seven degree of unsaturation 
implied by the molecular formula were ascribed to four rings, one C=O bond (δC 
203.6), also supported by strong IR adsorption at ν=1710 cm-1, one 
tetrasubstituted double bond (δC 167.5 and 130.9) and the usual methylidene 
functionality at C-4 (δC 150.6 and 104.1). The low field region of the 1H NMR 
spectrum contained, in addition to a double doublet at δH 3.59 assigned to the 3α-
proton, a broad doublet proton signal (δH 4.76) ascribable to a secondary carbinol. 
The carbonyl group was placed at C-7 on the basis of HMBC correlations (Figure 
46) from H2-6 to C-7 (δC 203.6), and of diagnostic chemical shift values and 
multiplicity of resonances of H2-6 [δH 2.16 (t, J = 16.1 Hz) and 2.37 (dd, J = 16.1, 
12.3 Hz). The placement of a conjugated double bond at 8(14) position was 
inferred by HMBC correlation (Figure 46) from Me-18 to C-14 (δC 167.5) and 
supported by 13C chemical shifts of C-9 and C-14. Finally the presence of a 
secondary hydroxy group at C-15 follows from 1H,1H-COSY correlations and 
from the key HMBC correlation H-15 (δH 4.76)/C-17 (δC 53.8). As previously 
reported,122 the configuration of the 15-OH (as depicted in Figure 45) was 
established by downfield shift exhibited by H-17 (δH 2.07). Conicasterol H (51) 
was obtained as a white amorphous powder. The molecular formula of 51 was 
determined as C29H48O3 by HR ESIMS (m/z 451.3770 [M+Li]+), 32 mass higher 
than parent conicasterol (39). Respect to 39, the 1H NMR spectrum showed the 
presence of an additional olefinic proton signal at δH 5.52. This proton showed, in 
the 1H-1H COSY spectrum 3J correlations with H2-6 at δH 1.85 and 1.99 and a 
long range coupling with H-9 at δH 2.06, consistent with a trisubstituted double 
bond at the C-7/C-8 position. The presence in the 13C NMR spectrum of only one 
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oxygen-bearing quaternary carbon, its low-field resonance (δC 97.8) and mass data 
indicated the presence of an hydroperoxy group in the molecule. As shown in 
Figure 46 the placement of this group at C-14 was inferred by diagnostic HMBC 
correlations and also confirmed by chemical shift values of ring C and D nuclei 
(Table 4). The downfield shift exhibited by H-17 (δH 2.09) was indicative of the α 
configuration of the 14 hydroperoxy group. The 1H NMR spectrum of 
conicasterol I (52, C29H48O4, as determined by HRESIMS) is almost 
superimposable to those of theonellasterol G122 with the exception of the 0.4-1.0 
ppm region where a methyl doublet [δH 0.88 (d, J= 6.8 Hz)] replaced the methyl 
triplet of a 24-ethyl theonellasterol-like side chain. Conicasterol J (53) was 
isomeric with conicasterol G (50). As for 50, NMR analysis revealed the presence 
of a tetrasubstituted double bond (δC 149.5 and 142.4), one carbonyl carbon (δC 
205.7) and one oxygen bearing methine (δC 60.9 and δH 6.27). COSY correlations 
delineated the spin system H-1 through H-7, in which the chemical shift of H-7 
(δH 6.27) implied OH substitution, whereas HMBC correlations H3-18 to C-14 (δC 
142.4), H-9 to C-8 (δC 149.5) and C-14 (Figure 46) pointed out the location of 
double bound at 8(14) position. Finally, a conjugate carbonyl was placed at C-15 
on the basis of HMBC cross-peaks between H2-16 (δH 1.94 and 2.38) and the 
carbon resonance at δC 205.7 and also confirmed by chemical shift of C-16 (δC 
42.3). The unusual downfield shift exhibited by the carbinol proton at C-7 
position (δH 6.27) could be explained involving the anisotropic effect of carbonyl 
group at C-15 position, as already reported for H-7β in 9α-hydroxy-15-
oxoconicasterol, previously isolated from a Chinese collection of Theonella 
swinhoei116. Following this consideration, the α configuration of the hydroxyl 
group at C-7 was established and confirmed by small vicinal coupling constant of 
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H-7 (br t, J = 2.9 Hz) and the relatively low-field shifts of H-5 (δH 2.46) and H-9 
(δH 2.57). The molecular formula of conicasterol K (54) was determined to be 
C29H46O, two hydrogen less respect to conicasterol (39). NMR data revealed the 
presence of two trisubstituted double bonds (Table 4). The placement of a ∆7 
double bond derived from COSY analysis that disclosed the spin system from H-1 
to H-7, in which the chemical shift of H-7 proton was indicative of its olefinic 
nature (δH 5.45, δC 102.7). The second double bond was placed at C-14 on the 
basis of HMBC correlations (Figure 46) from H-9, Me-18 and H2-16 with carbon 
resonance at δC 163.1 (C-14). Definitive confirmation to the structure 54 reported 
in Figure 45 derived from chemical shift values of the protons at C-16 (δH 1.87 
and 2.30) and their COSY correlations with the olefinic proton at δH 5.27 (H-15).  
NMR (Tables 4 and 5) and mass data clearly evidenced that theonellasterol J (55) 
shared the same tetracyclic nucleus as conicasterol K (54), while featured a 24-
ethyl side chain.  The 24R stereochemistry of the side chains of conicasterols G-K 
(50-54) and 24S of theonellasterol J (55) were determined by comparison of 1H126 
and 13C chemical shifts123.  
 
 
 
 
 
 
 
 
 
Figure 46. Key HMBC correlations for conicasterols G (50), H (51), J (53) and K (54). 
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The structures of compounds 39, 56-59 as conicasterol, dehydroconicasterol, 7α-
hydroxyconicasterol, 15β-hydroxyconicasterol, and swinhosterol B, respectively, 
were deduced by NMR and mass analysis and by direct comparison of their 
chemical shift data with existing literature values (Figure 47). 65,117,120,134 
 
 
 
 
 
Figure 47. Known 4-methylenesterols isolated from Theonella swinhoei, phenotype III. 
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Table 4. 13C NMR data for compounds 50-55 (175 and 125 MHz, C6D6).a 
C 
  50   51   52   53   54   55 
1 36.1 37.4 34.4 36.8 36.8 36.9 
2 33.1 33.2 32.9 33.1 33.3 33.1 
3 72.7 73.2 72.7 73.1 73.0 73.2 
4 150.6 152.4 152.4 152.3 152.1 152.0 
5 46.4 45.2 46.4 42.0 44.8 44.7 
6 41.8 25.4 20.9 32.5 24.2 24.1 
7 203.6 124.8 25.9 60.9 102.7 102.8 
8 130.9 136.0 133.6 149.5 154.7 154.9 
9 48.9 45.7 142.5 44.3 52.1 52.0 
10 38.9 37.4 37.7 41.7 39.3 39.3 
11 20.3 21.3 71.1 19.7 22.7 22.7 
12 36.1 31.2 39.9 37.1 46.3 46.2 
13 45.5 47.8 45.0 42.4 47.4 47.3 
14 167.5 97.8 89.7 142.4 163.1 163.1 
15 70.3 25.2 71.4 205.7 110.8 110.9 
16 37.1 27.6 40.0 42.3 31.7 31.6 
17 53.8 51.6 51.8 51.0 56.1 56.2 
18 20.4 17.1 20.5 18.7 18.5 18.6 
19 12.5 13.9 18.6 12.8 12.7 12.6 
20 34.3 36.5 35.0 35.0 35.4 35.3 
21 19.5 19.2 18.7 19.4 19.6 19.6 
22 34.0 34.2 33.7 33.7 33.4 33.1 
23 31.2 30.9 30.7 30.5 30.3 26.8 
24 39.4 39.3 39.4 39.3 39.3 46.7 
25 32.8 32.8 32.7 32.8 32.6 29.5 
26 18.5 18.6 18.6 18.5 18.6 19.4 
27 20.5 20.5 20.6 20.4 20.3 19.8 
28 15.8 15.7 15.8 15.7 15.9 23.6 
29 104.1 104.0 103.5 103.8 104.5 12.7 
30      104.5 
a 13C assignments aided by COSY, HSQC and HMBC experiments. 
Table 5. 1H NMR data for tetracyclic nucleus of compounds 50-55 (700 and 500 MHz, C6D6).a 
H 50 51 52 53 54 55 
3 3.59 dd (4.7, 11.2) 3.75 m 3.71 dd (5.8, 11.3) 3.75 dd (5.2, 11.5) 3.68 dd (5.2, 11.1) 3.69 dd (5.3, 11.1) 
5 1.63 m 1.69 dd (3.8, 11.4) 1.85 ovl 2.46 br d (13.6) 1.79 dd (4.1, 11.3) 1.78 dd (4.0, 11.4) 
6 2.16 t (16.1)  
2.37 dd (12.3, 16.1) 
1.85 m 
1.99 m 
1.44 ovl 
1.59 m 
1.59 m 
1.72 dt (3.1, 13.8) 
1.90 m  
2.09 br t (13.8) 
1.91 m 
2.09 m 
7 - 5.52 br d (5.6) 2.01 dd (5.7, 18.0) 
2.61 ddd (6.5, 11.3, 
 18.0) 
6.27 br t (2.9) 5.45 m 5.46 m 
9 1.70 m 2.06 ovl - 2.57 dd (7.6, 10.2) 1.98 ovl 1.97 ovl 
11 1.35 ovl 1.37 ovl 
1.51 m 
4.37 br t (2.6) 1.23 ovl 
1.42 ovl 
1.45 m 
1.58 ovl 
1.46 m 
1.58 ovl 
12 1.40 ovl 
1.92 br d (11.9) 
1.65 br d (13.0) 
2.07 ovl 
2.16 dd (2.6, 13.4) 
0.81 dd (1.5, 13.4) 
1.11 m 
1.88 dt (3.3, 12.3) 
1.38 m 
1.99 ovl 
1.37 br t (6.7) 
1.99 ovl 
15 4.76 br d (6.2) 1.56 ovl 
2.23 m 
4.46 dd (6.2, 9.8) - 5.27 t (2.3) 5.28 t (2.3) 
16 1.66 m 
2.33 m 
1.35 ovl 
2.17 m 
1.88 m 
1.92 m 
1.94 dd (12.6, 18.3) 
2.38 dd (7.7, 18.2) 
1.87 m  
2.30 dd (8.1, 15.3) 
1.89 m 
2.31 ddd (2.8, 8.1, 
 15.4) 
17 2.07 m 2.09 ovl 2.41 m 1.33 m 1.75 ovl 1.75 ovl 
18 0.77 s 0.72 s 0.43 s 0.80 s 1.16 s 1.15 s 
19 0.49 s 0.66 s 0.58 s 0.47 s 0.64 s 0.66 s 
aCoupling costants are in parentheses and given in hertz. 1H assignments aided by COSY experiments. 
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3.3.2 Pharmacological evaluation of  4-methylenesterols (phenotype III). 
As mentioned before, we demonstrated that specimens belonging to Theonella 
swinhoei phenotype I produce almost exclusively 24-ethylsterols (Figure 36), 
most of them endowed with potent activity towards to FXR and PXR.122 Within 
this library of compounds, we have also established that the presence of a methyl 
group at position 24 (conicasterols B-D, 47-49) allows stronger interactions in the 
external part of FXR molecular surface, with respect to compounds bearing an 
ethyl group (theonellasterols B-H, 40-46). Therefore, following this acquisition, 
all compounds isolated from Theonella swinhoei phenotype III (Figure 45,47) 
were tested in vitro, in a transactivation assay (Figure 48). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48. Luciferase reporter assay performed in HepG2 transiently transfected with pSG5-FXR, 
pSG5-RXR, pCMV-βgalactosidase, and p(HSP27)-TK-Luc vectors and stimulated 18 h with (A) 
CDCA (10 µM) and compounds 50-55, 39, 56-59 (10 µM). (B) CDCA (10 µM) alone or in 
combination with compounds 50-55, 39, 56-59 (50 µM). *P < 0.05 versus not treated (NT). **P < 
0.05 versus CDCA (n = 4). 
 
HepG2 cells were stimulated with compounds 39, 50-59 alone or in combination 
with CDCA and, as shown in Figure 48, even if none of these compounds appears 
to be an FXR agonist in the transactivation assay, several compounds, tested at the 
concentration of 50 µM, showed a slight inhibitory activity against FXR 
transactivation induced by 10 µM of CDCA with conicasterol H (51), conicasterol 
J (53), swinhosterol B (59) and the parent conicasterol (39) the most potent of this 
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series. In addition, many of these steroids effectively induced PXR expression 
with compounds 54, 55, 39 and compounds 57-59 being as effective as rifaximin 
in inducing PXR transactivation (Figure 49). 
 
 
 
 
 
 
 
Figure 49. Luciferase reporter assay performed in HepG2 transiently transfected with pSG5-PXR, 
pSG5-RXR, pCMV-βgalactosidase, and p(CYP3A4)-TK-Luc vectors and stimulated 18 h with (A) 
rifaximin (10 µM) and with 50-55, 39, 56-59 (10 µM). (B) Rifaximin (10 µM) alone or in 
combination with 50-55, 39, 56-59 (50 µM). *P < 0.05 versus not treated (NT).**P< 0.05 versus 
rifaximin (n = 4). 
Again, these data indicated that 4-methylenesterols from Theonella hold the 
potential to act as PXR agonists and FXR antagonists, and therefore the activity of 
a select sample against expression of a whole family of nuclear receptors has been 
evaluated. Among all molecules showing this dual behavior, swinhosterol B (59) 
was selected because it is a potent PXR agonist endowed with a robust FXR 
antagonism. By profiling the expression of 86 genes using a microarray system 
(Figure 50) we found that exposure of human HepG2 cells to 10 µM of 
swinhosterol B (59) had no effect on the expression of the waste majority of these 
genes. However, 59 induced the expression of ESR1, NC0A6, NR1D2, NR2C1, 
PPARGC1A, PSMC3, PSMC5, RARG, RORA and RXRA. None of these genes 
were known target for FXR or PXR. 
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Figure 50. RT2 profile PCR array analysis showing the relative mRNA expression of (A) various 
nuclear receptors, (B) histone deacetylases and (C) transcriptional co-regulators (co-activators and 
co-repressors) following stimulation of HepG2 cells with 10 µM swinhosterol B (59). Data are the 
mean ± S.E. of three experiments. 
 
Because both PXR and FXR have been shown to exert immunomodulatory effects 
on macrophages we have then investigated whether 59 modulates immune 
response of macrophages, using cells from the spleen of wild type mice, 
transgenic mice expressing the human PXR (hPXR) and the spleen of FXR 
deficient mice (FXR-/-). Results of these experiments are shown in Figures 51A-C 
and demonstrate that swinhosterol B (59) effectively counteracts stimulation of 
hPXR-macrophages caused by LPS. Indeed, at the concentration of 10 µM, 
swinhosterol B (59) causes a robust attenuation of TNFα, IL-1β and IL-6 
generation induced by LPS. 
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Figure 51. Swinhosterol B (59) abrogates stimulation of macrophages caused by LPS. Panel A-C. 
Transgenic mice expressing the human PXR were used for this experiments. Cells were stimulated 
with 5 µM LPS alone or in combination with 10 µM of 59. Data are mean ± SE of 4 spleens. 
*P<0.01 versus untreated cells (NT). **P<0.01 versus hPXR macrophages exposed to LPS alone. 
Panel D and E. Swinhosterol B (59) fails to recognize the murine PXR in macrophages prepared 
from wild type mice. Cells were stimulated with 5 µM LPS alone or in combination with 10 µM of 
59. Data are mean ± SE of 4 spleens. *P<0.01 versus untreated cells (NT). 
 
To further investigate if the FXR antagonistic profile was maintained in 
macrophages expressing the murine PXR, we have challenged spleen-derived 
monocytes with swinhosterol B (59) in the presence of LPS. As shown in Figure 
52, in this context swinhosterol B (59) fails to inhibit cytokine generation caused 
by LPS indicating that this compound activates selectively the human PXR and 
fails to recognize the murine PXR. We have then investigated whether these 
immunological effects extended to cells of adaptive immunity. For these purposes 
CD4+ T cells were prepared from the spleen on transgenic mice expressing the 
hPXR and wild type mice expressing the murine PXR. Data shown on Figure 52 
illustrate that, similarly to solomonsterol A (1), swinhosterol B (59) had no effect 
on generation of IFNγ (Figure 52A), but potently stimulated the production of IL-
10, an anti-inflammatory cytokine from cells isolated from hPXR transgenic mice 
[Figure 52B; n=4; *P<0.05 versus not treated (NT)]. The relative potency of the 
effect of swinhosterol B (59) at the concentration of 10 µM was comparable to 
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that of solomonsterol A, 10 µM, and to that of T cell activator and mitogen 
concanavallin A, 2 µg/ml. Of interest, the ability to induce IL-10 mRNA was lost 
in CD4+ T cells prepared from wild type mice, i.e. mice expressing the murine 
PXR [Figures 52C and D; n= 4; *P<0.05 versus untreated (NT)]. Thus 
swinhosterol B (59) induces generation of anti-inflammatory IL-10 via induction 
of h-PXR. 
 
 
 
 
Figure 52. Swinhosterol B (59) modulates T cell functions. Panel A and B. Transgenic mice 
expressing the human PXR were used for these experiments. CD4+ T cells were stimulated with 10 
µM of 59 or solomonsterol A (1), a potent agonist of hPXR or 2 µg/ml concanavallin A (CA). 
Data are mean ± SE of 4 spleens. *P<P0.01 versus untreated cells (NT). Panel C and D. 
Swinhosterol B (59) fails to recognize the murine PXR in CD4+ T cells prepared from wild type 
mice. Data are mean ± SE of 4 spleens. *P<0.01 versus untreated cells (NT).  
 
We finally assayed the FXR antagonistic effect of swinhosterol B (59) in HepG2 
cells stimulated with the FXR agonist CDCA. As shown in Figure 53, stimulation 
of HepG2 with 59 was itself sufficient to inhibit FXR target genes such as OSTα, 
BSEP and SHP [Figures 53A, B and C; n=3; *P<0.05 versus untreated cells 
(NT)]. In addition, when 59 was combined with CDCA, a robust down-regulation 
of FXR target genes mediated by CDCA was reported (Figures 53A, B and C; 
n=3; #P<0.05 versus CDCA stimulated cells). The antagonistic activity of 59 was 
maintained also for CYP7A1. Indeed, this gene was down-regulated by CDCA 
and this inhibition was significantly reversed by 59 co-treatment (Figure 53D; 
n=3; #P<0.05 versus CDCA stimulated cells). 
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Figure 53. Swinhosterol B (59) antagonizes FXR activity in HepG2 cells. HepG2 cells were 
stimulated with 10 µM of 59, 10 µM of CDCA or with the combination of the two. Relative 
mRNA expression of FXR targets (A: OSTα; B: SHP; C: BSEP; D: CYP7α1) was assayed by 
quantitative Real-Time PCR. Data are mean ± SE of 3 experiments. *P<0.05 versus untreated cells 
(NT); #P<0.05 versus CDCA stimulated cells.  
 
3.3.3 Docking studies (phenotype III). 
Also in this case the binding mode of the 4-methylenesterols isolated from 
Theonella swinhoei sponge (phenotype III) on FXR receptor, was rationalized by 
molecular docking experiments using Autodock 4.2 software.108 In particular, we 
used the detailed binding mode analysis of sterols with new substitution patterns 
(50 and 53) and/or with different or original nuclei (39, 54-55 and 59) to obtain 
useful information for tracing an accurate profile of new potential steroid-based 
FXR antagonists. Considering the possible hydrophilic interactions with the FXR 
ligand binding domain, we have focused our attention on 50, 53 and 59 presenting 
both carbonyl and hydroxyl groups in different position of tetracyclic nucleus. In 
this way, comparing docking results, we aimed to rationalize the influence of the 
different H-bond donor and acceptor pattern on steroids biological activity. For 
these reasons, we excluded the detailed analysis of compounds with only one OH 
group at C-7 as in compound 57 or at C-15 as in compound 58 or, as the case of 
conicasterol I (52), presenting the same nucleus of theonellasterol G, already 
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described above.121 For what concern the other compounds, comparing the diverse 
rigidity of the nucleus of conicasterol (39) vs conicasterol K (54), and 
swinhosterol B (59) combined with the different substitution at the C-24 (39, 55 
and 56), we have tried to rationalize the influence of the hydrophobic interactions 
on FXR antagonist behavior of marine steroids. On this basis, compounds 39, 50, 
53-56, and 59 are able to interact by the OH at C-3 with FXR binding triad 
(namely Tyr358 in Helix 7, His444 in Helix 10/11, Trp466 Helix12)38 (Figure 
54A), that, as previously described,38,121,135 represents one of the principal factor 
responsible of activity on this nuclear receptor. In particular conicasterol (39) and 
swinhosterol B (59), both able to antagonize CDCA (see biological section), form 
hydrogen bonds with Tyr358 (Helix 7) and His444 (Helix 10/11); on the other 
hand conicasterol G (50), conicasterol J (53), theonellasterol J (55), and 
dehydroconicasterol (56) interact only with the hydroxyl group of Tyr358 (Helix 
7). Comparing the docking pose of our series with respect to the co-crystallized 
agonist 6-ECDCA and the isomers E and Z of gugglusterone, it is evident that all 
the molecules bind FXR-LBD between the Helix 2, 3, 5-7, and 10/11.  
 
 
 
 
 
 
 
Figure 54. (A) Superimposition of 6-ECDCA (sky blue), and Z (yellow)/E (blue) gugglusterone 
with 50 (orange), 53 (pink), 54 (dark green), 55 (light blue), 39 (red), 56 (brown), and 59 
(emerald) in the binding pocket of FXR (pdb code:1OSV). The FXR molecule is depicted by 
purple ribbon and the crucial amino acids by sticks (by atom type: C, purple; O, red; N, dark blue, 
H, white). (B) Amino acids interacting with 6-ECDCA (sky blue) and Z (yellow)/E (blue) 
gugglusterone are depicted in black; amino acids interacting with 39 (red) are depicted in green. 
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Also the molecule side chain, as reported above, influences the activity on FXR; 
in fact, the methyl group at position 24 of conicasterol (39) (red), conicasterol K 
(54) and swinhosterol B (59) is in close contact with Ile332 on the surface 
receptor with respect to theonellasterol J (55), bearing an ethyl group with 
different configuration at the same position (Figure 55A). On the other hand, the 
major rigidity of the side chain of dehydroconicasterol (56) in comparison with 
the parent conicasterol (39) (red) does not allow further hydrophobic interactions 
with Met262 (Coil 2) and His291 (Helix 3). Moreover, the different positioning of 
the unsaturations of conicasterol K (54) and theonellasterol J (55) with respect to 
conicasterol (39) and dehydroconicasterol (56) causes a further loss of 
hydrophobic interactions with the amino acids Leu284, Ile349, and Ile354 (Figure 
55A). On the other hand, the unusual open nucleus of swinhosterol B (59) 
maintains the same hydrophobic interactions with respect to 39 with the exception 
of Leu284 and Met262 (Figure 55A). Considering the other nucleus substitutions, 
the inverted positions of CO and OH groups at C-7 and C-15 of conicasterols G 
(50) and J (53) cause a different pattern of hydrogen bonds; in fact conicasterol G 
(50) is in close contact only with Ser329, while the α-OH at C-7 of conicasterols J 
(53) forms two hydrogen bonds with FXR binding pocket, as H-bond acceptor 
with OH of Ser329 and as H-bond donor with the OH group of Tyr366. Moreover 
its CO at C-15, as well as the carbonyl group at C-14 of 59, establishes a further 
weak interaction with Ser329 (Figure 55B). 
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Figure 55. (A) Superimposition between 54 (dark green), 55 (light blue), 39 (red), 56 (brown), and 
59 (emerald) in the FXR binding site. (B) Three dimensional model of the different hydrogen bond 
pattern of 53 (pink), 50 (orange) and 59 (emerald) with FXR. In both figures the crucial amino 
acids of FXR receptor are depicted by purple sticks. 
 
Swinhosterol B (59) was studied in PXR-LBD and three different docking poses 
are possible. As shown in Figure 56, the OH at C-3 forms hydrogen bonds with 
CO of Gln285, OH of Ser247, and with CO of His407 for the docking poses A, B, 
C, respectively. The CO at C-8 establishes further hydrogen bonds with OH of Ser 
247 for pose A, while the CO at C-14 interacts with NH of His407 for poses A 
and B. Besides the different pattern of hydrogen bonds, all the three poses 
establish different Van der Waal interactions with PXR large ligand binding 
pocket (Figure 56) formed by hydrophobic (Cys284, Leu206, Leu209, Leu239, 
Leu240, Leu411, Met243, Met423, Met425, Phe288, Phe420, Trp299, Val211), 
polar, and charged (Arg410, Tyr306) amino acids. 136,137,138 
 
 
 
 
 
 
Figure 56. Three dimensional models of the possible docking poses (A-C) of swinhosterol B (59) 
with hPXR. 
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CHAPTER 4 
 
FXR MODULATORS 
Among nuclear receptors, farnesoid-X-receptor (FXR) has emerged as a valuable 
pharmacological target28,139-142  due to its role in regulating bile acids (BAs), lipid 
and glucose homeostasis. After its de-orphanization35,37 a number of 
nonsteroidal39 and steroidal compounds,126 have been shown to interact with the 
ligand binding domain (LBD) of the receptor and to promote FXR mediated gene 
transcription. Among these, 6-ECDCA has emerged as a potent, orally 
bioavailable, FXR agonist41 and ongoing clinical trials have shown its utility in 
the treatment of type 2 diabetes.143 In this scenario the discovery of FXR ligands 
represents an important answer to the urgent demand of new drugs for the 
treatment of relevant human diseases including dyslipidemia, cholestasis, non-
alcoholic steatohepatitis (NASH) and type-2 diabetes. Nevertheless the use of 
potent FXR agonists holds some potential risk. Indeed, it has been shown that 
FXR activation in mammalian cells and tissues inhibits biosynthesis of 
endogenous bile acids by indirect transrepression of cholesterol-7alpha-
hydroxylase (CYP7A1), a gene encoding for the first and rate limiting enzyme 
involved in their biosynthesis. This effect is indirect and mediated by activation of 
SHP (small heterodimer partner), an atypical nuclear receptor lacking the DNA 
binding domain, that binds to liver-X-receptor (LXR) causing its displacement 
from a positive regulatory element in the CYP7A1 promoter. Despite the effect of 
SHP has been shown to be dispensable in some settings, it is well recognized that 
SHP activation amplify the effects of FXR on bile acids uptake and biosynthesis, 
strongly suggesting that identification of SHP-sparing FXR modulators and FXR 
Chapter 4 
91 
 
antagonists might have the potential to promote bile acid detoxification without 
interfering on the biosynthesis. Indeed, FXR antagonists/modulators are rare and 
to date only few molecules are endowed with this pharmacological profile. The 
main contribute has been derived from natural compounds. Guggulsterone, the 
active components of the resin extract of the tree Commiphora mukul,43 and 
xanthohumol,144 the principal prenylated chalcone from beer hops, were the first 
examples of FXR antagonists to be reported from Nature. However 
Guggulsterone is a promiscuous agent which binds and actives PXR and GR at 
concentrations that are approximately 100 fold lower than required for FXR 
antagonism. In this context the sea has recently emerged as an available source of 
scalarane sesterterpenes,145 isoprenoids146 and polyhydroxylated sulfated 
steroids135 as FXR antagonists. Once again a considerable contribute derivated 
from the sponge Theonella swinhoei. As mentioned in chapter 3, analysis of the 
apolar extracts allowed the isolation of a small library of 4-methylenesteroids 
proved to be potent PXR agonist able to antagonize the effect of CDCA on human 
FXR. 121,134 Within this series, we found also conicasterol E (60), a 7α,15β-
dihydroxyconicasterol derivative, as the first example of SHP-sparing FXR 
modulator endowed with PXR agonistic activity from a marine source. 
Furthermore, in order to prove its efficiency in transactivation assays in 
comparison to a well validated FXR agonist, we have generated a novel synthetic 
strategy to obtain 6-ECDCA, a widely used CDCA derivative.147 
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Figure 57. Conicasterol E (60), the first example of SHP-sparing marine FXR modulator, and 6α-
ethyl-chenodeoxycholic acid (61). 
 
4.1 Isolation and structural characterization of conicasterols E (60) 
The initial processing of the Theonella swinhoei (coll. No. R3159) was 
conducted according to procedures previously described.74 The n-hexane 
extract from a solvent partitioning Kupchan procedure was cromatographed by 
silica gel and the fraction eluted with CH2Cl2:MeOH (96:4) was further 
purified by reverse phase HPLC to give 2.1 mg of conicasterol E (60) as a 
colourless amorphous solid ([α]D25 +59.6). The molecular formula of 
C29H48O3, established by HR ESIMS, [M+Li]+ at m/z 451.3769 (calculated 
451.3763) and NMR data (Table 18) were compatible with a steroidal 
tetracyclic nucleus, two double bond and three hydroxyl groups in the 
molecule. COSY correlations delineated the spin system H-1 through H-7 and 
the spin system H-15/H-17 with OH substitutions at C-7 (δH 4.63) and at C-15 
(δH 4.57) whereas the presence of a ∆8(14) double bound was inferred from 
careful analysis of HMBC data reported in the Table 18 and in Figure 58. The 
small vicinal coupling constant of H-7 (br t, J=2.9 Hz) allowed us to establish 
an equatorial disposition for this proton, thereby placing the hydroxyl group in 
an axial α-orientation, while the ROE effect H-15/H-17α (Figure 58) was 
indicative of a β-orientation of the hydroxy group at C15. 
HO
OH
OH
Conicasterol E (60)
H
COOH
HO OH
H
6-ECDCA (61)
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Figure 58. COSY connectivities (bold bonds), HMBC (blue arrows) and ROESY correlations (red 
arrows) for conicasterol E (60). 
 
Comparison with NMR data of theonellasterol F (44) evidenced a strong 
resemblance with conicasterol E. The difference between 60 and theonellasterol F 
(44) lies in the side chain with a methyl group (δH 0.88, 3H, d, J = 6.7 Hz ) 
replacing the C24 ethyl group present in all theonellasterol -like compounds.  
Table 6. NMR data (500 MHz, C6D6) for 60. 
position δH δC Key HMBC 
1 1.11 m, 1.52 ovl 36.7  
2 1.30 ovl, 1.82 m 33.4  
3 3.77 m 73.4  
4 - 153.3  
5 2.41 m 43.2  
6 1.65 ovl, 1.91 ovl 31.7  
7 4.63 br t (2.9) 66.6  
8 - 136.7  
9 2.40 m 45.5  
10 - 40.0  
11 1.54 ovl 20.3  
12 1.31 ovl, 1.92 ovl 38.1  
13 - 43.8  
14 - 151.5  
15 4.57 br d (4.8)  70.1 C13, C14, C17 
16 1.50 ovl, 1.66 ovl 39.5 C13, C14, C15, C17 
17 1.64 ovl 53.4 C13, C14, C15 
18 0.79 s 19.8 C12, C13, C14, C17 
19 0.59 s 12.7 C1, C5, C9, C10 
20 1.43 m 34.6  
21 1.00 d (6.3) 19.1  
22 1.20 m, 1.48 m 33.7  
23 1.16 m, 1.47 m 30.6  
24 1.33m 39.3  
25 1.59 m 32.8  
26 0.88 d (6.7) 18.6 C24, C25 
27 0.94 d (6.7) 20.4 C24, C25 
28 0.87 d (6.8) 15.7 C23, C24, C25 
29 4.72 br s, 5.32 br s  103.3 C3, C4, C5 
 
HO
OH
OH
H
H
60
H
Coupling constants are in parentheses and given in hertz.1H and 13C assignments aided by COSY, 
TOCSY, ROESY, HSQC and HMBC experiments. 
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4.2 New synthetic strategy of 6-ECDCA (61) 
 
So far two synthetic procedures of 6-ECDCA have been reported. The first 
process was based on the alkylation of the 3-tetrahydropyranyloxy derivative of 7-
keto-lithocholic acid (LCA) with lithium diisopropylamide and ethyl bromide 
followed by standard reduction and hydrolysis steps.41,148 Our preliminary 
screening of this synthesis revealed low-yielding steps, especially in the alkylation 
of 7-keto-LCA, and the need for chromatographic purification of each step. 
Recently an alternative procedure149 via aldol-type addition of a silyl enolether 
derivative of 7-keto-LCA methyl ester with acetaldehyde, followed by 
hydrogenolysis with PtO2, alkali hydrolysis (10% NaOH in refluxing methanol) 
and selective reduction of the C7-ketone with sodium borohydride has been 
reported (58% overall yield from 7-keto-lithocholic acid).  Despite our extensive 
effort, we faced several problems in reproducing the reported high yield in the 
hydrolysis and reduction steps. In fact the hydrolysis of methyl ester in alkaline 
condition proceeded with low yields and extensive epimerization at C-6 position 
due to the presence of the carbonyl group at C-7. Alternatively we tested the 
possibility to invert the last two steps of the reported protocol and to perform 
firstly the C-7 reduction followed by methyl ester hydrolysis. Despite the reported 
regio- and stero-selectivity of NaBH4 reduction, in our hand the reduction of 
methyl 3α-hydroxy-6α-ethyl-7-keto-5β-cholan-24-oate proceeded with the 
formation of large amount of the over-reduced product with the primary alcoholic 
function at C-24 and with scarce stereoselectivity in the introduction of hydroxyl 
group at C-7 with the required α-configuration. To overcome the inconvenience 
relaying on the coexistence of C-7-ketone and C-24-methyl ester, we initially 
attempted to perform the generation of silyl enolether on the 7-keto-LCA without 
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the protection of the carboxyl function at C-24 but, although our several efforts 
(DIPA, BuLi, TMSCl, Et3N, THF, -78 °C one pot procedure; generation of 3α-
silyl ether with Et3N and TMSCl followed by LDA/TMSCl formation of 
enolether), no transformation occurred. At this point we decided to protect the 
carboxyl function at C-24 as benzyl ester. The choice of benzyl as protecting 
group answered to two essential demands: reduction of synthetic steps in order to 
achieve better chemical yield and, importantly, improvement of regio- and 
stereoselectivity of the entire process. The synthesis of 61 starting from 
commercially available chenodeoxycholic acid is outlined in Scheme 8. Oxidation 
with sodium hypochlorite solution/NaBr and tetrabutylammonium bromide in a 
mixture of methanol/acetic acid/water/ethyl acetate as solvent afforded 7-keto-
lithocholic acid in nearly quantitative yield and without trace of 3-keto 
regioisomer and di-oxidated product. Benzylation, generation of silyl enolether 
followed by aldol addition with acetaldehyde in the presence of BF3.OEt2 gave the 
desired benzyl 3α-hydroxy-6-ethylidene-7-keto-5β-cholan-24-oate (65) in 42% 
yield over four steps. High selective reduction of the C7-ketone with 
NaBH4/CeCl3 in a mixture of THF/MeOH at room temperature followed by 
concomitant removal of the benzyl-protecting group and reduction of exocyclic 
double bond (H2 on Pd/C Degussa type) afforded the desidered 6-ECDCA (61). In 
vitro pharmacological screening demonstrated that the so obtained 6-ECDCA (61) 
is a potent FXR agonist (Figure 59). 
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Scheme 8. Reagents and conditions: (a) NaOCl/Bu4N+Br-, NaBr, 0 °C; (b) BnBr, Cs2CO3, CH3CN, 
reflux; (c) DIPA, n-BuLi, TMSCl, Et3N, THF, -78 °C; (d) MeCHO, CH2Cl2, BF3.OEt2, -60 °C; (e) 
NaBH4/CeCl3, THF/MeOH 4:1; (f) H2, Pd/C, THF/MeOH 1:1.  
 
4.2.1 Pharmacological evaluation 
Conicasterol E (60) was tested in vitro using a luciferase assay on HepG2 cells 
transfected with FXR. As shown in Figure 59, conicasterol E was almost as potent 
as the natural FXR ligand CDCA in transactivaring FXR, but less potent than the 
synthetic FXR ligand 6-ECDCA (61) (Figure 59). Conicasterol E (60) was devoid 
of any antagonistic activity when co-administered with CDCA (Figure 59B) and 
6-ECDCA (data not shown). 
 
 
 
 
 
 
 
Figure 59. Panel A. Relative potency of FXR activation by CDCA, 10 µM, conicasterol E (60), 10 
µM, and 6-ECDCA (61), 1 µM, as measured by transactivation assay in HepG2 cells. Panel B. 
Conicasterol E (60), 10 µM, does not revert the effect of CDCA, 10 µM, on FXR transactivation in 
HepG2 cells. Panel C. Relative potency of PXR activation by rifaximin, 10 µM, and conicasterol E 
(60) alone, 10 µM, or in combination, 50 µM. Data are mean ± SE of 4 experiments. 
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In addition to an FXR agonistic activity, conicasterol E (60) effectively induced 
PXR expression, being as effective as rifaximin in inducing PXR transactivation 
(Figure 59C). Thus conicatserol E (60) is an FXR and PXR agonist. To further 
characterize the biological activity of the conicasterol E (60), we have examined 
the effect of this agent on the expression of canonical FXR and PXR target genes 
in hepatocytes, and, as shown in Figure 60, we found that exposure to conicasterol 
E slightly increased the expression of OSTα and BSEP mRNAs (two FXR 
regulated genes) and the expression of CYP3A4 mRNA (a PXR-regulated gene), 
while no effect was observed on SHP mRNA expression. In addition, in contrast 
to CDCA, 60 failed to repress CYP7A1. Thus, while the expression of this gene 
was reduced by 30% by CDCA, exposure to conicasterol E (60) increased 
CYP7A1 mRNA by 2-3 folds. These data are a further evidence that in HepG2 
cells repression of CYP7A1 by FXR is indirect and requires induction of SHP. 
 
 
 
 
 
 
Figure 60. RT-PCR analysis of effects of CDCA, 10 µM, and conicasterol E (60), 10 µM, on 
expression of FXR-regulated genes in HepG2 cells. Conicasterol E (60) does not induce SHP and 
fails to repress the expression of CYP7A1. Data are mean ± SE of 4 experiments. 
 
Further on, when administered in combination with a concentration of CDCA of 
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SHP (Figure 61). Taken together, these data highlight that conicasterol E (60) is a 
FXR modulator whose potency on selective target genes is very close to that of  
the endogenous mammalian ligand CDCA and lower than that of a synthetic 
agonist 6-ECDCA. Interestingly, conicasterol E (60) failed to stimulate SHP even 
when co-administered in combination with CDCA. 
 
 
 
 
 
 
 
Figure 61. RT-PCR analysis of effects of CDCA, 10 µM, alone or in combination with 
conicasterol E (60), 10 µM, on expression of FXR-regulated genes in HepG2 cells. Conicasterol E 
(60) does not induce SHP even when cells were co-incubated with CDCA while the association of 
the two agents induce a robust expression of OSTα and BSEP.  Data are mean ± SE of 4 
experiments. 
 
Finally, analysis of CYP3A4 expression, shown in Figure 62, demonstrated that 
conicasterol E (60) has no antagonistic effects on expression of CYP3A4 mRNA 
induced by rifaximin, a potent PXR agonist. 
 
 
 
 
 
 
 
Figure 62. Activation of CYP3A4 by the PXR agonist rifaximin, 10 µM, is not modulated by  
conicasterol E (60) 50 µM . Data are mean ± SE of 4 experiments. 
 
4.2.2 Docking studies 
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located between the Helix 2, 3, 5-7 and 10/11, is occupied by 60 and, as 
previously reported,121 the β-OH groups at position 3 and 15, and the trans 
junction between A/B rings cause a different positioning with respect to the co-
crystallized molecule 6-ECDCA. In particular (Figure 63B) conicasterol E, 
compared to the synthetic agonist 6-ECDCA, is able to interact with two amino 
acids of the catalytic triad formed by Tyr358 in Helix 7, His444 in Helix 10/11, 
Trp466 Helix12, responsible of the activation of FXR.38 Specifically, the 3-OH 
group at β position forms a hydrogen bond with Tyr358 in Helix 7, while the trans 
junction between the A/Bring allows the hydrophobic interaction with His444 
(Helix 10/11). In previous chapter, we have described the influence of the side 
chain on the FXR binding; in fact, the methyl at position 24 of conicasterol E 
(yellow, Figure 63B) relating to 6-ECDCA (red, Figure 63B) is able to 
simultaneously interact with the Met262 (Coil 2), His291 (Helix 3), and Met287 
(Helix 3), present on the external part of the receptor molecule. Moreover, the OH 
at position 15β in 60 forms an additional hydrogen bond with the CO of Leu284 
(Helix 3), and the steroid skeleton is in close contact with Leu345, Ala288, 
Met447, Phe326 and Trp451 relating to the 6-ECDCA. On the other hand, the OH 
at 7α position does not seem to exert further polar interactions with the FXR 
binding site. 
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Figure 63. (A) Superimposition of 60 (yellow) with 6-ECDCA (red) in the binding pocket of FXR 
(pdb code:1OSV).Errore. Il segnalibro non è definito. (B) Amino acids interacting with 6-ECDCA (red) are 
depicted in white, amino acids interacting with 60 (yellow) are depicted in pink, and amino acids 
interacting with both molecules are depicted in blue. 
 
In summary, respect to the other 4-methylene-steroids endowed with FXR 
antagonistic profiles, the exclusive amino acid interactions exerted by conicasterol 
E (60) might support the notion that the compound is FXR agonist endowed with 
the ability to activate OSTα and BSEP without effect on SHP expression. These 
studies pave the way to further elaborating on the critical interactions on the FXR-
LBD aimed to the identification of site-specific ligand that could be used to 
induce selective genes.  
4.3 Theonellasterol, a new lead in cholestasis 
Cholestasis is a liver disorder that occurs primarily in the context of genetic 
mutation of basolateral or apical membrane transporters in hepatocytes. 
Cholestasis represents the main biochemical feature of primary biliary 
cirrhosis141,150 (PBC) and sclerosing cholangitis (PSC), two immune-mediated 
disorders characterized by progressive bile duct destruction for which medical 
therapy is still poorly effective and investigations are ongoing to identify novel 
therapeutic approaches. Theoretically, because PBC and PSC are characterized by 
bile duct destruction, therapy should be aimed at activating bile acid secretion 
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from the basolateral membrane of hepatocytes, while stimulation of bile acid 
secretion from the apical membrane is likely to worsens liver injury due to the 
obstruction of bile flow.141,150 While FXR activation favours bile acid 
detoxification by hepatocytes and FXR agonists have been proposed in the 
treatment of PBC patients,141 results from models of obstructive cholestasis in 
FXR2/2 mice have shown that FXR gene ablation protects against liver injury 
caused by ligation of common bile duct (BDL).151 Molecular decoding of the 
BDL model has lead to the demonstration that FXR functions as a negative 
regulator of multidrug resistance-associated protein (MRP)-4, a gene mediating 
basolateral secretion of bile acids. In vitro characterization of interaction of FXR 
with MRP-4 has lead to the demonstration that FXR functions as a braking signals 
for MRP-4 induction caused by activation of Constitutive Androstane Receptor 
(CAR).152 In aggregate, these data suggest that FXR activation in obstructive 
cholestasis might worsen liver injury by hijacking a protective mechanism 
regulated by CAR, i.e induction of MRP-4.143 While these data strongly advocate 
the utility of an FXR antagonist in the treatment of obstructive cholestasis, this 
concept has remained unproved for long time because the lack of a selective FXR 
antagonist. As detailed before, the major component of the steroidal fraction of 
Theonella swinhoei is theonellasterol (38),153 which is proposed as a taxonomic 
marker for the Theonella sponge phenotypes65 and the biogenetic precursor of all 
theonellasterols like 4-methylene steroids so far isolated. During the extraction 
procedure of 4-methylene steroids, theonellasterol (38) was isolated in high 
amounts following a very simple procedure. Following our acquisition of the 
ability of 4-methylene steroids to act as NRs ligands, theonellasterol (38) was 
evaluated on FXR in a luciferase transactivation assay. As shown in Figure 64A 
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and B, stimulation of HepG2 cells with 10µM of theonellasterol (38) failed to 
activate FXR. By contrast theonellasterol (38) effectively antagonized FXR 
transactivation induced by CDCA.  
 
 
 
 
 
  
 
 
 
 
Figure 64. Luciferase reporter assay performed in HepG2 transiently transfected with pSG5-PXR, 
pSG5-RXR, pCMV-bgal, pCYP3A4promoter-TKLuc vectors and stimulated 18 h with (A) 10 mM 
of CDCA or theonellasterol (38) and (B) 10 mM of CDCA alone or in combination with 
theonellasterol (38) 50 mM. (C) CHiP assay of NCoR binding to the OSTa promoter. RT-PCR 
analysis of proteins immune-precipitated with a control IgG are shown as control.  
 
The antagonistic activity was further confirmed examining the effect of 
theonellasterol (38) on the expression of canonical FXR target genes150. 
Theonellasterol (38) reversed the effect of CDCA on the expression of OSTα, 
BSEP, SHP and MRP-4 (Figure 65A–C; n =4; P,0.05 versus CDCA alone). 
Because the regulatory activity of theonellasterol (38) on MRP-4 holds promise 
for its potential therapeutic use in obstructive cholestasis, the antagonistic activity 
of theonellasterol (38) on MRP-4 was examined from a molecular point of view. 
For this purpose a ChIP assay was carried by immune-precipitating nuclear 
extracts from HepG2 cells left untreated or primed with CDCA alone or with the 
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combination of CDCA plus theonellasterol (38) with an anti-FXR antibody. As 
shown in Figure 65E, results of Real-Time PCRs demonstrated that while in basal 
conditions FXR is not constitutively bound to the MRP-4 promoter, but is 
recruited on the promoter following activation with CDCA. Recruitment of FXR 
to the MRP-4 promoter in the presence of CDCA was robustly attenuated by co-
incubating the cells with the theonellasterol (38) (n= 4; P,0.05 versus CDCA 
alone). All together these results indicate that theonellasterol (38) exerts its 
antagonistic activity by reducing the binding of FXR on the MRP-4 promoter, 
thus preventing its down-regulation caused by CDCA (Figures 65D and E). Thus, 
as illustrated in Figure 64C, the ChIP analysis demonstrates that while exposure to 
CDCA, 10 µM, released NCoR from the OSTα promoter, co-treating cells 
challenged with CDCA with the theonellasterol (38), 50 µM, abrogated this 
pattern (n= 3; P,0.05 versed CDCA alone). Finally, exposure of HepG2 cells to 50 
µM theonellasterol (38) effectively stabilized the nuclear corepressor NCoR at its 
binding site in the promoter of OSTα, a well characterized FXR-regulated gene. 
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Figure 65. Relative mRNA expression of (A) OSTa, (B) BSEP, (C) SHP and (D) MRP4 in HepG2 
cells treated with 10 mM CDCA alone or with the combination of CDCA plus theonellasterol (38) 
50 mM. (E) CHiP assay performed in HepG2 cells not stimulated or primed with CDCA, 10 mM, 
alone or in combination with theonellasterol (38) , 50 mM. 
Moreover theonellasterol (38) was demonstrated the first example of selective 
FXR antagonist. As shown in Figure 66A–D, theonellasterol (38) at the 
concentration of 10 µM failed to transactivate PPARγ, PXR, VDR and GR, nor it 
inhibited the activation of these receptor promoted by specific ligands, i.e. 
rosiglitazone, rifaximin, 1,25 dihydroxy colecalciferol and dexamethasone when 
co-incubated with these selective agonists at the concentration of 50 mmol/L. In 
addition microarray analysis demonstrated that theonellasterol (38) itself had no 
effect on the expression of any of these regulatory factors (not shown) and the 
sponge steroid caused no changes in the expression of these nuclear receptors and 
regulatory factors in cells challenged with CDCA. 
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Figure 66. (A) (C) and (D) HepG2 cells were co-transfected with the Gal4 luciferase reporter and 
a series of chimeras in which the Gal4 DNA binding domain is fused to the LBD of the indicated 
nuclear receptors. Cells were treated with the appropriate agonists or specific agonists in 
combination with theonellasterol (38). (B) HepG2 cells were co-transfected with pSG5-PXR, 
pSG5-RXR and with the reporter pCYP3A4promoter-TKLuc and then stimulated with rifaximin, a 
PXR agonist, alone or in combination with theonellasterol (38). E) Microarray analysis showing 
the relative mRNA expression of various nuclear receptors and nuclear receptors co-activators 
following stimulation of HepG2 cells with CDCA, 10 mM, alone or in combination with 
theonellasterol (38) 50 mM.  
 
Because these data illustrate that theonellasterol (38) is a selective FXR 
antagonist, it was designed a proof-of-concept study to ascertain whether this 
compound was effective in attenuating liver injury caused by BDL in mice, a 
model of obstructive cholestasis that is attenuated by FXR gene ablation.151 For 
this purpose BDL mice were administered the theonellasterol (38), 10 mg/kg, or 
an FXR agonist, 6-ECDCA (61), 30 mg/kg, for 3 days. In this model 
theonellasterol (38) reduced intrahepatic bile duct pressure and attenuated liver 
injury caused by bile duct ligation as measured by serum alanine aminotransferase 
(ALT) levels and  extent of liver necrosis at histopatology. On the contrary 
administering bile duct legated mice with 6-ECDCA (61) failed to rescue from 
liver injury (Figure 67-68). 
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Figure 67. (A) Common bile duct dilation, 3 days after BDL, is worsened by 6-ECDCA (61) and 
attenuated by theonellasterol (38). (B) Representative macroscopic features of common bile duct 
(white arrows) in 3-day BDL mice administered theonellasterol (38) and 6-ECDCA (61). (C) BDL 
increases serum levels of alkaline phosphatase, a marker of bile duct obstruction. (D) Serum 
concentration of total bile acids. (E) Quantitative analysis of tauro-conjugated bile acids in BDL 
animals.  
 
 
 
 
 
 
 
 
Figure 68. (A and B) Liver necrosis was robustly attenuated by theonellasterol (38) as confirmed 
by assessment of ALT and histopathology analysis. C) Representative liver histology from an 
individual mice per group. Liver sections were stained with H&E, original magnification 106. 
 
4.4 Preliminary Structure-Activity Relationship on Theonellasterol 
Having established the therapeutic potential of theonellasterol (38) in cholestasis, 
the effect of chemical transformations on its biological activity and the first 
structure-activity relationship (SAR) study have been performed in the last period 
of my research work.154 As the highly hindered 8,14 double bond was found to be 
chemically unreactive toward most chemical reagents, two are the points for 
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chemical modification in the structure of theonellasterol (38): the exocyclic 
carbon-carbon double bond at C-4 and the hydroxyl group at C-3. These 
functionalities were subjected to simple chemical reactions and the products 
obtained (67–77) were fully characterized by means of MS, and 1D and 2D NMR 
spectroscopy. The methyl ether derivative (67), the 3-O-acetyl derivative (68) and 
the α,β-unsaturated ketone (69), already known as theonellasterone,65 were 
prepared from theonellasterol (38) (Scheme 9) to explore the pharmacophoric role 
of the hydroxyl group at C-3 as hydrogen bond donor in the FXR-LBD (Scheme 
9). 
 
 
 
 
 
 
 
 
Scheme 9. Modification at C-3 hydroxyl group. Reagents and conditions: (a) NaH, THF, MeI, 0 
°C, 79%; (b) Ac2O, pyridine (pyr), room temperature (rt), 96%; (c) PCC, CH2Cl2, quantitative 
yield.  
 
As concern the exomethylene on ring A, hydrogenation of theonellasterol (38) on 
different catalysts (Pt/C, Pd(OH)2 Degussa type, PtO2) produced exclusively the 
4β-methyl derivative (70) through the approach of the hydrogen from the α-face 
of the steroid nucleus (Scheme 10). To obtain the 4α-methyl theonellasterol 
derivative, a synthetic procedure via theonellasterone (Scheme 10) was set up. 
Theonellasterone (69) was reduced to a mixture of the two 4-methyl 
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diasteroisomers (H2, 10% Pt/C, THF/MeOH), 71 and 72, which were efficiently 
separated by HPLC. In the 1H NMR spectrum of 72, H-4 was observed as a 
double quartet (2.05, dq, J = 14.2, 6.1 Hz) and the large coupling constant with H-
5 clearly pointed towards its axial position, thus implying the α-orientation of the 
methyl group at C-4. Chemical correlation gave definitive confirmation of the 
above stereochemical assignment. As depicted in Scheme 10, for the concomitant 
steric effect played by Me-19 and Me-30, both orientated on the β-face of the 
steroidal nucleus, NaBH4 reduction of 71 afforded exclusively 3β-hydroxy-4β-
methyl steroisomer (70). On the other hand, reduction of  72 gave a mixture of 3β-
hydroxy-4α-methyl theonellasterol derivative (73) with its C-3 epimer, 3α-
hydroxy-4α-methyl- derivative (74). As previously reported for several natural 
and synthetic 4-methyl cholestane derivatives,155 in the 4α-methyl-3β-ol 
derivative (73), the 3α-proton resonance is consistently shifted upfield with 
respect to the corresponding resonances in the 4α-methyl-3α-ol (74) and 4β-
methyl-3β-ol diasteroisomers (70) (δH 2.93 in 73, δH 3.55 in 74, δH 3.54 in 70), 
thus substantiating the stereochemical assignment reported in Scheme 10. 
Moreover in the 1H NMR of 74, H-3 was observed as a broad multiplet, allowing 
its assignment as equatorial and therefore establishing the orientation of the 
hydroxyl group at C-3 on the α-face of the molecule. To access the 4β-methyl-3α-
ol derivative, the 4β-methyl theonellasterol derivative (70) was subjected to a two 
step sequence involving treatment with tosyl chloride in pyridine followed by 
potassium acetate in DMF/H2O (Scheme 10). Unfortunately the basic treatment of 
the 3-O-tosyl intermediate produced β-elimination with the formation of 
derivative 75 with the 3,4 double bond. Nevertheless, 75 could be instrumental in 
the evaluation of the pharmacophoric role played by the oxygen atom on ring A. 
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Scheme 10. Modification at C-4 double-bond. Reagents and conditions: (a) H2, 10% Pt/C, 
THF:MeOH 1:1; (b) NaBH4, absolute MeOH, 0 °C; (c) TsCl, pyr, rt; (d) CH3COOK, DMF:H2O 
7:1, reflux, 75%, over two steps. 
 
Finally we decided to investigate the effects of the introduction of a polar group at 
C-4 in the binding of theonellasterol (38) in FXR-LBD. Oxidative cleavage with 
ozone (O3, CH2Cl2, −78 °C, 5 min) followed by dimethylsulfide or NaBH4 work-
up afforded the 4-keto derivative (76) and the 4-hydroxy derivative (77), 
respectively (Scheme 11). The presence in the 13C NMR spectrum of a signal at 
δC 212.1 clearly inferred the presence of a ketone at C-4 in 76 that was also 
confirmed by the chemical shift value of the H-3 resonance, shifted downfield 
with respect to 70 (δH 3.80 in 76, δH 3.54 in 70). In agreement with the steric 
influence played by Me-19, 1H NMR spectrum analysis revealed that the sodium 
borohydride work-up proceeded in a stereoselective manner affording the 
exclusive formation of 4β-hydroxy derivative (77) as judged by the shape of H-4 
as a broad singlet. This is consistent with an equatorial disposition for this proton, 
and therefore with the axial β-orientation of the hydroxyl group. It was confirmed 
by the strong downfield shift exhibited by Me-19 (δH 1.12 in 77, δH 0.63 in 38) 
caused by the 1,3-diaxial relationship with the hydroxy group at C-4. 
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Scheme 11. Modification at C-4 double-bond. Reagents and conditions: (a) O3 solution in CH2Cl2, 
−78 °C, then DMS, 84%; (b) O3 solution in CH2Cl2, −78 °C, then NaBH4, 93%.  
 
4.4.1 Pharmacological evaluation in vitro 
All derivatives of this small library were tested in vitro on FXR. HepG2 cells 
were stimulated with compounds theonellasterol and with its semi-synthetic 
derivatives (67–77) in the presence or in the absence of CDCA (10 µM). As 
shown in Figure 69A, none of these compounds appears to be an FXR agonist in 
the transactivation assay. However, when HepG2 cells transfected with FXR 
vectors were treated with compounds 67–77 (Figure 69B) in the presence of 10 
µM CDCA, several derivatives, in accordance with the antagonistic behaviour of 
theonellasterol (38), showed inhibitory activity against FXR transactivation 
induced by CDCA. 
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Figure 69. (A) Luciferase reporter assay performed in HepG2 transiently transfected with 
pCMVSPORT-FXR, pSG5-RXR, pGL4.70-Renilla, and p(hsp27)TKLUC vectors and stimulated 
18 h with chenodeoxycholic acid (CDCA), 10 µM, and compounds 38, 67–77, 10 µM. # P < 0.05 
vs. NT (n = 4); (B) Luciferase reporter assay performed in HepG2 transiently transfected with 
pCMVSPORT-FXR, pSG5-RXR, pGL4.70-Renilla, and p(hsp27)TKLUC vectors and stimulated 
18 h with CDCA, 10 µM, alone or in combination with compounds 38, 67–77, 50 µM. * P < 0.05 
vs. CDCA (n = 4); (C) Antagonism reported as percent of inhibition normalized to CDCA as 
100%. 
 
Among these synthetic derivatives, compounds (69, 71, 72, 77) were judged the 
most active and their relative efficacy in inhibiting FXR transactivation caused by 
CDCA was measured in a luciferase reporter assay. Data shown in Figure 70 
demonstrated that, in comparison to theonellasterol (38) (EC50 approximately 50 
µM), the selected derivatives had an EC50 ranging from 35 to 50 µM with a 
relative potency in inhibiting FXR transactivation similar to that of the parent 
theonellasterol (38) (i.e., 50%–60%). 
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Figure 70. Luciferase reporter assay on HepG2 transiently transfected with pCMVSPORT-FXR, 
pSG5-RXR, pGL4.70-Renilla, and p(hsp27)TKLUC vectors and stimulated with 10 µM CDCA 
alone (black bar), or in combination with increasing concentrations (10, 50 and 100 µM, grey bars) 
of derivatives 69, 71, 72, 77 and with theonellasterol (38) 100 µM (red bar). # P < 0.05 vs. CDCA 
(n = 3). 
 
4.4.2 Docking studies 
To clarify the effects of the chemical modifications at C-3 and at C-4 of 
theonellasterol (38) at the atomic level, molecular docking calculations108 were 
performed. In our three dimensional models (Figure 71), all synthetic derivatives 
67–77 adopt the same positioning in the FXR-LBD with respect to the parent 
compound theonellasterol (38) maintaining hydrophobic contacts of their 
tetracyclic cores with the receptor (Leu345, Met287, Met325, Met262, Ser329, 
Trp466), and interacting in a different manner with the key aminoacids Tyr358, 
His444, and Trp466 (Figure 71).38 
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Figure 71. Superimposition of the binding modes of 38, 67–77, and of the co-crystallized agonist 
6-ECDCA (61) in the FXR-LBD. The chain A of FXR (pdb code: 1OSV) and the key amino acids 
(see main text for details) are represented by grey ribbon, cpk and stick and balls respectively 
colored by atom type (C, grey; O, red; N, dark blue; S, yellow; H, light grey). 6-ECDCA (dark 
blue), 38 (red), 67 (light yellow), 68 (green), 69 (emerald green), 70 (olive green), 71 (purple), 72 
(dark green), 73 (pink), 74 (yellow), 75 (orange), 76 (cyan), and 77 (light pink) are represented by 
stick and balls.  
 
Interestingly, when a hydroxyl group was introduced in place of the exomethylene 
functionality (Figure 72, panels B and C), the resulting derivative 77 showed an 
antagonistic activity comparable with 38 thus suggesting a role of hydrogen bond 
donor for this group in FXR-LBD as confirmed by the inactivity of derivative 76 
with a ketone functionality at C-4. In fact, with respect to 38 and 76, in the 
derivative 77 the OH group forms an additional hydrogen bond with the side 
chain of Met447 (Figure 72A). Concerning the C-3 hydroxyl group, the complete 
inefficacy of derivatives 67 and 68 (Figure 72, panels B and C), confirms its role 
as hydrogen bond donor as demonstrated for 38 (Figure 72B).153 On the other 
hand, theonellasterone (69) maintained the antagonistic activity, with the ketone 
functionality at C-3 acting as H bond acceptor through the interactions with the 
Tyr358 and the His444 as for theonellasterol. As shown in Figure 72B these 
contacts are hampered in 67 and 68 for the steric effects played by the methyl or 
acetyl substitution, respectively. Moreover, the binding of theonellasterone (69) in 
Chapter 4 
114 
 
the FXR-LBD is also stabilized by additional interactions, mainly a carbonyl-π 
contact with Tyr358 and His444 and an exomethylene-π interaction with Tyr358 
of the aromatic pocket formed by His444, Phe326, Phe363, Tyr358, Tyr366, 
Trp466 and Trp451 (Figure 72B). 
 
 
 
 
 
 
Figure 72. (A) Superimposition of the docking poses of 38 (red), 76 (cyan), and 77 (light pink) in 
the FXR-LBD. (B) Three dimensional model of the different interaction pattern of 38 (red), 67 
(light yellow), 68 (green), 69 (emerald green), with FXR. In both figures the crucial amino acids 
(see main text for details) of the receptor are depicted by grey ribbon, cpk, and stick and balls 
respectively colored by atom type (C, grey; O, red; N, dark blue; S, yellow; H, light grey).  
 
These interactions may be also responsible for the retained FXR antagonist 
activity of 71 and 72 (Figure 73A) with respect to the 4-methyl theonellasterol 
derivatives (70, 73 and 74), which were found to be inactive towards FXR (Figure 
73B). In other words these data suggest that in the 3-keto derivatives the 
antagonistic activity is also retained when the exomethylene at C-4 is replaced by 
a methyl group. Further on, the presence of the above aromatic pocket in the LBD 
is also responsible for the ability of the derivative 75 to antagonize CDCA in FXR 
transactivation suggesting that modifications at C-3 and C-4 with concomitant 
elimination of the hydroxyl and the exomethylene group could produce active 
compounds if the π interactions with Tyr358, His444, and Trp451 are maintained 
(Figure 73C). Therefore, the ability to form hydrogen bonds and π interactions 
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with the FXR-LBD seems to represent the main driving force to obtain stable and 
efficient sterol-receptor complexes. 
 
 
 
 
 
 
 
 
 
 
Figure 73. (A) Superimposition of the binding modes of 69 (emerald green) with 71 (purple) and 
72 (dark green). (B) 69 (emerald green) with 70 (olive green), 73 (pink) and 74 (yellow). (C) 69 
(emerald green) with 38 (red) and 77 (orange) in the FXR-LBD. In all the figures the crucial 
aminoacids (see main text for details) of the receptor are depicted by grey ribbon, cpk, and stick 
and balls respectively colored by atom type (C, grey; O, red; N, dark blue; H, light grey).  
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CHAPTER 5 
Stereochemical studies of Perthamide C 
The study of the polar n-BuOH extract of Theonella swinhoei sponge afforded 
several new cyclic peptides, perthamides C-K.74,75,156 Perthamide C was isolated 
in gram scale in our laboratories and when it was tested in a well characterised 
model of inflammation in vivo, i.e., mouse paw oedema,157 significantly reduced 
carrageenan-induced paw oedema, thus displaying potent dose-dependent anti-
inflammatory activity. Structurally, perthamide C comprises a 25-membered 
macrocycle with several non-proteinogenic amino acid residues, such as γ-
methylproline, β-hydroxyasparagine, o-tyrosine and 3-amino-2-hydroxy-6-
methylheptanoic acid (AHMHA). Whereas the configuration of non-conventional 
residues was secured through an integrated approach, which combined NMR 
analysis, chemical degradation, stereoselective synthesis and LC/MS analysis, the 
remaining stereochemical uncertainty of perthamide C concerns the configuration 
of the two stereogenic centres in the AHMHA unit. Previously a threo relative 
disposition of the hydroxyl and the amino group on the α- and β-position, 
respectively, was proposed on the basis of the J coupling analysis, whereas, due to 
the lack of adequate standards the absolute configuration remained unassigned. 
Subsequently, the results of a stereochemical investigation on the AHMHA unit in 
perthamides allowed the revision of the relative configuration originally proposed 
and the unambiguous definition of the absolute configuration (Figure 74).158 
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Figure 74. Revised structure for perthamide C 
 
5.1 Application of quantitative QM-J method 
Previously,74 the application of the conventional J-based NMR method159 
evidenced some intrinsic difficulties, arising from the qualitative comparison of 
the predicted and some approximation in the measurement of the experimental 
coupling constants, which had been determined on the basis of the sole analysis of 
phase sensitive-HMBC spectra. For this reason an accurate determination of the 
heteronuclear J values, was afforded through the interpretation of a 2D-
HETLOC160 experiment. In addition, for the comparison of the experimental 
couplings, the more reliable from a quantitative point of viewd QM-NMR 
integrated approach161,162,163 was applied. In particular, we considered for our 
calculations the threo and the erythro arrangements of a simplified fragment 
representative of the AHMHA unit (Figure 75), containing, together with the β-
aminoacid unit, a N-methyl group and an acetyl group in the carboxy and amino 
terminal positions, respectively. 
 
 
 
Figure 75. Molecular fragment representing AHMHA; calculations for erythro and threo 
arrangements were performed varying C2 and C3 centres. 
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Following the protocol previously reported in literature161,162,163 the three 
staggered arrangements (gauche +, gauche- and anti) for both the threo and 
erythro configurations was optimized at QM chemical level. On the optimised 
geometries, J values at the MPW1PW91 level, using the 6-31G(d,p) basis set 
were calculated164 and the results of the calculation compared to the experimental 
data. Surprisingly, differently from what was found using the J-based method,74 
the quantitative QM-J method evidenced a better superimposition between the 
experimental and calculated data for the erythro arrangement. In fact, as displayed 
in Table 7, the lowest total absolute deviation (TAD) is observed for the erythro 
gauche+ arrangement (4.8 Hz), even though a comparable value of 6.4 Hz is 
observed for the gauche-conformation of the threo arrangement. 
Table 7. Calculated and experimental J values (Hz) for a fragment corresponding to AHMHA 
in perthamide C. 
 
                                                             Calcd.                                                                           Exp. 
                                               threo                                                 erythro                                
g+ anti g- g+ anti g- 
3JH2-H3 5.3 8.7 1.5 3.0 7.8 3.4 1.8 
3JH2-C4 4.2 1.2 1.7 4.1 4.3 1.0 1.9 
3JH3-C1 6.4 1.9 1.0 0.4 0.6 6.7 0.7 
2JH2-C3     -1.2      -1.5 1.8      -3.1      -3.0 0.5     -2.5 
2JH3-C2     -2.0      -3.0 1.3      -0.6      -3.7      -2.3 0.0 
TADa      14.9 12.7 6.4 4.8 12.6 13.7  
 
aTotal absolute deviation values (Σ׀Jcalcd.-Jexp.׀). 
5.2 Stereoselective synthesis of AHMHA 
 
Definitive confirmation to above results concerning the relative arrangement and 
for the complete and unambiguous definition of the absolute configuration of 
AHMHA residue, the stereoselective synthesis of all diastereomeric possibilities 
for the AHMHA residue was undertaken.165 For our purposes, trans α-β-epoxy 
esters, which are easily obtained in optically enriched form (ee >90%) by 
Sharpless asymmetric epoxidation (AE), were judged valuable intermediates to 
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access to both erythro and threo adducts. As shown in our retrosynthetical 
analysis (Figure 76), the key intermediate epoxy acid 79 would arise from allylic 
alcohol 80, which in turn could be prepared through a HWE olefination on 
aldehyde 81 and subsequent chemoselective reduction.  
 
 
 
 
 
 
 
 
 
Figure 76. Retrosynthetic analysis of (2R,3R)- and (2R,3S)-3-amino-2-hydroxy-6- 
methylheptanoic acids (78a and b). 
 
The synthetic sequence is outlined in Scheme 12, starting with commercially 
available alcohol 82. Primary alcohol 82 was submitted to oxidation under Swern 
condition166 and the unpurified aldehyde was subjected to standard HWE two-
carbon homologation giving (E)-unsaturated ester 83 in 72% yield (>98% de, as 
judged by NMR data) over two steps. Chemoselective reduction with DIBAL-H 
to allylic alcohol 80, followed by AE, afforded epoxy alcohol 84 in 76% yield 
over two steps, whose optical purity was judged to be >98% by the application of 
the modified Mosher’s method. Treatment of (2S,3S)-84 with ruthenium chloride 
and sodium periodate167 produced carboxylic acid (2R,3S)-79 in nearly 
quantitative yield. With optically active key intermediate 79 on our hand, the 
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synthesis of erythro diastereoisomer was completed through the one-pot metal 
catalyzed azidolysis/reduction of α-β-epoxycarboxylic acids developed by 
Fringuelli et al.168 Treatment of 79 with sodium azide in the presence of 10 mol % 
Cu(NO3)2, followed by in situ NaBH4 reduction furnished erythro α-hydroxy-β-
amino-6-methylheptanoic acid 78a in a 75% yield (Scheme 12). The reaction 
proceeded smoothly with excellent regio- and stereoselectivity as judged by NMR 
data of 78a when compared with those reported for allo-ethylnorstatine.168 
 
 
 
 
 
 
 
 
Scheme 12. Reagents and conditions: (a) COCl2, DMSO, TEA, CH2Cl2 dry, -78 °C; (b) TEPA, 
LiOH, THF dry, 72% two steps; (c) DIBAL-H, toluene dry, -78 °C; (d) Ti(Oi-Pr)4, (+)-DET, 
TBHP,4 A MS, CH2Cl2 dry, -20 °C, 76% two steps; (e) NaIO4, RuCl3, CH3CN/CCl4/H2O 2:2:3; (f) 
NaN3, Cu(NO3)2, H2O, 65 °C, then NaBH4, 0 °C, 75% two steps. 
 
Using Bonini’s methodology,169 threo diastereomer was synthesized with similar 
stereoselectivity and chemical yields starting from α-β -epoxycarboxylic acid 79 
(Scheme 13). Diazomethane esterification produced trans epoxy methyl ester 85 
that in turn was subjected to MgBr2-mediated epoxy-opening to give bromohydrin 
86. Azide substitution followed by hydrogenation and acid hydrolysis produced 
the targeted threo α-hydroxy-β-amino acid 78b. Also in this case the reaction 
sequence proceeded in good yields and in highly regio- and stereoselective 
manner in all steps. 
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Scheme 13. Reagents and conditions: (a) CH2N2, Et2O, 82% two steps from 84; (b) MgBr2.OEt2, 
Et2O, 98%; (c) NaN3, DMF, 65 °C, 92%; (d) H2, Pd/C; (e) 6N HCl, 120 °C, 75% two steps. 
 
Comparison of NMR spectra of the AHMHA obtained from the acid hydrolysis of 
perthamide C with those of the two synthetic analogues unambiguously indicates 
the configurational assignment of the natural fragment as either R,R or S,S (Table 
8). Besides slight differences in the chemical shift values of the methyl signals of 
(R,S)-78b and the natural fragment, the 1H NMR spectrum of (R,S)-78b displays 
two well distinguished proton signals (1.58 and 1.80 ppm) for the diastereotopic 
methylene at C-4 where the natural fragment displays a single broad 2H multiplet 
(1.62e1.69 ppm). Also 13C NMR data confirmed the stereochemical assignment 
made. Once again, while the spectrum of diastereoisomer 78a completely matches 
that of the natural material, 13C NMR data for threo stereoisomer differ especially 
in the chemical shift of carbon at position-4. 
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Table 8. Comparison of the NMR data of synthetic 2-hydroxy-3-amino-6-methylheptanoic acid 
diastereomers 78a- 78b with the natural fragment.a 
 
 
2R,3R-78a 
δ, multiplicity (J), H - 
2R,3S-78b 
δ, multiplicity (J), H  
natural fragment 
δ, multiplicity (J), H 
 δH δC δH  δC δH δC 
1  172.7  172.1  172.5 
2 4.01 m, 1H 72.5 4.00 m, 1H 71.3 4.04 m, 1H 72.5 
3 3.35 m, 1H 55.7 3.31 m, 1H 55.4 3.34 m, 1H 55.7 
4 1.63, 1.70 m, 2H 26.4 1.58, 1.80 m, 2H 28.4 1.62, 1.69 m, 2H 26.8 
5 1.30 m, 1H 35.6 1.34 m, 1H 35.4 1.29 m, 1H 35.6 
6 1.57 m, 1H 28.8 1.60 m, 1H 29.1 1.56 m, 1H 28.9 
7 0.9 d (6.7), 3H  22.5 0.95 d (6.7), 3H 22.5 0.93 d (6.5), 3H 22.6 
Me-6 0.92 d (6.7), 3H 22.2 0.95 d (6.7), 3H 22.5 0.92 d (6.5), 3H 22.1 
aAll chemical shifts are reported in ppm and were measured in CD3OD. Coupling constants (J) are 
expressed in Hz. 
 
With two diastereoisomers of AHMHA in our hands, it was then possible to 
proceed to the determination of the absolute configuration of this unit in 
perthamide C using a pre-column derivatization method. A small sample (1 mg 
each) of synthetic diastereomers 78a-78b was derivatized with both enantiomers 
of Marfey’s reagent (N-(3- fluoro-4,6-dinitrophenyl)-alaninamide; L-FDAA and 
D-FDAA). The L- and D-FDAA derivatives 88a-88d were analysed using ESI 
LC/MS in the positive ion mode. By monitoring for FDAA/AHMHA at m/z 428, 
they were detected as separate peaks at 48.50, 39.40, 40.99, 48.03 min, 
respectively (Scheme 14). The L-FDAA derivative of AHMHA unit in 
perthamide C was co-eluted with the L-FDAA derivative of (2R,3R)-2-hydroxy-3-
amino-6-methylheptanoic acid 78a. Thus, the (2R,3R) configuration for the 
AHMHA residue in perthamide C was unambiguously established (Scheme14), as 
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further confirmed by the optical rotation data [synthetic 78a: [α]D20 +8.6 (c 0.5, 
MeOH); natural AHMHA: [α]D20 +8.8 (c 0.55, MeOH)]. 
 
 
 
 
 
 
 
 
 
 
Scheme 14. HPLC retention times (rt) of FDAA derivatives of synthetic (2R, 3R)- and (2R, 3S)-3-
amino-2-hydroxy-5-methylheptanoic acid (78a and 78b) and configurational assignment 
of AHMHA in perthamide C. 
 
NHBn2
(2R, 3R)-78a
(2R, 3S)-78b
L-FDAA
D-FDAA
(2R, 3S)-88b
rt = 39.40
(2R, 3R)-88a
rt = 48.50
(2R, 3S)-88d
rt = 48.03
(2R, 3R)-88c
rt = 40.99
Perthamide C (i) 6N HCl 16 h(ii) L-FDAA
(iii) LC-MS
AHMHA
rt = 48.50
COOH
OH
NH2
COOH
OH
NH(L)-FDAA
COOH
OH
NH(D)-FDAA
COOH
OH
NH(L)-FDAA
COOH
OH
NH(D)-FDAA
COOH
OH
NH(L)-FDAA
Conclusions 
124 
 
CONCLUSIONS 
Living marine organisms, plants, animal and micro-organisms, were appeared in 
the sea more than 3500 million years ago and, in order to survive in a hostile 
milieu, they have developed exquisitely complex biological mechanisms able to 
produce a wide variety of secondary metabolites unlike those found in terrestrial 
species. Marine natural products cover a far greater area of chemical space than 
synthetic compounds, and have property distributions that are similar to those of 
drugs currently in use. When compared to synthetic compounds, marine products, 
on average, have higher molecular weights, are sterically more complex, with 
more bridgehead atoms, rings, and chiral centres. This simple observation can 
give an idea of the incredible potential represented by marine organisms. 
Secondary metabolites contained in these organisms are the result of millions of 
years of evolution and natural selection: even a single species constitutes a library 
of metabolites that is validated for the bioactivity. As the results of enzymatic 
reactions, natural products have an intrinsic capacity to recognize and bind 
macromolecules, perturb their activity, and modulate biological processes. Beside 
in the past century the high-throughput screening of natural sources has long been 
recognized as an invaluable source of new lead structures, today targeted oriented 
discovery, focused on the identification of natural products as ligands of specific 
proteins or enzymes, is considered the best rationale approach for the 
identification of novel therapeutic agents from Nature. Indeed natural products are 
being biosynthesized by their hosts to interact with proteins, such as enzymes or 
receptors, and many human protein targets contain structural domains similar to 
the targets with which small ligands (or natural products) have coevolved. Surely, 
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nuclear receptors (NRs) represent one of the most important drug targets in terms 
of potential therapeutic application, playing a role in every aspect of development, 
physiology and disease in humans. They are ubiquitous in the animal kingdom, 
suggesting that they may have played an important role in their evolution, and 
today are recognized important target for the discovery of new therapeutic 
opportunity in inflammation, cancer and several metabolic diseases.  
In this context my research work, described in this PhD thesis, has been addressed 
to the identification of new ligands of nuclear receptors, discovering potent and 
selective modulators of farnesoid-X-receptor (FXR) and pregnane-X-receptor 
(PXR). Specifically, structural characterization and biochemical decodification on 
steroidal composition of the marine sponge Theonella swinhoei allowed the 
identification, for the first time, of several molecules with promising activity on 
human nuclear receptors. Depending on the side chain and on the substitution of 
the tetracyclic nuclei, these molecules showed a pharmacological activity ranging 
from pure and potent PXR agonism to FXR antagonism, through dual modulation 
on these NRs. Solomonsterols are sulfated sterols with agonistic activity on the 
PXR and judged potential leads in inflammatory bowel diseases (IBDs), such as 
Crohn’s disease (CD) and ulcerative colitis (UC). In animal model, solomonsterol 
A effectively protects against the development of signs and symptoms of colitis 
by a mechanism involving inhibition of NF-κB. In addition, solomonsterol A 
attenuated the release of TNFα in the inflamed tissue and induced the expression 
of IL-10 and TGFβ, two key counter-regulatory cytokines. Total syntheses of the 
natural leads, as well as design and synthesis of several side chain modified 
derivatives, have been realized during my research work providing sufficient 
amounts for pharmacological characterization and discovery of cholestan disulfate 
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(Coldisolf) as a new, simplified agonist of PXR, currently in pharmacological 
evaluation on animal models of liver fibrosis induced by HIV infection. 
Theonellasterol was identified as the first example of a sponge derived highly 
selective FXR antagonist demonstrating its pharmacological potential in the 
treatment of cholestasis. Using this compound as a novel FXR antagonist hit, a 
series of semi-synthetic derivatives has been prepared in order to gain insights 
into the structural requirements for exhibiting antagonistic activity. These 
molecules could be used for the pharmacological treatment of cholestasis but also 
in chemotherapy of human carcinoma characterized by over-expression of FXR.  
Finally a library of 4-methylene-polyhydroxylated steroids have been isolated and 
identified as the first example of dual PXR/FXR ligands. Because PXR ligands 
are not ligand for FXR, the discovery of ancestral dual activators highlights the 
potential for the existence of similar ligands in the mammalian body. From the 
pharmacology stand point, a dual ligand holds potential in the treatment of liver 
disorders characterized by cholestasis and/or impaired metabolism of xenobiotics 
such as  primary biliary cirrhosis (PBC) and sclerosing cholangitis (PSC). 
In conclusion, this study reaffirms Nature as one of the best sources of new 
chemical entities representing an essential component of today’s research arsenal 
to shed light on complex biological processes, biochemical pathways and, in 
prospective, an inspiration for the discovery of new therapeutic strategies.  
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EXPERIMENTAL SECTION 
I. General experimental procedures. 
Chemistry.  
Specific rotations were measured on a Jasco P-2000 polarimeter. High-resolution ESI-MS spectra 
were performed with a Micromass Q-TOF mass spectrometer. ESI-MS experiments were 
performed on an Applied Biosystem API 2000 triple-quadrupole mass spectrometer. NMR spectra 
were obtained on Varian Inova 400, Varian Inova 500 and Varian Inova 700 NMR spectrometers 
(1H at 400, 500 and 700 MHz, 13C at 100, 125 and 175 MHz, respectively) equipped with a SUN 
micro system ultra5 hardware and recorded in CDCl3 (δH =7.26 and δC =77.0 ppm), in CD3OD (δH 
=3.30 and δC =49.0 ppm) and in C6D6 (δH =7.16, δC =128.4). All of the detected signals were in 
accordance with the proposed structures. Coupling constant (J values) are given in Hertz (Hz) and 
chemical shifts (δ) are reported in ppm and referred to CHCl3, CHD2OD and C6HD5 as internal 
standards. Spin multiplicities are given as: s (singlet), br s (broad singlet), d (doublet), or m 
(multiplet). HPLC was performed with a Waters Model 510 pump equipped with Waters Rheodine 
injector and a differential refractometer, model 401. The purity of all of the intermediates, checked 
by 1H NMR and HPLC, was greater than 95%. Through-space 1H connectivities were evidenced 
using a ROESY experiment with mixing times of 200 and 500 ms, respectively. Reaction progress 
was monitored via thin-layer chromatography (TLC) on Alugram silica gel G/UV254 plates. Silica 
gel MN Kieselgel 60 (70-230 mesh) from Macherey-Nagel Company was used for column 
chromatography. All chemicals were obtained from Sigma-Aldrich, Inc. Solvents and reagents 
were used as supplied from commercial sources with the following exceptions. Tetrahydrofuran, 
toluene, dichloromethane, ether and triethylamine were distilled from calcium hydride 
immediately prior to use. All reactions were carried out under argon atmosphere using flame-dried 
glassware. 
Biological assays.  
Plasmids, Cell Culture, Transfection, and Luciferase Assays. All transfections were made using 
Fugene HD transfection reagent (Roche). For FXR mediated transactivation, HepG2 cells, plated 
in a 6-well plate at 5x105 cells/well, were transfected with 100 ng pSG5-FXR, 100 ng pSG5-RXR, 
200 ng pCMV-βgalactosidase and with 500 ng of the reporter vector p(hsp27)-TK-LUC containing 
the FXR response element IR1 cloned from the promoter of heat shock protein 27 (hsp27). At 48 h 
post-transfection, cells were stimulated 18 h with 10 µM CDCA or with tested compounds (50 
µM) alone or in combination with CDCA. For PXR mediated transactivation, HepG2 cells, plated 
in a 6-well plate at 5x105 cells/well, were transfected with 100 ng pSG5-PXR, 100 ng pSG5-RXR, 
200 ng pCMV-βgalactosidase and with 500 ng of the reporter vector containing the PXR target 
gene promoter (CYP3A4 gene promoter) cloned upstream of the luciferase gene 
(pCYP3A4promoter-TKLuc). At 48 h post-transfection, cells were stimulated 18 h with 10 µM 
Rifaximin or with tested compounds (50 µM) alone or in combination with Rifaximin. Cells were 
lysed in 100 µL diluted reporter lysis buffer (Promega) and 0.2 µL of cellular lysates was assayed 
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for luciferase activity using the Luciferase Assay System (Promega). Luminescence was measured 
using an automated luminometer. Luciferase activities were normalized for transfection 
efficiencies by dividing the relative light units by β-galactosidase activity expressed from cells 
cotransfected with pCMV-βgal. 
Real-Time PCR. Total RNA was extracted using the TRIzol reagent (Invitrogen), purified of the 
genomic DNA by DNAase I treatment (Invitrogen) and random reverse-transcribed with 
Superscript II (Invitrogen). Fifty ng template was amplified using the following reagents: 0.2 µM 
of each primer and 12.5 µL of 2X SYBR Green qPCR master mix (Invitrogen). All reactions were 
performed in triplicate and the thermal cycling conditions were: 2 min at 95 °C, followed by 40 
cycles of 95 °C for 20 s, 55 °C for 20 s and 72 °C for 30 s in iCycler iQ instrument (Biorad). The 
relative mRNA expression was calculated and expressed as 2-(∆∆Ct). Primers used for qRT-PCR 
were: mGAPDH: CTGAGTATGTCGTGGAGTCTAC and GTTGGTGGTGCAGGATGCATTG; 
mCyp3A11: TGAAACCACCAGTAGCACAC and CCATATCCAGGTATTCCATCTCC; 
mIL1β: TCACAGCAGCACATCAACAA and TGTCCTCATCCTCGAAGGTC; mIL-6: 
CCGGAGAGGAGACTTCACAG and TCCACGATTTCCCAGAGAAC; mTNFα: 
ACGGCATGGATCTCAAAGAC and GTGGGTGAGGAGCACGTAGT; rGAPDH: 
ATGACTCTACCCACGGCAAG and   TACTCAGCACCAGCATCACC; rαSMA: 
GCTCCATCCTGGCTTCTCTA and TAGAAGCATTTGCGGTGGAC. Human primers were as 
follows: hSHP: GCTGTCTGGAGTCCTTCTGG  and CCAATGATAGGGCGAAAGAAGAG; 
hGAPDH: GAAGGTGAAGGTCGGAGT and CATGGGTGGAATCATATTGGAA; hCYP3A4: 
CAAGACCCCTTTGTGGAAAA and CGAGGCGACTTTCTTTCATC; hIL1β: 
GGACAAGCTGAGGAAGATGC and TCGTTATCCCATGTGTCGAA; hTNFα: 
AACCTCCTCTCTGCCATCAA and GGAAGACCCCTCCCAGATAG; hMCP-1: 
CCCCAGTCACCTGCTGTTAT and TCCTGAACCCACTTCTGCTT; hB2M: 
TGCTATGTGTCTGGGTTTCATC and TGACAAAGTCACATGGTTCACA; hCYP3A7: 
CAAGACCCCTTTGTGGAAAA and TGTCTCTTTGAGGCGACCTT; hSULT2A1: 
GATCCAATCTGTGCCCATCT and TAAATCACCTTGGCCTTGGA; hMDR1: 
GTGGGGCAAGTCAGTTCATT and TCTTCACCTCCAGGCTCAGT; hBSEP: 
GGGCCATTGTACGAGATCCTAA and TGCACCGTCTTTTCACTTTCTG; hCYP7A1: 
CACCTTGAGGACGGTTCCTA and CGATCCAAAGGGCATGTAGT; hOSTα: 
TGTTGGGCCCTTTCCAATAC and GGCTCCCATGTTCTGCTCAC. 
Computational details. 
We performed molecular docking experiments by Autodock 4.2 software on 4 x AMD Opteron 
SixCore 2.4 GHz. We used a grid box size of 94 x 96 x 68 for chain A of FXR (pdb code:1OSV), 
and 90 x 106 x 92 for PXR (pdb code: 1M13) with spacing of 0.375 Å between the grid points, 
and centered at 20.689 (x), 39.478 (y), 10.921 (z) between the SCH3 of Met262 and the OH group 
of Thr267 for FXR, and at 14.282 (x), 74.983 (y), 0.974 (z) between the ring of His407 and the 
side chain of Leu209 for PXR, covering the active site of both the receptors. To achieve a 
representative conformational space during the docking studies and for taking into account the 
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variable number of active torsions, 10 calculations consisting of 256 runs were performed, 
obtaining 2560 structures for each ligand. The Lamarckian genetic algorithm (LGA) was 
employed for docking experiments, choosing an initial population of 600 randomly placed 
individuals. The maximum number of energy evaluations and of generations was set up to 5 x 106 
and to 6 x 106 respectively. For all the docked structures, all bonds were treated as active torsional 
bonds except the bonds in cycles, which are considered fixed together with the receptors. Results 
differing by less than 3.5 Å in positional root-mean-square deviation (RMSD) were clustered 
together and represented by the result with the most favorable free energy of binding. Illustrations 
of the 3D models were generated using the Python115 and Chimera software.137 
II. Experimental section of PXR agonists  
Synthesis of solomonsterol A (1)  
Methyl hyodeoxy-5-cholan-24-oate (4). To a solution of hyodeoxycholic acid 3  (2.5 g, 6.4 mmol) 
in dry diethyl ether (15 mL)  a solution of diazomethane in dry diethyl ether was added until 
yellow persistent coloration. The mixture was stirred at room temperature for four hours. The 
solution was dried  under vacuum without any further purification to give the methyl 
hyodeoxycholate 4  (2.5 g, quantitative yield). [α]24D= +1.68 (c 6.86, CHCl3); selected 1H NMR 
(400 MHz CDCl3): δ 4.06 (1H, dt, J= 4.86, 9.7 Hz), 3.63 (1H, m), 3.66 (3H, s), 2.36 (1H, m), 0.64 
(3H, s), 0.90 (3H, s), 0.91(3H, d, J=5.9 Hz). 13C NMR (100 MHz CDCl3): δ 75.2, 71.7, 68.3, 56.4, 
56.2, 54.6, 51.7, 48.7, 43.0, 40.2, 40.1, 36.1, 35.8, 35.6, 35.0, 31.8, 31.2, 30.2, 29.4, 28.3, 24.4, 
21.0, 18.5, 14.1, 12.2; HRMS-ESI m/z 407.3173  ([M + H]+, C25H43O4 requires 407.3161. 
Methyl 3,6-ditosyloxy-5-cholan-24-oate (5). To a solution of methyl hyodeoxycholate 4 (2.5 g, 6.1 
mmol) in dry pyridine (14 ml) a solution of tosyl chloride (3.4 g, 18.3 mmol) in dry pyridine (6 
ml) was added, and the mixture was stirred at room temperature for 2 days. It was  poured into 
cold water (20 mL) and extracted with CH2Cl2 (3 × 30 mL). The combined organic layer was 
washed with saturated NaHCO3 solution (30 mL), and water (30 mL), and then dried over 
anhydrous MgSO4 and evaporated in vacuo to give 4.2 g of 5 (quantitative yield ) in the form of 
colorless needles, that was subjected to next step without any purification. [α]24D= +7.2 (c 6.84, 
CHCl3) selected 1H NMR (400 MHz CDCl3): δ 0.56 (3H, s), 0.80 (3H, s), 0.88 (3H, d, J= 5.9 Hz), 
2.46 (6H, s), 2.33 (1H, m), 2.22 (1H, m), 3.66 (3H, s), 4.30 (1H, m), 4.78 (1H, m), 7.34, 7.72 e 
7.78 (8H, m). 13C NMR (100 MHz CDCl3): δ 174.9, 144.9 (2C), 144.0 (2C), 130.0 (4C), 127.9 
(4C), 82.1, 80.0, 56.0, 55.9, 54.6, 51.7, 46.6, 43.0, 39.8, 39.6, 36.4, 35.5, 35.0 (2C), 32.3, 31.2, 
31.1, 28.2, 26.7, 24.2, 21.9 (2C), 20.7, 18.4, 14.4, 12.2. HRMS-ESI m/z 715.3350 ([M + H]+ , 
C39H55O8S2 requires 715.3338. 
Methyl 3-hydroxy-5-cholen-24-oate (6). A solution of the ditosylate 5 (4.2 g, 5.9 mmol) and 
CH3COOK (579 mg, 5.9 mmol) dissolved in water (3 ml) and N,N’- dimethylformamide (DMF 27 
ml) was refluxed for 4h. The solution was cooled at room temperature and poured into cold water 
(20 mL) and extracted with ethyl acetate (3 × 30 mL). Then, it was dried over anhydrous MgSO4 
and evaporated in vacuo to give a  oleos residue that was purified on a silica gel column  by 
eluting with hexane-EtOAc (9:1, 0.5% TEA) to obtain 2.0 g of 6 (78% yield); [α]24D= -9.0 (c 0.73, 
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CHCl3). Selected 1H NMR (400 MHz CDCl3): δ 5.34 (1H, d, J= 4.8 Hz), 3.65 (3H, s), 3.51 (1H, 
m), 2.33 (1H, m), 2.23 (1H, m), 1.00 (3H, s), 0.92 (3H, d, J= 6.3 Hz), 0.67 (3H, s). 13C NMR (100 
MHz CDCl3): δ 174.8, 140.8, 121.5, 71.6, 56.6, 55.7, 51.4, 50.0, 42.2, 41.1, 39.7, 37.2 (2C), 35.2, 
31.7 (2C), 31.4, 30.9, 30.8, 28.0, 24.2, 20.9, 19.3, 18.2, 11.7; HRMS-ESI m/z 389.3062 ([M + H]+, 
C25H41O3 requires 389.3056. 
Methyl 3β-hydroxy-5α-cholan-24-oate (7). An oven-dried 250 mL flask was charged with 10% 
palladium on carbon (100 mg) and compound 6 (2.00 g, 5.15 mmol) and the flask was evacuated 
and flushed with argon. Absolute methanol (50 mL) and dry THF (50 mL) were added, and the 
flask was flushed with hydrogen. The reaction was stirred at room temperature under H2 (1 atm) 
for 4 h. The mixture was filtered through celite, and the recovered filtrate was concentrated to give 
1.70 g of crude product. The residue was subjected to column chromatography on silica gel eluting 
with hexane-EtOAc (9:1, 0.5% TEA) to give 1.60 g of pure 7 (80%). [α]24D= +3.4 (c 0.54, CHCl3); 
selected 1H NMR (400 MHz, CDCl3): δ 3.64 (3H, s), 3.56 (1H, m), 2.33 (1H, m), 2.19 (1H, m), 
0.89 (3H, d, J= 6.3 Hz), 0.78 (3H, s), 0.63 (3H, s). 13C NMR (100 MHz, CDCl3): δ 174.8, 71.3, 
56.4, 55.8, 54.3, 51.5, 44.8, 42.6, 41.1, 38.0, 36.9, 35.4, 35.3 (2C), 32.0, 31.3, 31.0, 30.9, 28.6, 
28.1, 24.1, 21.2, 18.2, 12.5, 12.3; HRMS-ESI m/z 391.3227 ([M + H]+, C25H43O3 requires 
391.3212. 
Methyl 3β-tosyloxy-5α-cholan-24-oate (8). To a solution of 7 (1.50 g, 3.84 mmol) in dry pyridine 
(30 mL), p-toluenesulfonyl chloride (2.20 g, 11.52 mmol) was added. The solution was stirred at 
room temperature for 24 h and then poured into cold water (20 mL) and extracted with CH2Cl2 (3 
× 15 mL). The combined organic layer was washed saturated NaHCO3 solution (30 mL), and 
water (30 mL), and then dried over anhydrous MgSO4 and evaporated in vacuo to give 2.09 g of 8, 
that was subjected to next step without any purification. [α]24D= +15.54 (c 0.47, CHCl3) Selected 
1H NMR (400 MHz CDCl3): δ 7.79 (2H, d, J= 8.2 Hz), 7.33 (2H, d, J= 8.2 Hz), 4.41 (1H, m), 4.23 
(1H, m), 3.66 (3H, s), 2.45 (3H, s), 2.34 (1H, m), 2.22 (1H, m), 0.89 (3H, d, J= 5.9 Hz), 0.77 (3H, 
s), 0.63 (3H, s); 13C NMR (100 MHz CDCl3): δ 174.8, 148.8, 129.8 (2C), 127.7 (2C), 124.3, 82.7, 
56.6, 56.1, 54.2, 51.7, 45.0, 41.6, 40.1, 37.0, 35.5 (2C), 35.2, 35.0, 32.1, 31.3, 31.2, 29.9, 28.6, 
28.3, 24.4, 21.9, 21.4, 18.5, 14.4, 12.3; HRMS-ESI m/z 545.3311 ([M + H]+), C32H49O5S requires 
545.3301. 
Methyl 5α-chol-2-en-24-oate (9). Lithium bromide (3.30 g, 38.4 mmol) and lithium carbonate (2.8 
g, 38.4 mmol) were added to a solution of 8 (2.08 g, 3.84 mmol) in dry DMF (150 mL), and the 
mixture was refluxed for 1.5 h. After cooling to room temperature, the mixture was slowly poured 
into 10% HCl solution (150 mL) and extracted with CH2Cl2 (3 × 150 mL). The combined organic 
layer was washed successively with water, saturated NaHCO3 solution and water, and then dried 
over anhydrous MgSO4 and evaporated to dryness to give a white solid residue that was purified 
on a silica gel column  by eluting with hexane-EtOAc (9:1, 0.5% TEA) to obtain pure 9 (1.19 g, 
83% over two steps). [α]24D= +18.6 (c 2.07, CHCl3); selected 1H NMR (400 MHz CDCl3): δ 5.48 
(2H, br s), 2.25 (1H, m), 2.11 (1H, m), 0.83 (3H, d, J= 6.2 Hz), 0.65 (3H, s), 0.56 (3H, s). 13C 
NMR (100 MHz CDCl3): δ 175.2, 126.2 (2C), 56.7, 56.0, 54.2, 51.7, 42.8, 41.6, 40.2, 39.9, 35.8, 
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35.5, 34.3, 32.0, 31.3, 31.1, 30.5, 28.9, 28.3, 24.4, 21.1, 18.5, 12.2 (2C); HRMS-ESI m/z 373.3117 
([M + H]+, C25H41O2 requires 373.3107. 
Methyl 2α,3α-epoxy-5α-cholan-24-oate (10). To a solution of 9 (1.09 g, 2.93 mmol) in CH2Cl2 (66 
mL) were added water (46.2 mL) and Na2CO3 (1.15 g, 10.8 mmol). The reaction mixture was 
stirred vigorously and m-chloroperbenzoic acid (708 mg, 4.1 mmol) was added slowly. The 
mixture was stirred for 4 h at room temperature, and then the aqueous layer was extracted with 
CH2Cl2 (3 × 35 mL). The combined CH2Cl2 extracts were washed successively with 5% Na2SO3 
solution (100 mL), saturated NaHCO3 solution (100 mL), and water (100 mL), dried over 
anhydrous MgSO4 and evaporated to dryness to give 1.13 g of crude epoxide 10, that was 
subjected to next step without any purification. [α]24D= +13.7 (c 0.42, CHCl3) Selected 1H NMR 
(400 MHz CDCl3): δ 3.65 (3H, s), 3.14 (1H, br s), 3.09 (1H, br s), 2.34 (1H, m), 2.20 (1H, m), 
0.90 (3H, d, J = 6.7 Hz), 0.74 (3H, s), 0.63 (3H, s); 13C NMR (100 MHz CDCl3): δ 175.2, 56.5, 
56.0, 53.8, 52.6, 51.7, 51.3, 42.6, 40.2, 40.7, 38.5, 36.4, 35.8, 35.6, 31.9, 31.3, 31.2, 30.9, 28.6, 
28.3, 24.4, 21.1, 18.5, 13.2, 12.2; HRMS-ESI m/z 389.3036 ([M + H]+, C25H41O3 requires 
389.3056. 
Methyl 2β,3α-dihydroxy-5α-cholan-24-oate (11). A solution of epoxide 10 (1.13 g, 2.93 mmol) in 
THF (70 mL) was treated with 1 N H2SO4 (7.32 mL, 7.32 mmol) solution and stirred for 24 h at 
room temperature. After neutralization with saturated NaHCO3 solution, the mixture was 
evaporated to a fifth of the initial volume, diluted with water (50 mL), and extracted with ethyl 
acetate (3 x 50 mL). The combined organic extracts were washed with water, dried over anhydrous 
MgSO4, filtered and evaporated to dryness. Purification on a silica gel column by eluting with 
CH2Cl2-MeOH (9:1) afforded pure 11 (870 mg, 73% over two steps). [α]24D= +0.67 (c 0.46, 
CHCl3); selected 1H NMR (400 MHz CDCl3): δ 3.89 (1H, br s), 3.85 (1H, br s), 3.64 (3H, s), 2.34 
(1H, m), 2.20 (1H, m), 0.97 (3H, s), 0.89 (3H, d, J = 6.7 Hz), 0.63 (3H, s); 13C NMR (100 MHz 
CDCl3): δ 175.4, 72.1, 70.9, 56.6, 56.0, 53.7, 51.7, 42.6, 40.7, 40.2, 39.2, 36.3, 35.6, 35.1, 32.1, 
31.9, 31.3, 31.2, 28.4, 28.3, 24.4, 21.1, 18.5, 14.9, 12.4; HRMS-ESI m/z 407.3181 ([M + H]+, 
C25H43O4 requires 407.3161. 
5α-Cholan-2β,3α,24-triol (12). Dry methanol (320 µL, 7.88 mmol) and LiBH4 (3.94 mL, 2 M in 
THF, 7.88 mmol) were added to a solution of the methyl ester 11 (800 mg, 1.97 mmol) in dry THF 
(10 mL) at 0 °C under argon and the resulting mixture was stirred for 4 h at 0 °C. The mixture was 
quenched by addition of NaOH (1 M, 4 mL) and then allowed to warm to room temperature. Ethyl 
acetate was added and the separated aqueous phase was extracted with ethyl acetate (3 ×1 5 mL). 
The combined organic phases were washed with water, dried (Na2SO4) and concentrated. 
Purification by silica gel eluting with CH2Cl2-MeOH (9:1) gave the alcohol 12 as a white solid 
(685 mg, 92%). [α]24D= -1.2 (c 0.12, CHCl3); selected 1H NMR (400 MHz CD3OD): δ 3.81 (1H, br 
s), 3.77 (1H, m), 3.67 (1H, br s), 3.52 (1H, m), 1.01 (3H, s), 0.96 (3H, d, J = 6.0 Hz), 0.70 (3H, s); 
13C NMR (100 MHz CD3OD): δ 73.3, 70.5, 63.1, 57.0, 56.6, 55.6, 43.0, 41.6, 40.5, 40.2, 36.0, 
35.3, 35.2, 32.3, 31.7, 29.6, 29.5, 28.7, 28.6, 24.6, 21.1, 18.9, 14.2, 12.3; HRMS-ESI m/z 379.3154 
([M + H]+, C24H43O3 requires 378.3134. 
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5α-Cholan-2β,3α,24-tryl-2,3,24-sodium trisulfate (1). The triethylamine-sulfur trioxide complex 
(1.81 g, 10.0 mmol) was added to a solution of triol 12 (600 mg, 1.58 mmol) in DMF dry (2 mL) 
under an argon atmosphere, and the mixture was stirred at 95 ◦C over the week-end. Then, the 
reaction mixture was quenched with water (1.6 mL). The solution was poured over a silica gel 
column to remove excess SO3·NEt3. The product was eluted by MeOH and followed by 
evaporation of the solvent to yield a yellow solid [tris-(triethylammonium sulphate) salt]. To the 
solution of the solid in methanol (15 mL) was added Amberlite CG 120 sodium form (20 g). The 
mixture was stirred for 5 h at room temperature. The resin was removed by filtration, and the 
filtrate was concentrated to obtain compound 1 as a white solid (972 mg, 90%). [α]24D= +4.6 (c 
0.8, CH3OH); selected 1H NMR (400 MHz CD3OD): δ 4.73 (1H, br s), 4.70 (1H, br s), 3.69 (2H, 
m), 1.00 (3H, s), 0.95 (3H, d, J= 6.3 Hz), 0.69 (3H, s) ; 13C NMR (100 MHz CD3OD): δ 76.2, 75.6, 
69.3, 57.5, 57.3, 56.4, 43.2, 41.3, 39.7, 38.5, 36.4, 36.2 (2C), 32.8, 32.6, 30.3, 28.8, 28.7, 26.9, 
24.7, 21.5, 18.6, 14.4, 12.3. HRMS-ESI m/z 661.1415 [M-Na]-, C24H39Na2O12S3 requires 
661.1399. 
Specific biological assays.  
Electrophoretic mobility shift assay (EMSA). The NF-κB DNA-binding activity was determined by 
EMSA. After treatment, nuclear and cytoplasmic extracts were prepared using the NE-PER 
Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnology, Inc.). EMSA probes were 
created by biotinylating the 3’ end of the single stranded oligonucleotides using a biotin 3’ end 
DNA labelling kit (Pierce Biotechnology, Inc.) according to the manufacturer’s protocol. The 
biotinylated oligonucleotides were annealed by boiling for 1 min and then allowing them to slowly 
cool to room temperature. The consensus nucleotide sequence for NF-κB was 5’-AGA GAT TGC 
CTG ACG TCA GAC AGC TAG-3’. The EMSA binding reaction was performed by utilizing a 
LightShift chemiluminescent EMSA kit (Pierce Biotechnology, Inc.). A nuclear extract was 
incubated in 1× binding reaction buffer containing 50 mM KCl, 10 mM EDTA, 25 ng/mL poly dI-
dC, 5 mM MgCl2, and the biotinylated probe. After a 20 min incubation at room temperature, the 
reaction mixture was electrophoresed on a non-denaturing 6% polyacrylamide gel and then 
transferred to a nylon membrane. The transferred mixture was UV-cross-linked to the membrane 
and detected by chemioluminescent reagents (Pierce Biotechnology, Inc.). For the competition 
assay, a 200-fold excess of unlabeled probe was added together with the labelled probe. For the 
supershift assay, 1 µg of antibody against NF-κB p65 was added together with the nuclear extract. 
Animals. For the TNBS studies humanized (h)PXR mice, 8–10 weeks of age, were provided by 
Frank J. Gonzalez (Laboratory of Metabolism, Centre for Cancer Research, National Cancer 
Institute, National Institutes of Health, Bethesda, Maryland). hPXR, male mice were housed in 
temperature- and light-controlled rooms and were given tap water and pelleted standars mouse 
chow ad libitum. The hPXR mice express the human PXR in the PXR-null background. Mice were 
housed under controlled temperatures (22 °C) and photoperiods (12:12-h light/dark cycle), allowed 
unrestricted access to standard mouse chow and tap water. The present protocol was approved by 
the Italian Minister Health and conforms to national guidelines. (The ID for this project is 
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#11/2010-B and authorization released to Prof. Stefano Fiorucci, as a principal investigator, lastly 
on January 25, 2010.) 
Induction of colitis. Mice were fasted for 16 h and lightly anesthetized by intraperitoneal injection 
of 100 µL of ketamine/xylazine solution96 for 10 g body weight and then administered intrarectally 
(i.r.) with the haptenating agent TNBS (0.5 mg/mouse) dissolved in ethanol 50%, via a 3.5 French 
(F) catheter equipped with a 1 mL syringe. The catheter was advanced into the rectum for 4 cm 
and then the haptenating agent was administered in a total volume of 150 µL. To ensure 
distribution of the agent within the entire colon and cecum, mice were held in a vertical position 
for 30 s. Solomonsterol A (10 mg/kg) and rifaximin (10 mg/kg) were dissolved in DMSO (10 
mg/100 µL), diluted in methylcellulose 1% and administered intraperitoneally (i.p.) and orally, 
respectively, at the final volume of 100 µL/mouse, 3 days before the induction of colitis. At this 
time, the TNBS-alone group received the vehicle alone (methylcellulose 1% in a final volume of 
100 µL/mouse), every day. In another experiment, a therapeutic model, solomonsterol A (10 
mg/kg) was administrated the day after colitis induction. Mice were analyzed for the presence of 
diarrhea, body weight, and survival. The body weight was expressed as delta percentage versus the 
weight of mice on the day before TNBS administration. Mice were analyzed for the presence of 
diarrhoea, body weight, and survival. Four days after TNBS administration, surviving mice were 
sacrificed, colons were removed and either immediately snap-frozen in liquid nitrogen and stored 
at −80 °C until use or formalin fixed. The macroscopic appearance was analyzed considering the 
presence of indurations, oedema, thickness and evidence of mucosal haemorrhage. Grading was 
performed in a blinded fashion. For histological examination, tissues were fixed in 10% buffered 
formalin phosphate, embedded in paraffin, sectioned, and stained with hematoxylin and eosin 
(H&E). Histology images were captured by a digital camera (SPOT-2; Diagnostic Instruments Inc, 
Burroughs, MI) and analyzed by specific software (Delta Sistemi, Rome, Italy). The degree of 
colon inflammation was examined microscopically in transversal sections97 and graded semi-
quantitatively from 0 to 4 (0, no signs of inflammation; 1, very low level; 2, low level of leukocyte 
infiltration; 3, high level of leukocyte infiltration, high vascular density, and thickening of the 
colon wall; and 4, transmural infiltration, loss of goblet cells, high vascular density, and thickening 
of the colon wall). Grading was performed by blinded observers. 
Colon myeloperoxidase (MPO) and cytokine levels. Colon samples were lysed in 1 mL of lysis 
buffer T-PER (Pierce, Rockford, USA) and finely minced. After the tissues were centrifuged at 
10,000 g for 15 min at 4 °C. Colon homogenates were used to determine MPO activity, after two 
freeze/thaw cycles, using a spectrophotometric assay with trimethylbenzidine (TMB) as a substrate 
and normalized for the protein levels. Colon TNFα and IL-10 levels in tissue homogenates were 
quantified by ELISA (SABioscences) according to the manufacturer’s instructions, and normalized 
for the protein levels. 
Statistical analysis. All values are expressed as the mean ± SE. Number (n) of experiments  or 
mice used in the experiments is shown. Comparisons of more than 2 groups were made with a one-
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way analysis of variance with post hoc Tukey tests. Differences were considered statistically 
significant if p was <0.05. 
Synthesis of derivatives of solomonsterol A 
Diol 11 was prepared according to the synthetic procedure previously described.89  
Methyl 2β,3α-disulfate-5α-cholan-24-oate (13). Triethylamine-sulfur trioxide complex (1.34 g, 7.4 
mmol) was added to diol 11 (300 mg, 0.74 mmol) in DMF dry (10 mL) under an argon 
atmosphere, and the mixture was stirred at 95 ◦C for 48 h. The reaction mixture was quenched with 
water (1.6 mL) and the solution was poured over a C18 silica gel column to remove excess 
Et3N.SO3. The product was eluted by MeOH and followed by evaporation of the solvent to yield a 
yellow solid [bis-(triethylammonium sulfate) salt]. To the solid dissolved in methanol (30 mL) was 
added Amberlite CG 120 sodium form (30 g) and the mixture was stirred for 5 h at room 
temperature. The resin was removed by filtration, and the filtrate was concentrated to obtain 
compound 13 as a white solid (270 mg, 60%). An analytical sample was obtained by HPLC on a 
Nucleodur 100-5 C18 (5µm; 4.6 mm i.d. x 250 mm, MeOH:H2O 34:66, flow rate 1.5 mL/min, 
tR=3.6 min). [α]24D=+9.6 (c 0.08, CH3OH); selected 1H NMR (400 MHz CD3OD): δ 4.69 (1H, br 
s), 4.66 (1H, br s), 3.61 (3H, s), 2.31 (1H, m), 2.17 (1H, m), 0.96 (3H, s), 0.90 (3H, d, J = 6.5 Hz), 
0.66 (3H, s); 13C NMR (100 MHz CD3OD): δ 176.5, 76.5, 76.1, 57.8, 57.4, 56.3, 51.8, 43.8, 41.4, 
40.3, 39.1, 36.8, 36.5, 36.4, 33.2, 32.5, 32.4, 30.5, 29.1 (2C), 25.2, 21.9, 18.8, 14.3, 12.5. HR 
ESIMS m/z 587.1975 [M-Na], C25H40NaO10S2 requires 587.1961. 
Disodium 2β,3α-disulfate-5α-cholan-24-oic acid (14). Compound 13 (160 mg, 0.26 mmol) was 
dissolved in 5% methanolic NaOH (10 mL) and water (2 mL) and the solution was refluxed for 5 
h. The resulting solution was adjusted to pH 5 and concentrated under reduced pressure. 
Purification by C18 silica gel column eluting with H2O:MeOH (99:1) gave the carboxylate 14 as a 
white solid (140 mg, 90%). An analytical sample was obtained by HPLC on a Nucleodur 100-5 
C18 (5µm; 4.6 mm i.d. x 250 mm, MeOH:H2O 30:70, flow rate 1.5 mL/min, tR=3.6 min). [α]24D= 
+2.7 (c 0.3, CH3OH); selected 1H NMR (400 MHz CD3OD): δ 4.73 (1H, br s), 4.69 (1H, br s), 2.31 
(1H, m), 2.17 (1H, m), 0.99 (3H, s), 0.94 (3H, d, J = 6.0 Hz), 0.69 (3H, s); 13C NMR (100 MHz 
CD3OD): δ 178.9, 76.4, 76.1, 57.8, 57.4, 56.5, 43.8, 41.4, 40.2, 39.2, 36.8, 36.4, 36.3, 33.2, 32.5 
(2C), 30.5, 29.2 (2C), 25.2, 22.0, 18.7, 14.3, 12.6. ESIMS m/z 595.1636 [M-Na]-, C24H37Na2O10S2 
requires 595.1624. 
2β,3α-disulfate-5α-cholan-24-oyl glycine trisodium salt (16). Carboxylate 14 (50 mg, 0.08 mmol) 
in DMF dry (2 mL) was treated with DMT-MM (66 mg, 0.24 mmol) and triethylamine (278 µL) 
and the mixture was stirred at room temperature for 10 min. Glycine ethyl ester (49.5 mg, 0.48 
mmol) was then added to the mixture and stirring was continued for 24 h. After adding 5% 
methanolic NaOH (5 mL) and stirring for 5 h at room temperature, the alkaline solution was 
adjusted to pH 5, diluted with water and loaded onto a C18 silica gel column, which was washed 
with water (50 mL). Elution with 10% methanol gave the compound 16 (31 mg, 58% over two 
steps). An analytical sample was obtained by HPLC on a Nucleodur 100-5 C18 (5µm; 4.6 mm i.d. 
x 250 mm, MeOH:H2O 30:70, flow rate 1.5 mL/min, tR=3.4 min). [α]24D= +10.8 (c 0.15, CH3OH); 
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selected 1H NMR (400 MHz CD3OD): δ 4.73 (1H, br s), 4.70 (1H, br s), 3.72 (2H, s), 2.28 (1H, 
m), 2.13 (1H, m), 1.00 (3H, s), 0.97 (3H, d, J = 6.0 Hz), 0.69 (3H, s); 13C NMR (100 MHz 
CD3OD): δ 176.5, 172.9, 76.5, 76.2, 57.8, 57.4, 56.6, 44.5, 43.8, 41.4, 40.2, 39.1, 36.9, 36.5, 36.4, 
36.3, 34.1, 33.2, 33.1, 30.5, 29.2, 25.2, 22.0, 18.8, 14.3, 12.6. HR ESIMS m/z 652.1855 [M-Na]-, 
C26H40NNa2O11S2 requires 652.1838. 
2β,3α-disulfate-5α-cholan-24-oyl taurine trisodium salt (17). Carboxylate 14 (50 mg, 0.08 mmol) 
in DMF dry (2 mL) was treated with DMT-MM (66 mg, 0.24 mmol) and triethylamine (278 µL) 
and taurine (60 mg, 0.48 mmol) was then added to the mixture, which was further stirred for 24 h. 
Then, the reaction mixture was concentrated under vacuo and dissolved in water (5 mL). The 
solution was poured over a C18 silica gel column. The product was eluted with H2O:MeOH 99:1. 
To the solution of the solid in methanol (2 mL) was added Amberlite CG 120 sodium form (1 
g)and the mixture was stirred for 5 h at room temperature. The resin was removed by filtration, 
and the filtrate was concentrated to obtain compound 17 as a white solid (39 mg, 67%). An 
analytical sample was obtained by HPLC on a Nucleodur 100-5 C18 (5µm; 4.6 mm i.d. x 250 mm, 
MeOH:H2O 30:70, flow rate 1.5 mL/min, tR=3.4 min). [α]24D= +7.1 (c 0.22, CH3OH); selected 1H 
NMR (400 MHz CD3OD): δ 4.73 (1H, br s), 4.70 (1H, br s), 3.57 (2H, t, J = 7.0 Hz), 2.95 (2H, t, J 
= 7.0 Hz), 2.23 (1H, m), 2.07 (1H, m), 0.99 (3H, s), 0.95 (3H, d, J = 6.4 Hz), 0.68 (3H, s) ; 13C 
NMR (100 MHz CD3OD): δ 176.7, 76.5, 70.5, 57.9, 57.3, 56.5, 51.5, 43.9, 41.4, 40.2 (2C), 39.2, 
36.9, 36.6, 36.4, 36.3, 34.2, 33.2, 33.1, 30.5, 29.1, 25.1, 22.0, 18.8, 14.3, 12.6. HR ESIMS m/z 
702.1685 [M-Na]-, C26H42NNa2O12S3 requires 702.1665. 
Trisodium 2β,3α-disulfate-5α-cholan-24-oyl 5-aminosalycilic acid (18). Carboxylate 14 (50 mg, 
0.08 mmol) in DMF dry (2 mL) was treated with DMT-MM (66 mg, 0.24 mmol), triethylamine 
(278 µL) and 5-aminosalicylic acid (5-ASA) (73 mg, 0.48 mmol) as described for compound 17 to 
obtain 18 as a white solid (43.3 mg, 72%). An analytical sample was obtained by HPLC on a 
Nucleodur 100-5 C18 (5µm; 4.6 mm i.d. x 250 mm, MeOH:H2O 30:70, flow rate 1.5 mL/min, 
tR=3.4 min). [α]24D= +8.2 (c 1.8, CH3OH); selected 1H NMR (400 MHz CD3OD): δ 7.71 (1H, δ, J 
=3.1Hz), 7.6 (1H, dd, J = 3.1 and 8.7 Hz), 6.7 (1H, d, J = 8.7 Hz), 4.75 (1H, br s), 4.72 (1H, br s), 
2.39 (1H, m), 2.25 (1H, m), 1.02 (3H, d, J = 6.0 Hz), 1.01 (3H, s), 0.72 (3H, s); 13C NMR (100 
MHz CD3OD): δ 181.2, 171.4, 142.1, 141.7, 131.8, 131.1, 129.8, 127.0, 76.5, 76.0, 57.9, 57.6, 
56.7, 43.5, 41.4, 40.2, 39.2, 37.2, 36.5, 36.4, 36.3, 34.0, 33.2, 33.1, 30.5, 29.2, 24.2, 22.0, 18.9, 
14.3, 12.6. HR ESIMS m/z 708.2135 [M-Na]-, C31H43NNaO12S2- requires 708.2124. HR ESIMS 
m/z 730.1927 [M-Na]-, C31H42NNa2O12S2 requires 730.1944. 
Sodium 2β,3α-disulfate-5α-cholan-24-ol (19). Dry methanol (26 µL, 0.65 mmol) and LiBH4 (325 
µL, 2 M in THF, 0.65 mmol) were added to a solution of the methyl ester 13 (100 mg, 0.16 mmol) 
in dry THF (5 mL) at 0 °C under argon and the resulting mixture was stirred for 4 h at 0 °C. The 
mixture was quenched by addition of MeOH (2 mL) and then concentrated under vacuo. 
Purification by C18 silica gel eluting with H2O:MeOH (7:3) gave the product 19 as a white solid 
(70 mg, 75%). An analytical sample was obtained by HPLC on a Nucleodur 100-5 C18 (5µm; 4.6 
mm i.d. x 250 mm, MeOH:H2O 32:68, flow rate 1.5 mL/min, tR=3.2 min). [α]24D= +7.8 (c 0.24, 
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CH3OH); selected 1H NMR (400 MHz CD3OD): δ 4.69 (1H, br s), 4.74 (1H, br, s), 4.70 (1H, br s), 
3.65 (1H, m), 3.50 (1H, m), 2.10 (1H, m), 2.00 (1H, m), 1.00 (3H, s), 0.95 (3H, d, J = 6.5 Hz), 
0.69 (3H, s); 13C NMR (100 MHz CD3OD): δ 76.5, 76.2, 63.6, 57.9, 57.6, 56.6, 43.8, 41.5, 40.2, 
39.1, 37.0, 36.4, 36.3, 33.2 (2C), 30.4, 30.3, 29.2, 29.1, 25.2, 22.0, 19.2, 14.3, 12.5; HR ESIMS 
m/z 559.2037 [M-Na]-, C24H40NaO9S2- requires 559.2011. 
5α-Cholest-2-ene (20). An oven-dried 250 mL flask was charged with 10% palladium on carbon 
(100 mg) and cholesterol (1.00 g, 2.6 mmol) and the flask was evacuated and flushed with argon. 
Absolute methanol (50 mL) and dry THF (50 mL) were added, and the flask was flushed with 
hydrogen. The reaction was stirred at room temperature under H2 (1 atm) for 4 h. The mixture was 
filtered through celite and the recovered filtrate was concentrated. The residue was subjected to 
column chromatography on silica gel eluting with hexane:AcOEt (9:1) to give 950 mg of pure 5α-
cholestan-3β-ol (90%). To a solution of this latter (950 mg, 2.4 mmol) in dry pyridine (50 mL), p-
toluenesulfonyl chloride (1.3 g, 7.2 mmol) was added. The solution was stirred at room 
temperature for 24 h and then poured into cold water (30 mL) and extracted with CH2Cl2 (3×50 
mL). The combined organic layer was washed with saturated NaHCO3 solution (50 mL), and 
water (50 mL), and then dried over anhydrous MgSO4 and evaporated in vacuo to give 1.2 g of 
residue, that was subjected to next step without any purification. Lithium bromide (1.9 g, 22.0 
mmol) and lithium carbonate (1.6 g, 22.0 mmol) were added to a solution of tosylate (1.2 g, 2.2 
mmol) in dry DMF (150 mL), and the mixture was refluxed for 1.5 h. After cooling to room 
temperature, the mixture was slowly poured into 10% HCl solution (150 mL) and extracted with 
CH2Cl2 (3×150 mL). The combined organic layer was washed successively with water, saturated 
NaHCO3 solution and water, and then dried over anhydrous MgSO4 and evaporated to dryness to 
obtain pure 20 (773.3 mg, 87% over two steps). [α]24D= +52.5 (c 0.11, CHCl3); selected 1H NMR 
(400 MHz CDCl3): δ 5.6 (2H, m), 0.91 (3H, d, J = 6.4 Hz), 0.87 (6H, d, J = 6.4 Hz), 0.75 (3H, s), 
0.66 (3H, s). 13C NMR (100 MHz CDCl3): δ 126.0, 125.8, 56.4, 56.2, 54.0, 41.4, 40.0, 39.7, 39.5 
(2C), 36.5, 36.1, 35.7, 35.6, 34.6, 31.8, 30.3, 28.7, 28.2, 28.0, 24.2, 22.8, 22.5, 20.9, 18.6, 12.0, 
11.6; HR ESIMS m/z 393.3487 [M+Na]+, C27H46Na requires 393.3497. 
 2α,3α-Epoxy-5α-cholestane (21). To a solution of 20 (750 mg, 2.02 mmol) in CHCl3 (50 mL) was 
added slowly m-chloroperbenzoic acid (488 mg, 2.8 mmol). The mixture was stirred for 4 h at 
room temperature, and then CH2Cl2 (50 mL) and 5% Na2SO3 solution (70 mL) were added. The 
CH2Cl2 phase was washed with water (70 mL), dried over anhydrous MgSO4 and evaporated to 
dryness to give 560 mg of crude epoxide 21, that was subjected to next step without any 
purification. Selected 1H NMR (400 MHz CDCl3): δ 3.16 (1H, br s), 3.11 (1H, br s), 0.88 (3H, d, J 
= 6.5 Hz), 0.85 (6H, d, J = 6.5 Hz), 0.73 (3H, s), 0.62 (3H, s); 13C NMR (100 MHz CDCl3): δ 56.2, 
56.1, 53.6, 52.6, 51.3, 42.4, 40.0, 39.8, 39.5, 38.2, 36.2, 36.1, 35.7, 35.6, 33.6, 31.6, 29.0, 28.4, 
28.2, 28.0, 24.2, 22.8, 22.5, 20.8, 18.6, 12.9, 11.9; HR ESIMS m/z 409.3458 ([M+Na]+, 
C27H46NaO requires 409.3446. 
5α-Cholestan-2β,3α-diol (22). A solution of epoxide 21 (560 mg, 1.45 mmol) in THF (15 mL) was 
treated with 1N H2SO4 (3.6 mL, 3.6 mmol) solution and stirred for 24 h at room temperature. After 
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neutralization with saturated NaHCO3 solution, the mixture was evaporated to a fifth of the initial 
volume, diluted with water (50 mL), and extracted with ethyl acetate (3x50 mL). The combined 
organic extracts were washed with water, dried over anhydrous MgSO4, filtered and evaporated to 
dryness. Purification on a silica gel column by eluting with hexane:AcOEt 7:3 afforded pure 22 
(637 mg, 78% over two steps). [α]24D= +13.2 (c 0.2, CH3OH); selected 1H NMR (400 MHz 
CDCl3): δ 3.90 (1H, br s), 3.87 (1H, br s), 0.90 (3H, d, J = 6.7 Hz), 0.87 (6H, d, J = 6.7 Hz), 0.80 
(3H, s), 0.65 (3H, s); 13C NMR (100 MHz CDCl3): δ 72.1, 71.0, 56.7, 56.5, 55.4, 42.7, 40.5, 39.9, 
39.5, 38.9, 36.2, 36.1, 35.8, 35.7, 35.3, 31.3, 31.0, 28.5, 28.2, 28.0, 24.1, 22.8, 22.5, 20.8, 18.6, 
14.6, 12.0; HR ESIMS m/z 427.3572 ([M + Na]+, C27H48NaO2 requires 427.3552. 
2β,3α-cholestane disulfate (23). Triethylamine-sulfur trioxide complex (4.07 g, 22.5 mmol) was 
added to a solution of diol 22 (600 mg, 1.5 mmol) in DMF dry (70 mL) under an argon 
atmosphere, and the mixture was stirred at 95 °C for 48 h. Then, the reaction mixture was 
quenched with water (30 mL). The solution was poured over a C18 silica gel column to remove 
excess Et3N.SO3. The product was eluted by MeOH and followed by evaporation of the solvent to 
yield a yellow solid [tris-(triethylammonium sulfate) salt]. To the solution of the solid in methanol 
(60 mL) was added Amberlite CG 120 sodium form (60 g). The mixture was stirred for 5 h at 
room temperature. The resin was removed by filtration, and the filtrate was concentrated to obtain 
compound 23 as a white solid (821 mg, 90%). An analytical sample was obtained by HPLC on a 
Nucleodur 100-5 C18 (5µm; 4.6 mm i.d. x 250 mm, MeOH:H2O 87:13, flow rate 1.5 mL/min, 
tR=2.6 min). [α]24D= +16 (c 0.2, CH3OH); selected 1H NMR (400 MHz CDCl3): δ 4.75 (1H, m), 
4.71 (1H, m), 0.97 (3H, s), 0.93 (3H, d, J = 6.4 Hz), 0.88 (6H, d, J = 6.4 Hz), 0.68 (3H, s); 13C 
NMR (100 MHz CDCl3): δ 76.5, 76.1, 57.8, 57.6, 56.6, 43.8, 41.4, 40.7, 40.2, 39.1, 37.3, 37.1, 
36.4, 36.3, 31.8, 30.7, 30.5, 29.3, 29.1 (2C), 25.2, 23.2, 22.9, 22.0, 19.2, 14.3, 12.5; HR ESIMS 
m/z 585.2527 [M-Na]-, C27H49NaO8S2 requires 585.2532.  
Methyl 3α-hydroxy-5α-cholan-24-oate (24). To a solution of methyl 3β-hydroxy-5α-cholan-24-
oate 789 (173 mg, 0.44 mmol) in dry pyridine (30 mL), p-toluenesulfonyl chloride (420 mg, 2.2 
mmol) was added. The solution was stirred at room temperature for 24 h and then poured into cold 
water (30 mL) and extracted with CH2Cl2 (3×50 mL). The combined organic layer was washed 
saturated NaHCO3 solution (50 mL), and water (50 mL), and then dried over anhydrous MgSO4 
and evaporated in vacuo to give 200 mg of residue, that was subjected to next step without any 
purification. A solution of methyl 3β-tosyl-5α-cholan-24-oate (200 mg, 0.36 mmol) and 
CH3COOK (36 mg, 0.36 mmol) dissolved in water (1 mL) and DMF (7 mL) was refluxed for 5 h. 
The solution was cooled at room temperature and then ethyl acetate and water were added. The 
separated aqueous phase was extracted with ethyl acetate (3×30 mL). The organic phase was 
washed with water, dried (Na2SO4) and evaporated to dryness to give 190 mg of mixture, that was 
subjected to next step without any purification. This residue was dissolved in 32 mL of mixture 
CHCl3:MeOH (5:3) and p-toluensulfonic acid (p-TsOH) (619 mg, 3.6 mmol) was added. The 
mixture was quenched by addition of NaHCO3 solution (30 mL) and then concentrated under 
vacuo. Ethyl acetate and water were added and the separated aqueous phase was extracted with 
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ethyl acetate (3×50 mL). The combined organic phase was washed with water, dried (Na2SO4) and 
concentrated. Purification by silica gel eluting with hexane-AcOEt 99:1 gave the alcohol 24 as a 
white solid (130 mg, 75% over three steps). [α]24D= +7.2 (c 0.05, CH3OH); selected 1H NMR (400 
MHz CDCl3): δ 4.03 (1H, br s), 3.66 (3H, s), 2.35 (1H, m), 2.20 (1H, m), 0.90 (3H, d, J = 6.0 Hz), 
0.77 (3H, s), 0.64 (3H, s); 13C NMR (100 MHz CDCl3): δ 175.3, 66.8, 56.8, 56.1, 54.6, 51.8, 42.8, 
40.2, 40.0, 39.3, 36.1, 35.7, 35.6, 32.4, 32.2, 31.3, 31.2, 29.2, 28.8, 28.3, 24.4, 21.0, 18.5, 14.2, 
12.3; HR ESIMS m/z 413.5867 [M+Na]+, C25H42NaO3 requires 413.5884. 
5α-cholan-3α,24-diyl-3,24-sodium disulfate (25). Dry methanol (70 µL, 1.8 mmol) and LiBH4 
(900 µL, 2 M in THF, 1.8 mmol) were added to a solution of the methyl ester 24 (100 mg, 0.25 
mmol) in dry THF (10 mL) at 0 °C under argon and the resulting mixture was stirred for 4 h at 0 
°C. The mixture was quenched by addition of MeOH (4 mL) and then concentrated under vacuo. 
Ethyl acetate and water were added and the separated aqueous phase was extracted with ethyl 
acetate (3×30 mL). The combined organic phase was washed with water, dried (Na2SO4) and 
concentrated to obtain 5α-cholan-3α,24-diol as a white solid (77 mg, 85%). The triethylamine-
sulfur trioxide complex (350 mg, 2 mmol) was added to a solution of diol (70 mg, 0.2 mmol) in 
DMF dry (2 mL) under an argon atmosphere, and the mixture was stirred at 95 °C for 24 h. Then, 
the reaction mixture was quenched with water (1.6 mL) and the solution was poured over a C18 
silica gel column to remove excess Et3N.SO3. The product was eluted by MeOH and followed by 
evaporation of the solvent to yield a yellow solid [tris-(triethylammonium sulfate) salt]. To the 
solution of the solid in methanol (4 mL) was added Amberlite CG 120 sodium form (2 g). The 
mixture was stirred for 5 h at room temperature. The resin was removed by filtration, and the 
filtrate was concentrated to obtain a residue that by purification on C18 [H2O:MeOH (7:3)] gave 
the product 25 as a white solid (71.3 mg, 63%). An analytical sample was obtained by HPLC on a 
Nucleodur 100-5 C18 (5µm; 4.6 mm i.d. x 250 mm, MeOH:H2O 25:75, flow rate 1.5 mL/min, 
tR=2.4 min). [α]24D= + 0.42 (c 1.2, CH3OH); selected 1H NMR (400 MHz CD3OD): δ 4.55 (1H, br 
s), 3.96 (2H, m), 0.90 (3H, d, J = 6.5 Hz), 0.80 (3H, s), 0.65 (3H, s) ; 13C NMR (100 MHz 
CD3OD): δ 76.5, 69.7, 57.9, 57.6, 55.1, 43.8, 41.6, 41.4, 40.8, 36.9, 36.8, 34.7, 33.8, 33.2, 33.1, 
29.6, 29.2, 27.9, 27.2, 25.2, 21.9, 19.0, 14.4, 12.5. HR ESIMS m/z 543.2078 [M-Na]-, 
C24H40NaO8S2 requires 543.2062. 
5α-Cholan-3β,24-diyl-3,24-sodium disulfate (26). Dry methanol (10 µL, 0.20 mmol) and LiBH4 
(100 µL, 2 M in THF, 0.20 mmol) were added to a solution of the methyl ester 7 (20 mg, 0.05 
mmol) in dry THF (2 mL) at 0 °C under argon and the resulting mixture was stirred for 4 h at 0 °C. 
The mixture was quenched by addition of MeOH (2 mL) and then allowed to warm to room 
temperature and concentrated under vacuo. Ethyl acetate and water were added and the separated 
aqueous phase was extracted with ethyl acetate (3×30 mL). The combined organic phases were 
washed with water, dried (Na2SO4) and concentrated to obtain 5α-cholan-3β,24-diol as a white 
solid (13 mg, 72%). The triethylamine-sulfur trioxide complex (63 mg, 0.35 mmol) was added to a 
solution of diol (13 mg, 0.035 mmol) in DMF dry (2 mL) under an argon atmosphere, and the 
mixture was stirred at 95 ◦C for 3 h. The resulting solution was concentrated under reduced 
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pressure. To the solution of the solid in methanol (3 mL) was added Amberlite CG 120 sodium 
form (1 g). The mixture was stirred for 5 h at room temperature. The resin was removed by 
filtration, and the filtrate was concentrated and then diluted with water and loaded onto a C18 
silica gel column, which was washed with water (50 mL). Elution with 30% aqueous methanol 
gave the compound 26 as a white solid (15 mg, 78%). An analytical sample was obtained by 
HPLC on a Nucleodur 100-5 C18 (5µm; 4.6 mm i.d. x 250 mm, MeOH:H2O 25:75, flow rate 1.5 
mL/min, tR=2.4 min). [α]24D= +6.4 (c 1.0, CH3OH); selected 1H NMR (400 MHz CD3OD): δ 4.59 
(1H, m), 3.95 (1H, br s), 0.95 (3H, d, J = 6.0 Hz), 0.82 (3H, s), 0.78 (3H, s); 13C NMR (100 MHz 
CD3OD): δ 79.9, 64.3, 57.9, 57.6, 55.4, 43.8, 41.4 (2C), 38.2, 36.8, 36.7, 36.3, 33.3, 33.1, 32.2, 
30.7, 29.2, 28.7, 27.1, 25.2, 22.3, 19.0, 14.4, 12.5. HR ESIMS m/z 543.2075 [M-Na]-, 
C24H40NaO8S2 requires 543.2062. 
Synthesis of solomonsterol B 
3α,6α-Diformyloxy-5β-cholan-24-oic Acid (27): A solution of hyodeoxycholic acid (3) (2 g, 5.09 
mmol) in 90% formic acid (30 mL) containing 70% perchloric acid (70 µL) was stirred at 50 °C 
for 1.5 h. The temperature was lowered to 40 °C. Acetic anhydride (24 mL) was added over 10 
min, and the mixture was stirred for an additional 10 min. The solution was cooled to room 
temperature and poured into water (50 mL) with vigorous stirring. The precipitate was filtered, 
washed with water (20 mL), and dissolved in diethyl ether. The solution was dried with sodium 
sulfate, and evaporated to give of 27 (1.9 g, 97 %), which was used in the next step without further 
purification. An analytical sample was obtained by silica gel chromatography, eluting with 
hexane/EtOAc (6:4). [α]24D = +5.8 (c = 1.3, CH3OH). Selected 1H NMR (400 MHz, CDCl3): δ  
7.90 (s, 1 H), 7.87 (s, 1 H), 5.15 (m, 1 H), 4.67 (m, 1 H), 2.24 (m, 1 H), 2.10 (m, 1 H), 0.85 (s, 3 
H), 0.77 (d, J = 6.5 Hz, 3 H), 0.5 (s, 3 H) ppm. 13C NMR (100 MHz, CDCl3): δ  179.7, 160.7, 
160.6, 73.4, 70.8, 55.7, 55.6, 50.0, 45.1, 42.6, 39.6, 35.8 (2 C), 35.0, 34.6, 34.4, 30.8, 30.5, 27.8, 
26.2, 25.9, 23.9, 23.1, 20.5, 18.1, 11.8 ppm. HRMS-ESI m/z 449.2913 ([M + H]+, C26H41O6+ 
requires 449.2903. 
3α,6α-Diformyloxy-24-nor-5β-cholane-23-nitrile (28). 1.9 g of 3α,6α-diformyloxy-5β-cholan-24-
oic acid, 27 (4.6 mmol), in 6.7 mL of trifluoroacetic acid and 1.8 mL (12.7 mmol) of 
trifluoroacetic anhydride were stirred at 5 °C until dissolution. Sodium nitrite (321 mg, 4.65 
mmol) was added in small portions and the reaction mixture  was stirred at 5 °C for 1 h and then at 
40 °C for 1.5 h. The solution was cooled to room temperature and poured into 30 mL of 2N 
NaOH. The mixture was extracted with ethyl ether and the organic layer was washed with 1N 
NaOH and water, dried with sodium sulfate, and evaporated to give 1.66 g of pure 28 (80%). 
[α]24D= +8.8 (c 0.22, CHCl3); 1H NMR (400 MHz, CD3OD): δ 8.08 (1H, s), 8.07 (1H, s), 5.27 (1H, 
m), 4.73 (1H, m), 2.46 (1H, dd, J= 4.1, 16.9 Hz), 2.34 (1H, dd, J= 6.0, 16.9 Hz), 0.93 (3H, s), 0.72 
(3H, d, J= 6.9 Hz), 0.71 (3H, s). 13C NMR (100 MHz, CD3OD): δ 162.7, 162.6, 120.3, 72.3, 68.6, 
57.3, 56.3, 49.6, 46.8, 43.9, 41.1, 40.9, 36.6, 36.4, 36.0, 35.3, 34.5, 29.8, 28.9, 26.3, 25.0, 24.1, 
21.8, 19.7, 12.5; HRMS-ESI m/z 416.2821 [M + H]+, C25H39NO4+ requires 416.2801. 
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24-nor-hyodeoxycholic acid (29). 1.66 g of crude 28 was refluxed with 30% KOH in ca. 50 mL of 
ethanol-water 1:l for 48 h. The ethanol was evaporated, the solution was saturated with sodium 
chloride and extracted with ethyl ether. The organic phase was washed with water, dried, and 
evaporated to give white solid residue 29 (1.18 g, 78%). [α]24D= +3.0 (c 2.9, CH3OH); 1H NMR 
(400 MHz, CD3OD): δ 4.01 (1H, dt, J= 4.6, 12.1 Hz), 3.52 (1H, m), 2.40 (1H, m), 1.99 (1H, m), 
0.98 (3H, d, J= 6.0 Hz), 0.91 (3H, s), 0.70 (3H, s). 13C NMR (100 MHz, CD3OD): δ 177.8, 72.4, 
68.7, 57.4, 57.2, 49.5, 43.9, 42.4, 41.1, 41.0, 36.8, 36.6, 36.0, 35.3, 34.8, 30.9, 29.7, 29.1, 25.1, 
23.9, 21.7, 19.9, 12.4; HRMS-ESI m/z 379.2858 [M + H]+, C23H39O4+ requires 379.2848. 
Methyl 3α,6α-dihydroxy-24-nor-5β-cholan-23-oate. A mixture of the 24-norhyodeoxycholic acid 
29 (1.18 g, 3.11 mmol) and p-toluenesulfonic acid (1.2 g, 6.22 mmol) in methanol dry (50 mL) 
was stirred at room temperature for over night. The mixture was quenched with NaHCO3 solution, 
most of the solvent was evaporated, and the residue was extracted with EtOAc. The combined 
extract was washed with brine, dried with Na2SO4, and evaporated to give the desired methyl ester 
as colorless amorphous solids: 1.0 g (96%). [α]24D= -1.0 (c 0.69, CHCl3); 1H NMR (400 MHz, 
CDCl3): δ 3.98 (1H, m), 3.61 (3H, s), 3.54 (1H, m), 2.38 (1H, m), 1.98 (1H, m), 0.92 (3H, d, J= 
6.0 Hz), 0.84 (3H, s), 0.62 (3H, s). 13C NMR (100 MHz, CDCl3): δ 174.1, 71.3, 67.8, 56.1, 56.0, 
51.3, 48.2, 42.8, 41.3, 39.7 (2C), 35.8, 35.4, 34.6, 34.4, 33.7, 29.7, 28.9, 28.1, 24.1, 23.3, 20.6, 
19.4, 11.9; HRMS-ESI m/z 393.3015 [M + H]+, C24H41O4+ requires 393.3005. 
Methyl 3,6-ditosyloxy-24-nor-5α-cholan-23-oate (30). To a solution of methyl ester (1.0 g, 2.55 
mmol) in dry pyridine (15 mL), a solution of tosyl chloride (2.4 g, 12.7 mmol) in dry pyridine (15 
mL) was added, and the mixture was stirred at room temperature for 4 h. The solvent was 
evaporated and the precipitate was re-dissolved in CH2Cl2, washed with NaHCO3 and water, dried 
with Na2SO4 and then evaporated to dryness. The residue was passed through a short column of 
silica gel (120 g) eluting with EtOAc/hexane (1:1, v/v) to give 30 as a white solid, 1.4 g (78%). 
[α]24D= +3.9 (c 1.2, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.78 (2H, d, J= 8.3 Hz), 7.71 (2H, d, 
J= 8.3 Hz), 7.35 (2H, d, 8.3 Hz), 7.33 (2H, d, J= 8.3 Hz), 4.77 (1H, m), 4.30 (1H, m), 3.65 (3H, s), 
2.5 (3H, s), 2.40 (1H, dd, J= 3.4, 15.0 Hz), 2.02 (1H, m), 0.93 (3H, d, J= 6.2 Hz), 0.79 (3H, s), 
0.62 (3H, s). 13C NMR (100 MHz, CDCl3): δ 174.2, 145.0 (2C), 134.7 (2C), 130.2 (4C), 127.8 
(4C), 82.0, 79.9, 56.1, 56.0, 51.7, 46.6, 43.2, 41.6, 39.7, 39.6, 36.4, 35.8, 35.0 (2C), 33.9, 28.4, 
27.6, 26.7, 24.2, 23.2 (2C), 21.9, 20.7, 19.7, 12.3; HRMS-ESI m/z 701.3192 [M + H]+, 
C38H53O8S2+ requires 701.3182. 
Methyl 3β-hydroxy-24-nor-5-cholen-23-oate (31). A solution of methyl 3,6-ditosyloxy-24-nor-5α-
cholan-23-oate (1.4 g, 2 mmol), CH3COOK (196.3 mg, 2 mmol) dissolved in water (2 mL) and 
N,N’-dimethylformamide (DMF, 14 mL) was refluxed for 4 h. The solution was cooled at room 
temperature and then ethyl acetate and water were added. The separated aqueous phase was 
extracted with ethyl acetate (3 ×30 mL) and the combined organic phases were washed with water, 
dried (Na2SO4) and evaporated to dryness to give 1 g of mixture, that was subjected to next step 
without any purification. The mixture was dissolved in 32 mL of CHCl3:MeOH (5:3) and to the 
solution was added p-toluensulfonic acid (p-TsOH) (1.14 g, 6 mmol). The mixture was quenched 
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by addition of NaHCO3 solution (30 mL) and then concentrated under vacuo. Ethyl acetate and 
water were added and the separated aqueous phase was extracted with ethyl acetate (3×50 mL). 
The combined organic phases were washed with water, dried (Na2SO4) and concentrated. 
Purification by silica gel eluting with hexane/AcOEt (97:3) gave the alcohol 31 as a white solid 
(600 mg, 80% over two steps). [α]24D= -2.4 (c 1.45, CHCl3); selected 1H NMR (400 MHz, CDCl3): 
δ 5.30 (1H, d, J= 2.4 Hz), 3.62 (3H, s), 3.48 (1H, m), 2.39 (1H, dd, J= 2.6, 13.7 Hz), 2.00 (1H, m), 
0.96 (3H, s), 0.94 (3H, d, J = 6.5 Hz), 0.67 (3H, s); 13C NMR (100 MHz, CDCl3): δ 174.4, 141.1, 
121.8, 71.9, 56.9, 56.1, 51.7, 42.6, 41.6, 41.1, 39.8, 37.5, 36.7, 34.0, 32.1, 32.0 (2C), 31.6, 28.4, 
24.4, 24.1, 21.2, 19.7, 12.3; HRMS-ESI m/z 375.2908 [M+H]+, C24H39O3+ requires 375.2899. 
Methyl 3β-hydroxy-24-nor-5α-cholan-23-oate (32). An oven-dried 100 mL flask was charged with 
10% palladium on carbon (50 mg) and compound 31 (600 mg, 1.6 mmol) and the flask was 
evacuated and flushed with argon. Absolute methanol (30 mL) and dry THF (30 mL) were added 
and the reaction was stirred at room temperature under H2 for 4 h. The mixture was filtered 
through celite and the recovered filtrate was concentrated to give 506 mg of pure 32 (84%). 
[α]24D= +1.0 (c 0.17, CHCl3); 1H NMR (400 MHz, CDCl3): δ 3.63 (3H, s), 3.56 (1H, m), 2.40 (1H, 
dd, J= 2.8, 14.3 Hz), 1.98 (1H, m), 0.94 (3H, d, J= 6.3 Hz), 0.77 (3H, s), 0.66 (3H, s). 13C NMR 
(100 MHz, CDCl3): δ 174.4, 71.6, 56.7, 56.3, 54.5, 51.6, 42.9, 41.7, 40.1, 38.4, 37.2, 35.7 (2C), 
34.1, 32.3 (2C), 31.7, 28.9, 28.5, 24.4, 21.4, 19.7, 12.5, 12.3; HRMS-ESI m/z 377.3060 ([M + H]+, 
C24H41O3+ requires 377.3050. 
Methyl 24-nor-5α-chol-2-en-23-oate (33). To a solution of 32 (500 mg, 1.3 mmol) in dry pyridine 
(25 mL), p-toluenesulfonyl chloride (1.2 g, 6.6 mmol) was added. The solution was stirred at room 
temperature for 24 h and then poured into cold water (20 mL) and extracted with CH2Cl2 (3 × 15 
ml). The combined organic layer was washed with saturated NaHCO3 solution (30 mL) and water 
(30 mL), dried over anhydrous MgSO4 and evaporated in vacuo to give 665 mg of 3-tosylate 
derivative that was subjected to next step without any purification. 1H NMR (400 MHz CDCl3): δ 
7.78 (2H, d, J= 8.1 Hz), 7.32 (2H, d, J= 8.1 Hz), 4.41 (1H, m),. 3.65 (3H, s), 2.44 (3H, s), 2.41 
(1H, dd, J= 2.7, 12.0 Hz), 1.96 (1H, m), 0.95 (3H, d, J= 6.3 Hz), 0.77 (3H, s), 0.66 (3H, s); 13C 
NMR (100 MHz CDCl3): δ 174.3, 144.6, 135.0, 130.0 (2C), 127.7 (2C), 82.7, 56.5, 56.2, 54.1, 
51.6, 42.9, 41.6, 41.2, 39.9, 36.9, 35.5 (2C), 35.3, 35.0, 34.0, 32.0, 28.5, 28.4, 24.3, 24.1, 21.4, 
21.3, 19.7, 12.2; HRMS-ESI m/z 531.3164 [M + H]+, C31H47O5S+ requires 531.3144. Lithium 
bromide (217 mg, 2.5 mmol) and lithium carbonate (184 mg, 2.5 mmol) were added to a solution 
of 3-tosylate derivative (665 mg, 1.25 mmol) in dry DMF (30 mL), and the mixture was refluxed 
for 5 h. After cooling to room temperature, the mixture was slowly poured into 10% HCl solution 
(150 mL) and extracted with CH2Cl2 (3 × 150 mL). The combined organic layer was washed 
successively with water, saturated NaHCO3 solution, and water, and then dried over anhydrous 
MgSO4 and evaporated to dryness to obtain pure 33 (380 mg, 81% over two steps). [α]24D= +3.1 (c 
0.76, CHCl3); 1H NMR (400 MHz CDCl3): δ 5.58 (2H, m), 3.65 (3H, s), 2.42 (1H, dd, J= 2.7, 14.0 
Hz), 1.96 (1H, m), 0.96 (3H, d, J= 6.5 Hz), 0.74 (3H, s), 0.69 (3H, s). 13C NMR (100 MHz 
CDCl3): δ 174.4, 126.2, 126.1, 56.7, 56.3, 54.2, 51.6, 42.8, 41.7, 41.6, 40.1, 40.0, 39.9, 35.8, 34.7, 
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34.1, 31.9, 30.5, 28.4, 24.4, 21.1, 20.9, 19.7, 12.2; HRMS-ESI m/z 359.2963 ([M + H]+, C24H39O2+ 
requires 359.2950. 
Methyl 2β,3α-dihydroxy-24-nor-5α-cholan-23-oate (35). To a solution of 33 (380 mg, 1.06 mmol) 
in CHCl3 (20 mL) was added slowly m-chloroperbenzoic acid (256 mg, 1.5 mmol). The mixture 
was stirred for 4 h at room temperature, and then CH2Cl2 (3 × 50 mL) and 5% Na2SO3 solution (70 
mL) were added. The combined CH2Cl2 extracts were washed with water (70 mL), dried over 
anhydrous MgSO4 and evaporated to dryness to give 400 mg of crude 2,3-epoxide, that was 
subjected to next step without any purification. A solution of epoxide (400 mg, 1.06 mmol) in 
THF (20 mL) was treated with 1N H2SO4 (5.3 mL, 2.65 mmol) solution and stirred for 24 h at 
room temperature. After neutralization with saturated NaHCO3 solution, the mixture was 
concentrated, diluted with water (50 mL), and extracted with ethyl acetate (3 x 50 mL). The 
combined organic extracts were washed with water, dried over anhydrous MgSO4, filtered and 
evaporated to dryness. Purification on silica gel column eluting with CH2Cl2-MeOH (9:1) afforded 
pure 35 (340 mg, 81% over two steps). [α]24D= -0.6 (c 0.5, CHCl3); 1H NMR (400 MHz CDCl3): δ 
3.85 (1H, br s), 3.80 (1H, br s), 3.63 (3H, s), 2.38 (1H, dd, J= 2.7, 14.0 Hz),  0.95 (3H, s), 0.90 
(3H, d, J = 6.5 Hz), 0.60 (3H, s); 13C NMR (100 MHz CDCl3): δ 171.3, 71.6, 70.5, 56.6, 56.2, 
55.2, 51.6, 41.7, 40.4, 40.0, 39.9, 39.1, 35.1 (2C), 34.1, 32.0, 31.8, 31.7, 28.4, 24.3, 21.0, 19.7, 
14.5, 12.3; HRMS-ESI m/z 393.3015 ([M + H]+, C24H41O4+ requires 393.3005. 
24-Nor-5α-cholan-2β,3α,23-triol (34). Dry methanol (122 µL, 3.03 mmol) and LiBH4 (1.5 mL, 2 
M in THF, 3.03 mmol) were added to a solution of the methyl ester 35 (170 mg, 0.43 mmol) in dry 
THF (10 mL) at 0 °C under argon and the resulting mixture was stirred for 8 h at 0 °C. The 
mixture was quenched by addition of NaOH (1N, 4 mL) and then allowed to warm to room 
temperature. Ethyl acetate was added and the separated aqueous phase was extracted with ethyl 
acetate (3×15 mL). The combined organic phases were washed with water, dried (Na2SO4) and 
concentrated. Purification by silica gel eluting with CH2Cl2-MeOH (95:5) gave the alcohol 34 as a 
white solid (110 mg, 69%). [α]24D= -9.8 (c 0.05, CH3OH); 1H NMR (400 MHz CD3OD): δ 3.80 
(1H, br s), 3.75 (1H, br s), 3.46 (2H, m), 0.99 (3H, s), 0.95 (3H, d, J = 6.3 Hz), 0.69 (3H, s); 13C 
NMR (100 MHz CD3OD): δ 72.2, 71.2, 60.8, 59.9, 57.9, 56.7, 41.5, 40.9, 40.1, 39.8, 36.9, 36.3, 
34.1, 33.3, 32.4, 30.7, 29.5, 29.3, 25.2, 22.0, 19.3, 14.6, 12.5; HRMS-ESI m/z 365.3078 ([M + H]+, 
C23H41O3+ requires 365.3056. 
24-Nor-5α-cholan-2β,3α,23-tryl-2,3,23-sodium trisulfate (2). The triethylamine-sulfur trioxide 
complex (272 mg, 1.5 mmol) was added to a solution of triol 34 (110 mg, 0.3 mmol) in DMF dry 
(5 mL) under argon and the mixture was stirred at 95 °C for 24 h. The reaction mixture was 
quenched with water (800 µL) and the resulting solution was poured over a silica gel column to 
remove the excess of SO3·NEt3. Elution with MeOH, followed by evaporation of the solvent, 
yielded a yellow solid (diammonium trisulfate salt). To the solution of the solid in methanol (15 
mL) was added Amberlite CG 120 sodium form (10 g), and the resulting mixture was stirred for 5 
h at room temperature. The resin was removed by filtration, and the filtrate was concentrated to 
obtain a mixture that was further purified by HPLC on a Nucleodur 100-5 C18 (5 µm, 10 mm i.d. 
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x 250 mm) with MeOH:H2O (34:66) as eluent (flow rate 3 mL/min) to give 144 mg (72%) of 
solomonsterol B (2) (tR=4.4 min), [α]24D= +2.1 (c 0.08, CH3OH); 1H NMR (700 MHz CD3OD): δ 
4.73 (1H, br s), 4.70 (1H, br s), 4.05 (1H, m), 4.01 (1H, m), 1.00 (3H, s), 0.98 (3H, d, J= 6.5 Hz), 
0.70 (3H, s); 13C NMR (100 MHz CD3OD): δ 76.5, 71.1, 67.3, 57.8, 56.6, 56.1, 43.5, 41.4, 39.8, 
38.7, 36.6, 36.4, 36.3, 34.2, 33.2, 30.5, 29.2, 29.1, 25.2, 22.0, 19.1, 14.3, 12.5. HRMS-ESI m/z 
647.1298 ([M - Na]-,C23H37Na2O12S3-, requires 647.1243. 
Sodium 2β,3α-disulfate-24-nor-5α-cholan-23-ol (37). Triethylamine-sulfur trioxide complex (780 
mg, 4.3 mmol) was added to diol 35 (170 mg, 0.43 mmol) in DMF dry (10 mL) under an argon 
atmosphere, and the mixture was stirred at 95 °C for 48 h. The reaction mixture was quenched 
with water (1.6 mL) and the solution was poured over a C18 silica gel column to remove excess 
SO3·NEt3. The product was eluted by MeOH and the evaporation of the solvent yielded a yellow 
solid [bis-(triethylammonium sulfate) salt]. To the solid dissolved in methanol (30 mL) was added 
Amberlite CG 120 sodium form (30 g) and the mixture was stirred for 5 h at room temperature. 
The resin was removed by filtration, and the filtrate was concentrated to obtain 250 mg methyl 
2β,3α-disulfate-24-nor-5α-cholan-23-oate 36, that was subjected to next step without any 
purification. Dry methanol (54 µL, 2.15 mmol) and LiBH4 (1.0 mL, 2 M in THF, 2.15 mmol) were 
added to a solution of 36 (250 mg, 0.43 mmol) in THF dry (5 mL) at 0 °C under argon and the 
resulting mixture was stirred for 3 h at 0 °C. The mixture was quenched by addition of MeOH (2 
mL) and then concentrated under vacuo. Purification by C18 cartige eluting with MeOH:H2O 
(1:99) gave the product 37 as a white solid (190 mg, 78% over two steps). [α]24D= +19.8 (c 0.02, 
CH3OH); selected 1H NMR (400 MHz CD3OD): δ 4.72 (1H, br s), 4.70 (1H, br, s), 3.64 (1H, m), 
3.63 (1H, m), 1.00 (3H, s), 0.95 (3H, d, J = 6.5 Hz), 0.70 (3H, s); HRMS-ESI m/z 545.1875 [M-
Na]-, C23H38NaO9S2- requires 545.1855. 
 
Spectroscopic Data  
1H NMR spectrum of Compound 4  in CDCl3 at 400 MHz. 
 
 
 
 
13C NMR spectrum of Compound 4  in CDCl3 at 100 MHz. 
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13C NMR spectrum of Compound 4  in CDCl3 at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 5  in CDCl3 at 400 MHz. 
 
 
 
 
 
13C NMR spectrum of Compound 5  in CDCl3 at 100 MHz. 
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13C NMR spectrum of Compound 5  in CDCl3 at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 6  in CDCl3 at 400 MHz. 
 
 
 
 
 
 
13C NMR spectrum of Compound 6  in CDCl3 at 100 MHz. 
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13C NMR spectrum of Compound 6  in CDCl3 at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 7  in CDCl3 at 400 MHz. 
 
 
 
 
 
13C NMR spectrum of Compound 7  in CDCl3 at 100 MHz. 
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13C NMR spectrum of Compound 7  in CDCl3 at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 8  in CDCl3 at 400 MHz. 
 
 
 
 
 
13C NMR spectrum of Compound 8  in CDCl3 at 100 MHz. 
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13C NMR spectrum of Compound 8  in CDCl3 at 100 MHz. 
 
 
 
 
 
 
1H NMR spectrum of Compound 9  in CDCl3 at 400 MHz. 
 
 
 
 
 
1H NMR spectrum of Compound 9  in CDCl3 at 400 MHz. 
 
 
 
 
 
13C NMR spectrum of Compound 9  in CDCl3 at 100 MHz. 
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13C NMR spectrum of Compound 9  in CDCl3 at 100 MHz. 
 
 
 
 
 
1H NMR spectrum of Compound 10  in CDCl3 at 400 MHz. 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 10  in CDCl3 at 400 MHz. 
 
 
 
 
 
 
 
13C NMR spectrum of Compound 10  in CDCl3 at 100 MHz. 
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13C NMR spectrum of Compound 10  in CDCl3 at 100 MHz. 
 
 
 
 
 
1H NMR spectrum of Compound 11  in CDCl3 at 400 MHz. 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 11  in CDCl3 at 400 MHz. 
 
 
 
 
 
13C NMR spectrum of Compound 11  in CDCl3 at 100 MHz. 
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13C NMR spectrum of Compound 11  in CDCl3 at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 12  in CD3OD at 400 MHz. 
 
 
 
 
 
13C NMR spectrum of Compound 12  in CD3OD at 100 MHz. 
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13C NMR spectrum of Compound 12  in CD3OD at 100 MHz. 
 
 
 
 
1H NMR spectrum of Compound 1  in CD3OD at 400 MHz. 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 1  in CD3OD at 400 MHz. 
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13C NMR spectrum of Compound 1  in CD3OD at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 13  in CD3OD at 400 MHz. 
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13C NMR spectrum of Compound 13  in CD3OD at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 15  in CD3OD at 400 MHz. 
 
 
 
 
 
 
 
 
 
13C NMR spectrum of Compound 14  in CD3OD at 100 MHz. 
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13C NMR spectrum of Compound 15  in CD3OD at 100 MHz. 
 
 
 
 
 
 
1H NMR spectrum of Compound 16  in CD3OD at 400 MHz. 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 16  in CD3OD at 400 MHz. 
 
 
 
 
 
13C NMR spectrum of Compound 17  in CD3OD at 400 MHz. 
 
 
 
 
 
 
 
Experimental section 
156 
 
13C NMR spectrum of Compound 16  in CD3OD at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 17  in CD3OD at 400 MHz. 
 
 
 
 
 
 
 
13C NMR spectrum of Compound 18  in CD3OD at 400 MHz. 
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13C NMR spectrum of Compound 17  in CD3OD at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 18  in CD3OD at 400 MHz. 
 
 
 
 
 
 
13C NMR spectrum of Compound 19  in CD3OD at 400 MHz. 
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13C NMR spectrum of Compound 18  in CD3OD at 100 MHz. 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 20 in CD3OD at 400 MHz. 
 
 
 
 
 
 
 
1HNMR spectrum of Compound 19  in CD3OD at 400 MHz. 
 
 
  
13CNMR spectrum of Compound 20  in CD3OD at 400 MHz. 
 
 
 
 
 
 
1H NMR spectrum of Compound 21 in CDCl3 at 400 MHz. 
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13CNMR spectrum of Compound 19  in CD3OD at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 20 in CDCl3 at 400 MHz. 
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13C NMR spectrum of Compound 20 in CDCl3 at 100 MHz. 
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1H NMR spectrum of Compound 21 in CDCl3 at 400 MHz. 
 
 
 
13C NMR spectrum of Compound 22 in CDCl3 at 400 MHz. 
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13C NMR spectrum of Compound 21 in CDCl3 at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 22 in CDCl3 at 400 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR spectrum of Compound 23 in CDCl3 at 400 MHz. 
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13C NMR spectrum of Compound 22 in CDCl3 at 100 MHz. 
 
 
1H NMR spectrum of Compound 24 in CD3OD at 400 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 23 in CD3OD at 400 MHz. 
 
 
 
 
 
 
 
 
 
 
13C NMR spectrum of Compound 24 in CD3OD at 400 MHz. 
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13C NMR spectrum of Compound 23 in CD3OD at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 24 in CDCl3 at 400 MHz. 
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13C NMR spectrum of Compound 24 in CDCl3 at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 25 in CD3OD at 400 MHz. 
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13C NMR spectrum of Compound 25 in CD3ODat 100 MHz 
 
 
 
1H NMR spectrum of Compound 28 in CD3OD at 400 MHz. 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 26 in CD3ODat 400 MHz. 
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13C NMR spectrum of Compound 26 in CD3ODat 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 27 in CDCl3 at 400 MHz. 
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13C NMR spectrum of Compound 27 in CDCl3 at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 28 in CD3ODat 400 MHz. 
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13C NMR spectrum of Compound 28 in CD3ODat 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 29 in CD3ODat 100 MHz. 
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13C NMR spectrum of Compound 29 in CD3ODat 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 30 in CDCl3 at 400 MHz. 
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13C NMR spectrum of Compound 30 in CDCl3 at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 31 in CDCl3 at 400 MHz. 
 
 
 
 
 
 
 
 
Experimental section 
171 
 
13C NMR spectrum of Compound 31 in CDCl3 at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 32 in CDCl3 at 400 MHz. 
 
 
 
 
 
 
 
 
 
 
Experimental section 
172 
 
13C NMR spectrum of Compound 32 in CDCl3 at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 33 in CDCl3 at 400 MHz. 
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13C NMR spectrum of Compound 33 in CDCl3 at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 34 in CD3OD at 400 MHz. 
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13C NMR spectrum of Compound 34 in CD3OD at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 2 in CD3OD at 700 MHz. 
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13C NMR spectrum of Compound 2 in CD3OD at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 35 in CDCl3 at 400 MHz. 
 
 
 
 
 
 
 
13C NMR spectrum of Compound 35 in CDCl3 at 400 MHz. 
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13C NMR spectrum of Compound 35 in CDCl3 at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 37 in CD3OD at 400 MHz. 
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III. Experimental section of dual PXR/FXR ligands 
Sponge material and separation of individual sterols (Compounds  40-49). Two taxonomic 
vouchers (field collection references R3170 and R3144) both assigned to the widespread species 
Theonella swinhoei (order Lithistida, family Theonellidae) were collected on the barrier reef of 
Vangunu and Malaita Island, Solomon Islands, in July 2004. The samples were frozen 
immediately after collection and lyophilized to yield 600 g and 355 g (dry mass) of R3170 and 
R3144, respectively. Taxonomic identification was performed by Dr John Hooper of Queensland 
Museum, Brisbane, Australia, where specimens are deposited under the accession number 
G3122662 and G323969, respectively. 
Theonella swinhoei (R3170). The lyophilized material (600 g) was extracted with methanol (3×2.7 
L) at room temperature and the methanolic extract, taken to dryness, was subjected to a modified 
Kupchan's partitioning procedure as follows. The methanol extract was dissolved in a mixture of 
MeOH/H2O containing 10% H2O and partitioned against n-hexane (19.7 g). The water content (% 
v/v) of the MeOH extract was adjusted to 30% and partitioned against CHCl3 (17.8 g). The 
aqueous phase was concentrated to remove MeOH and then extracted with n-BuOH (10 g). The 
hexane extract was chromatographed in two runs by silica gel MPLC using a solvent gradient 
system from CH2Cl2 to CHCl2:MeOH 1:1. Fractions eluted with CH2Cl2:MeOH 96:4 (419 mg) 
were further purified by HPLC on a Nucleodur 100-5 C18 (5µm; 10 mm i.d. x 250 mm) with 
MeOH:H2O (92:8) as eluent (flow rate 5 mL/min) to give 1.6 mg of theonellasterol H (46) (tR=9.5 
min), 12 mg of theonellasterol G (45) (tR=11.6), 3.5 mg of theonellasterol F (44) (tR=12.4 min), 0.8 
mg of conicasterol D (49) (tR=12.8 min), 3.3 mg of theonellasterol D (42) (tR=14.2 min) and 3.6 
mg of theonellasterol E (43) (tR=16 min). Fractions eluted with CH2Cl2:MeOH 95:5 (40 mg) were 
further purified by HPLC on a Nucleodur 100-5 C18 (5µm; 10 mm i.d. x 250 mm) with 
MeOH:H2O (92:8) as eluent (flow rate 5 mL/min) to give 0.6 mg of conicasterol B (47) (tR=7.8 
min) and 0.8 mg of theonellasterol B (40) (tR= 8.4 min).  
Theonella swinhoei (R3144) was extracted with methanol (3×1.7 L) at room temperature and the 
crude methanolic extract (32 g) was subjected to a modified Kupchan's partitioning procedure as 
described for Theonella  swinhoei R3170, to obtain 3.9 g of n-hexane extract. The hexane extract 
was chromatographed in two runs by silica gel MPLC using a solvent gradient system from 
CH2Cl2 to CHCl2:MeOH 1:1. Fractions eluted with CH2Cl2:MeOH 97:3 (15.5 mg) were further 
purified by HPLC on a Nucleodur 100-5 C18 (5µm; 10 mm i.d. x 250 mm) with MeOH:H2O 
(92:8) as eluent (flow rate 5 mL/min) to give 3.4 mg of theonellasterol D (42) and 1.1 mg of 
theonellasterol C (41) (tR=20.4 min). Fractions eluted with CH2Cl2:MeOH 94:6 (12.0 mg) were 
further purified by HPLC on a Nucleodur 100-5 C18 (5µm; 10 mm i.d. x 250 mm) with 
MeOH:H2O (92:8) as eluent (flow rate 5 mL/min) to give 1.2 mg of theonellasterol D (42), 4.0 mg 
of theonellasterol E (43), 0.5 mg conicasterol C (48) (tR=15 min) and 0.8 mg of conicasterol D 
(49). 
Sponge material and separation of individual sterols (Compounds 39, 50-59). Theonella 
swinhoei (order Lithistida, family Theonellidae) was collected at a depth of 22 m, on an isolated 
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reef off the western coast of Malaita Island, Solomon Islands, in July 2004 and reference 
specimens are on file (R3159) at the ORSTOM, Centre of Noumea. The samples were frozen 
immediately after collection and lyophilized to yield 207 g of dry mass. Taxonomic identification 
was performed by Dr John Hooper at Queensland Museum, Brisbane, Australia. The lyophilized 
material (207 g) was extracted with methanol (3×1.5 L) at room temperature and the crude 
methanolic extract was subjected to a modified Kupchan's partitioning procedure as follows. The 
methanol extract was dissolved in a mixture of MeOH/H2O containing 10% H2O and partitioned 
against n-hexane (4.5 g). The water content (% v/v) of the MeOH extract was adjusted to 30% and 
partitioned against CHCl3 (6.0 g). The aqueous phase was concentrated to remove MeOH and then 
extracted with n-BuOH (10.3 g).  The hexane extract (4.5 g) was chromatographed by silica gel 
MPLC using a solvent gradient system from CH2Cl2 to CHCl2:MeOH 1:1.  Fractions eluted with 
CH2Cl2:MeOH 99:1 (340.4 mg) were further purified by HPLC on a Nucleodur 100-5 C18 (5µm; 
10 mm i.d. x 250 mm) with MeOH:H2O (95:5) as eluent (flow rate 5 mL/min) to give 1.5 mg of 
conicasterol (39) (tR=4.2 min) and 2.0 mg of conicasterol H (51) (tR=15.8 min). Fractions eluted 
with CH2Cl2:MeOH 97:3 (242.5 mg) were further purified by HPLC on a Nucleodur 100-5 C18 
(5µm; 10 mm i.d. x 250 mm) with MeOH:H2O (92:8) as eluent (flow rate 5 mL/min) to give  5.8 
mg of swinhosterol B (59) (tR=7.5 min), 1.2 mg of conicasterol I (52) (tR=8.5 min), 2.5 mg of 
conicasterol G (50) (tR=11.0 min), 1.2 mg of 7α-hydroxyconicasterol (57) (tR=17 min) and 1.0 mg 
of 15β-hydroxyconicasterol (58) (tR=17.2 min). Fractions eluted with CH2Cl2:MeOH 99:1 (351 
mg) were further purified by HPLC on a Nucleodur 100-5 C18 (5µm; 10 mm i.d. x 250 mm) with 
MeOH:H2O (998:2) as eluent (flow rate 3 mL/min) to give 9.3 mg of conicasterol K (54) (tR=7.8 
min), 8.9 mg of theonellasterol J (55) (tR=8.2 min), 7.5 mg of dehydroconicasterol (56) (tR=12.0 
min). The CHCl3 extract (6.0 g) was chromatographed by silica gel MPLC using a solvent gradient 
system from CH2Cl2 to CHCl2:MeOH 3:7. Fractions eluted with CH2Cl2:MeOH 96:4 (80 mg) were 
further purified by HPLC on a Nucleodur 100-5 C18 (5µm; 10 mm i.d. x 250 mm) with 
MeOH:H2O (92:8) as eluent (flow rate 3 mL/min) to give 1.3 mg of conicasterol I (53) (tR=8.0 
min). 
Characteristic data for each compounds 
Theonellasterol B (40): pale yellow oil; [α]D25 +1.6 (c 0.08, MeOH); UV (MeOH): λmax (log ε) 
275 nm (3.62); 1H and 13C NMR data in C6D6 given in Table 1-3; ESI-MS: m/z 429.4 [M+Li]+. 
HRMS (ESI): calcd. for C30H46LiO: 429.3709; found 429.3729 [M+Li]+. 
Theonellasterol C (41): pale yellow oil; [α]D25 +5.7 (c 0.16, MeOH); 1H and 13C NMR data in 
C6D6 given in Table 1-3; ESI-MS: m/z 447.4 [M+Li]+. HRMS (ESI): calcd. for C30H48LiO2: 
447.3814; found 447.3834 [M+Li]+. 
Theonellasterol D (42): white amorphous solid; [α]D25 +3.3 (c 0.17, MeOH); 1H and 13C NMR 
data in C6D6 given in Table 1-3; ESI-MS: m/z 479.4 [M+Li]+. HRMS (ESI): calcd. for 
C31H52LiO3: 479.4076; found 479.4093 [M+Li]+. 
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Theonellasterol E (43): white amorphous solid; [α]D25 +34 (c 0.1, MeOH); 1H and 13C NMR data 
in C6D6 given in Table 1-3; ESI-MS: m/z 465.4 [M+Li]+. HRMS (ESI): calcd. for C30H50LiO3: 
465.3920; found 465.3244 [M+Li]+. 
Theonellasterol F (44): white amorphous solid; [α]D25 +4.3 (c 0.23, MeOH); 1H and 13C NMR 
data in C6D6 given in Table 1-3; ESI-MS: m/z 465.4 [M+Li]+. HRMS (ESI): calcd. for 
C30H50LiO3: 465.3920; found 465.3247 [M+Li]+. 
Theonellasterol G (45): pale yellow oil; [α]D25 +68 (c 1.0, MeOH); 1H and 13C NMR data in C6D6 
given in Table 1-3; ESI-MS: m/z 481.4 [M+Li]+. HRMS (ESI): calcd. for C30H50LiO4: 481.3869; 
found 481.3889 [M+Li]+. 
Theonellasterol H (46): pale yellow oil; [α]D25 +16 (c 0.1, MeOH); 1H and 13C NMR data in C6D6 
given in Table 1-3; ESI-MS: m/z 481.4 [M+Li]+. HRMS (ESI): calcd. for C30H50LiO4: 481.3869; 
found 481.3875 [M+Li]+. 
Conicasterol B (47): pale yellow oil; [α]D25 +29 (c 0.06, MeOH); UV (MeOH): λmax (log ε) 275 
nm (3.56);1H and 13C NMR data in C6D6 given in Table 1-3; ESI-MS: m/z 415.4 [M+Li]+. HRMS 
(ESI): calcd. for C29H44LiO: 415.3552; found 415.3532 [M+Li]+. 
Conicasterol C (48): white amorphous solid ; [α]D25 +43 (c 0.13, MeOH); 1H and 13C NMR data 
in C6D6 given in Table 1-3; ESI-MS: m/z 465.4 [M+Li]+. HRMS (ESI): calcd. for C30H50LiO3: 
465.3920; found 465.3942 [M+Li]+. 
Conicasterol D (49): white amorphous solid; [α]D25 +33 (c 0.08, MeOH); 1H and 13C NMR data in 
C6D6 given in Table 1-3; ESI-MS: m/z 451.4 [M+Li]+. HRMS (ESI): calcd. for C29H48LiO3: 
451.3763; found 451.3739 [M+Li]+. 
Conicasterol G (50): white amorphous solid; [α]D25 +17.4 (c 0.2, MeOH); selected 1H and 13C 
NMR data in C6D6 given in Tables 4 and 5; ESI-MS: m/z 449.4 [M+Li]+. HRMS (ESI): calcd. for 
C29H46LiO3: 449.3607; found 449.3611 [M+Li]+. 
Conicasterol H (51): white amorphous solid; [α]D25 +70.0 (c 0.2, MeOH); selected 1H and 13C 
NMR data in C6D6 given in Tables 4 and 5; ESI-MS: m/z 451.4 [M+Li]+. HRMS (ESI): calcd. for 
C29H48LiO3: 451.3763; found 451.3770 [M+Li]+. 
Conicasterol I (52): pale yellow oil; [α]D25 +58.2 (c 0.12, MeOH); selected 1H and 13C NMR data 
in C6D6 given in Tables 4 and 5; ESI-MS: m/z 467.4 [M+Li]+. HRMS (ESI): calcd. for 
C29H48LiO4: 467.3713; found 467.3724 [M+Li]+. 
Conicasterol J (53): pale yellow oil; [α]D25 +37.2 (c 0.13, MeOH); selected 1H and 13C NMR data 
in C6D6 given in Tables 4 and 5; ESI-MS: m/z 449.4 [M+Li]+. HRMS (ESI): calcd. for 
C29H46LiO3: 449.3607; found 449.3620 [M+Li]+. 
Conicasterol K (54): white amorphous solid; [α]D25 +5.9 (c 0.93, MeOH); selected 1H and 13C 
NMR data in C6D6 given in Tables 4 and 5; ESI-MS: m/z 417.4 [M+Li]+. HRMS (ESI): calcd. for 
C29H46LiO: 417.3709; found 417.3723 [M+Li]+. 
Theonellasterol J (55): pale yellow oil; [α]D25 +6.9 (c 0.37, MeOH); selected 1H and 13C NMR 
data in C6D6 given in Tables 4 and 5; ESI-MS: m/z 431.4 [M+Li]+. HRMS (ESI): calcd. for 
C29H48LiO: 431.3865; found 431.3875 [M+Li]+. 
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Conicasterol (39): white amorphous solid; [α]D25 +52.5 (c 0.15, MeOH); ESI-MS: m/z 419.4 
[M+Li]+. 
Dehydroconicasterol (56): white amorphous solid; [α]D25 +31.7 (c 0.31, MeOH); ESI-MS: m/z 
417.4 [M+Li]+.  
7α-Hydroxyconicasterol (57): yellow amorphous solid; [α]D25 +3.5 (c 0.12, MeOH); ESI-MS: m/z 
435.4 [M+Li]+. 
15β-Hydroxyconicasterol (58): white amorphous solid; [α]D25 +5.1 (c 0.1, MeOH); ESI-MS: m/z 
435.4 [M+Li]+.  
Swinhosterol B (59): white amorphous solid; [α]D25 -14.6 (c 0.58, MeOH); ESI-MS: m/z 451.4 
[M+Li]+.  
Specific biological assays. 
RT2 Profiler PCR array. Total RNA from HepG2 cells left untreated or stimulated with 
swinhosterol B (59) was extracted with Trizol reagent (Invitrogen) and reverse transcribed with 
Superscript-II reverse transcriptase (Invitrogen) following the manual instructions. 100 ng cDNA 
was pipetted in each well of a 96 well gene array plate (Human Nuclear Receptors and 
Coregulators RT² Profiler™ PCR Array-
http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-056A.html -Superarray Bioscence, 
Frederick, MD, USA) and amplified following the manual instructions. Genes selected for this 
array encode several classes of nuclear receptors and co-regulators of transcription, including co-
activators and co-repressors. Array analysis was carried out with the on-line software RT2 Profiler 
PCR Array Data Analysis (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). 
Macrophages preparation and in vitro testing. Animals. Humanized (h)PXR mice, 8-10 weeks of 
age, were provided by Frank J. Gonzalez (Laboratory of Metabolism, Centre for Cancer Research, 
National Cancer Institute, National Institutes of Health, Bethesda, Maryland). The hPXR mice 
express the human PXR in the mice PXR-null background.17 FXR-/-mice (C57BL/6BJ6 
background) were originally provided by F. Gonzales (NIH, Bethesda). All mice were housed in a 
temperature-controlled room and had free access to food and water.136 The present protocol was 
approved by the Italian Minister Health and conforms to national guidelines. The ID for this 
project is #11/2010-B and authorization released to Prof. Stefano Fiorucci, as a principal 
investigator, lastly on January 25, 2010. 
Isolation of mouse macrophages. Monocytes were isolated from spleen of hPXR and FXR-/-mice 
(N=4); monocytes were obtained by means of a magnetic cell separation isolation system as 
previously described using mouse CD11b Microbeads (Milteny Biotech; Germany). CD11b+ cells 
were then suspended in complete medium (RPMI 1640, 10% heat-inactivated fetal bovine serum, 
3 mmol/L L-glutamine, 100 U/mL penicillin, 100 U/mL streptomycin) and cultured at a 
concentration of 1 × 106 cells/mL. The isolated cells were placed into culture wells (Tissue 
Culture Plate, 24 wells) with or without LPS (5 µg/mL) alone or in combination with 59 (10 µM; 2 
h of pre-treatment) and with 59 (10 µM) alone, and maintained in an atmosphere of 5% CO2 and 
95% air at 37 °C for 18 h. 
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Statistical Analysis. All values were expressed as the mean ± SE. The analysis of variance 
(ANOVA) with Bonferroni correction for multiple comparisons (Graphpad Software. Inc., San 
Diego, CA) was used to assess significant statistical difference between groups. 
 
Spectroscopic Data 
  
1H NMR (500 MHz, C6D6) of Theonellasterol B (40) 
 
 
 
 
 
 
 
 
 
 
 
COSY spectrum (500 MHz, C6D6) of Theonellasterol B (40)  
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HMBC spectrum (500 MHz, C6D6) of Theonellasterol B (40)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (700 MHz, C6D6) of Theonellasterol C (41)  
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COSY spectrum (700 MHz, C6D6) of Theonellasterol C (41)  
 
 
 
 
 
 
 
 
 
 
 
 
 
HSQC spectrum (700 MHz, C6D6) of Theonellasterol C (41)  
 
 
 
 
 
 
 
 
 
 
 
 
Experimental section 
184 
 
HMBC spectrum (700 MHz, C6D6) of Theonellasterol C (41)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (500 MHz, C6D6) of Theonellasterol D (42)  
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COSY spectrum (500 MHz, C6D6) of Theonellasterol D (42)  
 
 
 
 
 
 
 
 
 
 
 
 
 
HSQC spectrum (700 MHz, C6D6) of Theonellasterol D (42)  
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HMBC spectrum (700 MHz, C6D6) of Theonellasterol D (42)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ROESY spectrum (700 MHz, C6D6, 200 ms) of Theonellasterol D (42)  
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1H NMR (700 MHz, C6D6) of Theonellasterol E (43) 
 
COSY spectrum (500 MHz, C6D6) of Theonellasterol E (43) 
 
 
 
 
 
 
 
 
 
 
 
 
COSY spectrum (500 MHz, C6D6) of Theonellasterol E (43) 
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HSQC spectrum (700 MHz, C6D6) of Theonellasterol E (43)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expanded HMBC spectrum (500 MHz, C6D6) of Theonellasterol E (43)  
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1H NMR (500 MHz, C6D6) of Theonellasterol F (44) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COSY spectrum (500 MHz, C6D6) of Theonellasterol F (44) 
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HSQC spectrum (500 MHz, C6D6) of Theonellasterol F (44) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMBC spectrum (500 MHz, C6D6) of Theonellasterol F (44) 
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1H NMR (500 MHz, C6D6) of Theonellasterol G (45) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COSY spectrum (500 MHz, C6D6) of Theonellasterol G (45) 
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HSQC spectrum (500 MHz, C6D6) of Theonellasterol G (45)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMBC spectrum (500 MHz, C6D6) of Theonellasterol G (45)  
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ROESY spectrum (500 MHz, C6D6, 200 ms) of Theonellasterol G (45) 
 
 
 
 
 
 
 
 
 
 
 
 
 
ROESY spectrum (500 MHz, C6D6 ,500 ms) of Theonellasterol G (45) 
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1H NMR (700 MHz, C6D6) of Theonellasterol H (46) 
 
 
 
 
 
 
 
 
 
 
 
 
 
COSY spectrum (700 MHz, C6D6) of Theonellasterol H (46) 
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HSQC spectrum (700 MHz, C6D6) of Theonellasterol H (46) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMBC spectrum (700 MHz, C6D6) of Theonellasterol H (46) 
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ROESY spectrum (500 MHz, C6D6, 500 ms) of Theonellasterol H (46) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (500 MHz, C6D6) of Conicasterol B (47)  
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1H NMR (500 MHz, C6D6) of Conicasterol C (48) 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (500 MHz, C6D6) of Conicasterol D (49) 
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COSY spectrum (500 MHz, C6D6) of Conicasterol D (49) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMBC spectrum (500 MHz, C6D6) of Conicasterol D (49) 
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1H NMR (C6D6, 500 MHz) of conicasterol G (50) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COSY spectrum (C6D6, 500 MHz) of conicasterol G (50) 
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HSQC spectrum (C6D6, 500 MHz) of conicasterol G (50) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMBC spectrum (C6D6, 500 MHz) of conicasterol G (50) 
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1H NMR (C6D6, 700 MHz) of conicasterol H (51) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COSY spectrum (C6D6, 500 MHz) of conicasterol H (51) 
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HSQC spectrum (C6D6, 700 MHz) of conicasterol H (51) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMBC spectrum (C6D6, 700 MHz) of conicasterol H (51) 
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1H NMR (C6D6, 500 MHz) of conicasterol I (52) 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (C6D6, 500 MHz) of conicasterol J (53) 
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COSY spectrum (C6D6, 500 MHz) of conicasterol J (53) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HSQC spectrum (C6D6, 500 MHz) of conicasterol J (53) 
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HMBC spectrum (C6D6, 500 MHz) of conicasterol J (53) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (C6D6, 500 MHz) of conicasterol K (54) 
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1H NMR (C6D6, 500 MHz) of Theonellasterol J (55) 
 
 
 
 
 
 
 
 
 
 
 
 
 
COSY spectrum (C6D6, 500 MHz) of theonellasterol J (55) 
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HSQC spectrum (C6D6, 500 MHz) of theonellasterol J (55) 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMBC spectrum (C6D6, 500 MHz) of Theonellasterol J (55) 
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IV. Experimental section of FXR modulators 
Sponge material and isolation of conicasterol E (60).  
The hexane extract (4.5 g) of sponge Theonella swinhoei (R3159) was chromatographed in two 
runs by silica gel MPLC using a solvent gradient system from CH2Cl2 to CHCl2:MeOH 1:1. 
Fractions eluted with CH2Cl2:MeOH 96:4 (18.5 mg) were further purified by HPLC on a 
Nucleodur 100-5 C18 (5µm; 10 mm i.d. x 250 mm) with MeOH:H2O (92:8) as eluent (flow rate 5 
mL/min) to give 2.1 mg of conicasterol E (60) (tR=14.5 min). 
Conicasterol E (60): white amorphous solid; [α]D25 +59.6 (c 0.06, MeOH); 1H and 13C NMR data 
in C6D6 given in Table 18; ESI-MS: m/z 451.4 [M+Li]+. HRMS (ESI): calcd. for C29H48LiO3: 
451.3763; found 451.3769 [M+Li]+. 
Total synthesis of 6-ECDCA (61). 
Benzyl 3α-hydroxy-7-keto-5β-cholan-24-oate (63). An oven-dried 250 mL flask was charged with 
chenodeoxycholic acid (62) (2.00 g, 5.1 mmol), sodium bromide (30 mg, 0.25 mmol), 
tetrabutylammonium bromide (5.4 g, 16.8 mmol) and 43 mL of a solution of 
MeOH:CH3COOH:H2O:AcOEt 3:1:0.25:6.5 v/v. The mixture was stirred at room temperature 
until a homogeneous solution formed and then cooled at 0 °C. Sodium hypochlorite solution (10%, 
5 mL, 5.6 mmol) was added, until the test for hypochlorite (peroxide test paper) was positive and 
the yellow suspension was stirred. The reaction was stirred at room temperature for 6 h. Aqueous 
sodium bisulfite (3.3%) was added to afford a white suspension (negative test for peroxide). Water 
(50 ml) was added and mixture stirred at 15 °C for 5 min. Aqueous solution was extracted with 
AcOEt (3 × 50 mL). The combined organic layer was washed with aqueous sodium bisulfite (50 
mL) and water (50 mL), and then dried over anhydrous MgSO4 and evaporated in vacuo to give 
2.0 g of 3α-hydroxy-7-keto-5β-cholan-24-oic acid, that was subjected to next step without any 
purification. To a solution of this latter intermediate (2.0 g, 5.1 mmol) in CH3CN dry (30 mL), 
Cs2CO3 (2.5 g, 7.6 mmol) was added. The solution was heated to 150 °C and BnBr (3.0 mL, 25.5 
mmol) was added under reflux. The solution was stirred at this temperature for 24 h and then after 
cooled to room temperature and after removal CH3CN in the rotavapor, poured into saturated 
NaHCO3 solution (50 mL) and extracted with AcOEt (3 × 30 mL). The combined organic layer 
was washed with water (30 mL), and then dried over anhydrous MgSO4 and evaporated in vacuo. 
Purification on silica gel column eluting with hexane:AcOEt (7:3) and 0.5% Et3N, afforded pure 
63 (1.5 g, 60% over two steps). [α]24 D= -10.9 (c 0.99, CHCl3); 1H NMR (400 MHz, CDCl3): δ 
7.33 (5H, m), 5.09 (2H, dd, J = 12.9, 15.6 Hz), 3.57 (1H, m), 2.83 (1H, m), 2.37 (1H, m, ovl), 2.26 
(1H, m), 2.15 (1H, m), 1.37 (3H, s), 0.89 (3H, d, J= 6.0 Hz), 0.61 (3H, s); 13C NMR (100 MHz, 
CDCl3): δ 212.0, 174.0, 136.2, 128.5 (2C), 128.2 (2C), 128.1,  70.7, 66.0, 54.7, 49.4, 48.8, 46.0, 
45.3, 42.7, 42.5, 38.9, 37.3, 35.1, 34.1, 31.2, 30.9, 29.8 (2C), 28.2, 24.7, 23.0, 21.6, 18.3, 11.9; 
HRMS-ESI m/z 480.3240 ([M + H]+, C31H44O4 requires 480.3235. 
Benzyl 3α-trimethylsilyloxy-5β-cholan-6-en-24-oate (64). To a solution of diisopropylamine (5.5 
mL, 39 mmol) in dry THF (50 mL) was added dropwise a solution of n-butyllithium (15 mL, 2.5M 
in hexane, 37.2 mmol) at -78°C under nitrogen atmosphere. After 30 min, trimethylchlorosilane 
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(3.9 mL, 31 mmol) was added and the resulting mixture was reacted for additional 20 min. A 
solution of benzyl 3α-hydroxy-7-keto-5β-cholan-24-oate (1.5 g, 3.1 mmol) in dry THF (20 mL) 
was added dropwise in 10 min. The reaction was stirred at -78 °C for an additional 45 min and 
then triethylamine (7.8 mL, 56 mmol) was added. After 1 h, the reaction mixture was allowed to 
warm to -20 °C, treated with aqueous saturated solution of NaHCO3 (10 mL) and brought up to 
room temperature in 2 h. The organic phase was separated, and aqueous phase was extracted with 
ethyl acetate (3x50 mL). The combined organic phases were washed several times with saturated 
solution of NaHCO3, water and brine. After drying over anhydrous Na2SO4, the residue was 
evaporated under vacuum to give 1.8 g of yellow residue, that was subjected to next step without 
any purification. [α]24 D= +4.3 (c 0.58, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.35 (5H, m), 5.10 
(1H, dd, J= 15.8, 12.4 Hz), 4.72 (1H, d, J= 6.1 Hz), 3.50 (1H, m), 2.40 (1H, m), 2.28 (1H, m), 0.90 
(3H, d, J= 6.3 Hz), 0.81 (3H, s), 0.64 (3H, s), 0.18-0.001 (18H, ovl). 13C NMR (100 MHz CDCl3): 
δ 174.0, 151.7, 136.2, 128.5 (2C), 128.2 (2C), 128.1, 108.8, 71.5, 66.1, 54.8, 54.1, 44.3, 42.6, 41.0, 
40.9, 40.3, 40.1, 35.2, 34.6, 32.9, 31.4, 31.0, 30.7, 28.6, 27.0, 22.5, 20.9, 18.4, 12.4, 1.4 (3C), 0.4 
(2C), 0.2; HRMS-ESI m/z 624.4030 ([M + H]+, C37H60O4Si2 requires 624.4047. 
Benzyl 3α-hydroxy-6-ethyliden-7-keto-5β-cholan-24-oate (65). To a cooled (-60 °C) and stirred 
solution of acetaldehyde (328 µL, 5.86 mmol) and benzyl 3α-trimethylsilyloxy-5β-cholan-6-en-24-
oate (64) (1.8 g, 2.93 mmol) in dry CH2Cl2 (30 mL) was added dropwise BF3·OEt2 (3.7 mL, 29.3 
mmol). The reaction mixture was stirred for 2 h at -60 °C and allowed to warm to room 
temperature. The mixture was quenched with saturated aqueous solution of NaHCO3 and extracted 
with CH2Cl2. The combined organic phases were washed with brine, dried over anhydrous MgSO4 
and concentrated under vacuum. Purification on silica gel column eluting with hexane:AcOEt (9:1) 
and 0.5% Et3N, afforded pure 65 (1.09 g, 70% over two steps). [α]24 D= -42.5 (c 0.12, CHCl3); 1H 
NMR (400 MHz, CDCl3): δ 7.34 (5H, m), 6.16 (1H, q, J = 6.7 Hz), 5.10 (2H, dd, J = 13.0, 17.8 
Hz), 3.64 (1H, m), 2.56 (1H, m), 2.38 (1H, m), 2.27 (1H, m), 1.67 (3H, d, J = 6.7 Hz), 0.99 (3H, 
s), 0.91 (3H, d, J = 6.0 Hz), 0.60 (3H, s); 13C NMR (100 MHz, CDCl3): δ 215.2, 174.0, 143.3, 
140.9, 129.8, 128.5 (2C), 128.2 (2C), 128.1, 70.5, 66.1, 54.5, 50.6, 48.6, 45.5, 43.5, 39.1, 38.9, 
37.5, 35.1, 34.4, 31.2, 30.9, 29.6 (2C), 28.4, 25.9, 22.8, 21.3, 18.4, 12.6, 12.0; HRMS-ESI m/z 
506.3396 ([M + H]+, C33H46O4 requires 506.3378. 
Benzyl 3α,7α-dihydroxy-6-ethyliden-5β-cholan-24-oate (66). The residual (1.00 g, 1.97 mmol) was 
dissolved in a solution of dry tetrahydrofuran/dry methanol (50 mL, 4/1 v/v) and treated with 
CeCl3 (1.46 g, 5.93 mmol) and NaBH4 (667 mg, 2.36 mmol). After 3 h, water and MeOH was 
added. Then after evaporation of the solvents, the residue was diluted with water and extracted 
with ether (3x50 mL). The combined organic phases were washed with brine, dried over Na2SO4 
anhydrous and evaporated under reduced pressure. The crude residue was purified by flash 
chromatography on silica gel using dichloromethane/ methanol (7:3 v/v) and 0.5% Et3N as eluent, 
to afford 950 mg of 66 (95 % yield). [α]24 D= + 18 (c 0.06, CHCl3); 1H NMR (400 MHz, CDCl3): δ 
7.34 (5H, m), 5.64 (1H, q, J = 6.2 Hz), 5.10 (2H, dd, J = 12.5, 17.3 Hz), 3.98 (1H, m), 3.64 (1H, 
m), 2.47 (1H, m), 2.39 (1H, m), 2.27 (1H, m), 1.60 ( 3H, d, J = 6.6 Hz), 0.91 (3H, d, J = 6.2 Hz), 
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0.77 (3H, s), 0.61 (3H, s); 13C NMR (100 MHz, CDCl3): δ 174.0, 141.6, 136.1, 128.5 (2C), 128.3 
(2C), 128.2, 114.4, 73.3, 71.2, 66.1, 56.0, 55.0, 45.5, 44.0, 40.0, 39.5, 36.3, 35.4, 35.2, 34.7, 31.3, 
31.0, 30.2, 29.6, 28.6, 27.1, 22.8, 21.2, 18.4, 12.4, 12.2; HRMS-ESI m/z 508.3553 ([M + H]+, 
C33H48O4 requires 508.3565. 
6-ECDCA (61). An oven-dried 50 mL flask was charged with 10% palladium on carbon (50 mg) 
and compound 66 (950 mg, 1.87 mmol) and the flask was evacuated and flushed with argon. 
Absolute methanol (10 mL) and dry THF (10 mL) were added, and the flask was flushed with 
hydrogen. The reaction was stirred at room temperature under H2 for 4 h. The mixture was filtered 
through celite, and the recovered filtrate was evaporated under vacuum to give pure 6α-ethyl-
chenodeoxycholic acid 61 (630 mg, 80%). [α]24 D= +5.11 (c 1.8, CH3OH);  1H NMR (400 MHz, 
CD3OD): δ 3.60 (1H, brs), 3.32 (1H, m), 2.33 (1H, m), 2.20 (1H, m), 0.97 (3H, d, J= 6.2 Hz), 0.91 
(3H, s), 0.90 (3H, t, J= 7.0 Hz), 0.69 (3H, s). 13C NMR (100 MHz, CD3OD): δ 178.4, 73.3, 71.2, 
57.4, 51.7, 46.9, 43.8, 43.2, 41.6, 41.1, 36.8 (2C), 36.6, 34.5, 34.4, 32.4, 32.2, 31.2, 29.3, 24.6, 
23.7, 23.5, 21.9, 18.8, 12.2, 12.0; HRMS-ESI m/z 420.3240 ([M + H]+, C26H44O4 requires 
420.3237. 
Synthesis of derivatives of theonellasterol.  
3β-O-Methyl-theonellasterol (67). To a solution of theonellasterol (38) (10 mg, 0.023 mmol) in 
dry THF (5 mL) at 0 °C was added NaH (5.5 mg, 0.23 mmol). After 10 min methyl iodide (28.6 
µL, 0.46 mmol) was added and the mixture was left to stand at room temperature for 4 h. The 
mixture was quenched by addition at 0 °C of methanol (2 mL) and then concentrated in vacuo. 
Ethyl acetate and water were added and the separated aqueous phase was extracted with ethyl 
acetate (3 × 50 mL). The combined organic phases were washed with water, dried (Na2SO4) and 
concentrated. Purification by silica gel eluting with CH2Cl2 gave the methyl ether 67 as an 
amorphous solid (8.0 mg, 79%). [α]25D = +4.0 (c 0.75, CH3OH); selected 1H NMR (400 MHz 
C6D6): δ 5.49 (1H, s, H-30a), 4.77 (1H, s, H-30b), 3.39 (1H, dd, J = 4.5, 11.7 Hz, H-3), 3.33 (3H, 
s, OCH3), 1.06 (3H, d, J = 6.9 Hz, H3-21), 0.94 (3H, t, J = 7.0 Hz, H3-29), 0.93 (3H, s, H3-18), 
0.91 (3H, d, J = 7.0 Hz, H3-26), 0.90 (3H, d, J = 7.0 Hz, H3-27), 0.67 (3H, s, H3-19). 13C NMR 
(100 MHz C6D6): δ 150.7 (C-4), 143.3 (C-14), 126.8 (C-8), 104.5 (C-30), 83.4 (C-3), 57.6 (C-17), 
57.4 (-OCH3), 50.4 (C-9), 50.1 (C-5), 47.0 (C-24), 43.5 (C-13), 40.8 (C-10), 38.2 (C-12), 37.5 (C-
1), 35.7 (C-20), 34.6 (C-22), 31.0 (C-2), 30.2 (C-6), 29.7 (C-25), 27.9 (C-7), 27.0 (C-23), 26.5 (C-
16), 25.4 (C-15), 23.8 (C-28), 21.2 (C-11), 20.1 (C-27), 19.9 (C-21), 19.6 (C-26), 18.9 (C-18), 
13.7 (C-19), 13.0 (C-29); HRESI MS m/z 441.4092 (calcd for C31H53O 441.4096). 
3β-O-Acetyl-theonellasterol (68). A mixture of theonellasterol (38) (10 mg, 0.023 mmol) and 
acetic anhydride (55 µL, 0.575 mmol) in dry pyridine (10 mL) was left to stand at room 
temperature for 8 h. Then the solvent was evaporated and purification by silica gel eluting with 
CH2Cl2 gave 68 as an amorphous solid (10.3 mg, 96%). [α]25 D = +0.5 (c 2.4, CH3OH); selected 1H 
NMR (400 MHz C6D6): δ 5.37 (1H, dd, J = 4.7, 11.5 Hz, H-3), 5.15 (1H, s, H-30a), 4.69 (1H, s, H-
30b), 1.80 (3H, s, CH3CO), 1.05 (3H, d, J = 6.6 Hz, H3-21), 0.94 (3H, t, J = 7.0 Hz, H3-29), 0.91 
(3H, d, J = 6.5 Hz, H3-26), 0.91 (3H, s, H3-18), 0.90 (3H, d, J = 6.5 Hz, H3-27), 0.63 (3H, s, H3-
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19). 13C NMR (100 MHz C6D6): δ 169.7 (CH3CO), 149.1 (C-4), 143.4 (C-14), 126.6 (C-8), 104.4 
(C-30), 75.1 (C-3), 57.6 (C-17), 50.0 (C-9), 49.6 (C-5), 46.9 (C-24), 43.5 (C-13), 40.3 (C-10), 38.1 
(C-12), 36.9 (C-1), 35.7 (C-20), 34.6 (C-22), 30.4 (C-6), 29.9 (C-2), 29.7 (C-25), 27.9 (C-7), 27.0 
(C-23), 26.6 (C-16), 25.2 (C-15), 23.8 (C-28), 21.1 (2C, C-11 and CH3CO), 20.1 (C-27), 19.9 (C-
21), 19.6 (C-26), 18.8 (C-18), 13.6 (C-19), 13.0 (C-29); HRESI MS m/z 469.4098 (calcd for 
C32H53O 469.4096). 
Theonellasterone (69). To the solution of theonellasterol (38) (100 mg, 0.23 mmol) in 
dichloromethane (5 mL) was added pyridinium chlorochromate (99 mg, 0.46 mmol). The reaction 
mixture was stirred at room temperature for 3 h, and then dichloromethane and water were added. 
The separated aqueous phase was extracted with dichloromethane (3 × 30 mL). The combined 
organic phases were washed with water, dried (Na2SO4) and evaporated to dryness. The brown 
oily residue was passed through a short column of silica gel (10 g) and eluted with CH2Cl2 to give 
69 (95 mg, quantitative yield) as an amorphous solid. [α]25D = +2.2 (c 0.07, CH3OH); selected 1H 
NMR (400 MHz C6D6): δ 6.04 (1H, s, H-30a), 4.86 (1H, s, H-30b), 2.39 (1H, dd, J = 2.1, 13.8 Hz, 
H-2a), 1.06 (3H, d, J = 6.5 Hz, H3-21), 0.95 (3H, t, J = 7.3 Hz, H3-29), 0.92 (3H, d, J = 6.6 Hz, H3-
26), 0.90 (3H, s, H3-18), 0.90 (3H, d, J = 6.6 Hz, H3-27), 0.57 (3H, s, H3-19); 13C NMR (100 MHz 
C6D6): δ 200.9 (C-3), 150.3 (C-4), 143.7 (C-14), 127.4 (C-8), 118.2 (C-30), 57.6 (C-17), 50.0 (C-
9), 49.0 (C-5), 46.9 (C-24), 43.4 (C-13), 40.0 (C-10), 38.0 (C-12), 37.5 (C-1), 35.9 (C-2), 35.7 (C-
20), 34.6 (C-22), 34.5 (C-6), 29.8 (C-25), 27.9 (C-7), 27.1 (C-3), 26.6 (C-16), 25.3 (C-15), 23.8 
(C-28), 20.9 (C-11), 20.1 (C-27), 19.9 (C-21), 19.6 (C-26), 18.8 (C-18), 12.9 (C-29), 12.8 (C-19). 
HRESI MS m/z 425.3795 (calcd for C30H49O 425.3783). 
(24S)-24-Ethyl-4β-methyl-5α-cholestan-3β-ol (70). An oven-dried 50 mL flask was charged with 
10% platinum on carbon (20 mg) and theonellasterol (38) (100 mg, 0.23 mmol) and the flask was 
evacuated and flushed with argon. Absolute methanol (10 mL) and dry THF (10 mL) were added, 
and the flask was flushed with hydrogen. The reaction was stirred at room temperature under H2 
for 5 h. The mixture was filtered through Celite, and the recovered filtrate was concentrated to 
give 85 mg of pure 70 as an amorphous solid (86%). [α]25D = +6.7 (c 0.25, CH3OH); selected 1H 
NMR (400 MHz C6D6): δ 3.54 (1H, m, H-3), 1.05 (3H, d, J = 6.2 Hz, H3-21), 0.95 (3H, d, ovl, H3-
30), 0.94 (3H, s, H3-18), 0.94 (3H, t, ovl, H3-29), 0.91 (3H, d, J = 7.0 Hz, H3-26), 0.89 (3H, d, J = 
7.0 Hz, H3-27), 0.75 (3H, s, H3-19). 13C NMR (100 MHz C6D6): δ 143.8 (C-14), 127.0 (C-8), 74.1 
(C-3), 57.7 (C-17), 51.7 (C-9), 48.6 (C-5), 46.9 (C-24), 43.8 (C-13), 40.9 (C-4), 40.5 (C-10), 38.1 
(C-12), 37.9 (C-1), 37.8 (C-2), 35.7 (C-20), 34.6 (C-22), 30.8 (C-6), 29.7 (C-25), 27.9 (C-7), 27.1 
(C-23), 26.6 (2C, C-15 and C-16), 23.8 (C-28), 20.1 (2C, C-11 and C-27), 19.9 (C-21), 19.6 (C-
26), 19.1 (C-18), 15.5 (C-30), 15.4 (C-19), 12.9 (C-29); HRESI MS m/z 429.4076 (calcd for 
C30H53O 429.4096). 
(24S)-24-Ethyl-4β-methyl-5α-cholestan-3-one (71) and (24S)-24-Ethyl-4α-methyl-5α-cholestan-3-
one (72).  An oven-dried 50 mL flask was charged with 10% platinum on carbon (20 mg) and 
theonellasterone (100 mg, 0.23 mmol) and the flask was evacuated and flushed with argon. 
Absolute methanol (10 mL) and dry THF (10 mL) were added, and the flask was flushed with 
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hydrogen. The reaction was stirred at room temperature under H2 for 5 h. The mixture was filtered 
through Celite, and the recovered filtrate was concentrated. The mixture was purified by HPLC on 
a Nucleodur Isis 100-5 C18 (5 µm; 4.5 mm internal diameter × 250 mm) with MeOH:H2O 
(999.5:0.5) as eluent (flow rate 1 mL/min) to give 39 mg (40% from 5) of 71 (tR = 55 min) and 30 
mg (31% from 5) of 72 (tR = 60 min) as amorphous solids. (24S)-24-Ethyl-4β-methyl-5α-
cholestan-3-one 71.  [α]25D = −0.7 (c 0.06, CH3OH); selected 1H NMR (400 MHz C6D6): δ 2.38 
(1H, m, H-4), 1.05 (3H, d, J = 6.8 Hz, H3-21), 0.95 (3H, t, J = 7.0 Hz, H3-29), 0.95 (3H, d, J = 7.0 
Hz, H3-30), 0.93 (3H, s, H3-18), 0.91 (3H, d, J = 7.0 Hz, H3-26), 0.90 (3H, d, J = 7.0 Hz, H3-27), 
0.73 (3H, s, H3-19). 13C NMR (100 MHz C6D6): δ 196.0 (C-3), 143.4 (C-14), 126.6 (C-8), 57.6 (C-
17), 50.8 (C-9), 49.6 (C-5), 48.7 (C-4), 46.9 (C-24), 43.4 (C-13), 39.0 (C-10), 38.3 (C-12), 37.9 
(C-1), 37.7 (C-2), 35.6 (C-20), 34.6 (C-22), 30.4 (C-6), 29.7 (C-25), 27.8 (C-7), 27.0 (C-23), 26.6 
(C-16), 26.5 (C-15), 23.8 (C-28), 20.1 (C-27), 19.9 (C-21), 19.7 (C-11), 19.6 (C-26), 19.0 (C-18), 
14.6 (C-19), 14.5 (C-30), 12.9 (C-29); HRESI MS m/z 427.3936 (calcd for C30H51O 427.3940). 
(24S)-24-Ethyl-4α-methyl-5α-cholestan-3-one 72. [α]25D = −12.3 (c 0.10, CH3OH); selected 1H 
NMR (400 MHz C6D6): δ 2.05 (1H, dq, J = 6.1, 14.2 Hz, H-4), 1.09 (3H, d, J = 6.1 Hz, H3-30), 
1.06 (3H, d, J = 6.7 Hz, H3-21), 0.94 (3H, s, H3-18), 0.94 (3H, t, J = 7.4 Hz, H3-29), 0.91 (3H, d, J 
= 6.7 Hz, H3-26), 0.89 (3H, d, J = 6.7 Hz, H3-27), 0.70 (3H, s, H3-19). 13C NMR (100 MHz C6D6): 
δ 199.1 (C-3), 143.2 (C-14), 126.4 (C-8), 57.5 (C-17), 53.8 (C-9), 49.5 (C-5), 46.9 (C-24), 45.5 
(C-4), 43.4 (C-13), 39.0 (C-10), 38.5 (C-12), 38.1 (2C, C-1 and C-2), 35.7 (C-20), 34.6 (C-22), 
30.1 (C-6), 29.7 (C-25), 27.9 (C-7), 27.0 (C-23), 26.8 (C-15), 26.6 (C-16), 23.8 (C-28), 20.7 (C-
11), 20.1 (C-27), 19.9 (C-21), 19.6 (C-26), 18.9 (C-18), 13.4 (C-30), 12.9 (C-29), 12.3 (C-19); 
HRESI MS m/z 427.3944 (calcd for C30H51O 427.3940). 
(24S)-24-Ethyl-4α-methyl-5α-cholestan-3β-ol (73) and (24S)-24-Ethyl-4α-methyl-5α-cholestan-
3α-ol (74). To a solution of 72 (30 mg, 0.070 mmol) in dry methanol (5 mL) was added NaBH4 
(13 mg, 0.35 mmol) at 0 °C. After 30 min the reaction was quenched by addition of MeOH (3 mL) 
and then concentrated in vacuo. Ethyl acetate and water were added and the separated aqueous 
phase was extracted with ethyl acetate (3 × 30 mL). The combined organic phases were washed 
with water, dried (Na2SO4) and concentrated. The mixture was purified by HPLC on a Nucleodur 
Isis 100-5 C18 (5 µm; 4.5 mm internal diameter × 250 mm) with MeOH:H2O (999.5:0.5) as eluent 
(flow rate 1 mL/min) to give 15 mg (50% from 72) of 73 (tR = 47.5 min) and 10 mg of 74 (34% 
from 72) (tR = 50 min) as amorphous solids. (24S)-24-Ethyl-4α-methyl-5α-cholestan-3β-ol (73). 
[α]25D = −2.1 (c 0.02, CH3OH); selected 1H NMR (400 MHz C6D6): δ 2.93 (1H, m, H-3), 2.01 (1H, 
dt, J = 6.0, 12.6 Hz, H-4), 1.06 (3H, d, J = 6.5 Hz, H-21), 1.02 (3H, d, J = 6.0 Hz, H-30), 0.95 (3H, 
s, H-18), 0.94 (3H, t, J = 7.3 Hz, H-29), 0.91 (3H, d, J = 7.3 Hz, H-26), 0.90 (3H, d, J = 7.3 Hz, H-
27), 0.71 (3H, s, H-19). HRESI MS m/z 429.4088 (calcd for C30H53O 429.4096). (24S)-24-Ethyl-
4α-methyl-5α-cholestan-3α-ol (74). [α]25D= +4.1 (c 0.04, CH3OH); selected 1H NMR (400 MHz 
C6D6): δ 3.55 (1H, br m, H-3), 1.05 (3H, d, J = 6.5 Hz, H3-21), 0.95 (3H, d, J = 6.5 Hz, H3-30), 
0.95 (3H, s, H3-18), 0.94 (3H, t, J = 6.8 Hz, H3-29), 0.91 (3H, d, J = 7.0 Hz, H3-26), 0.89 (3H, d, J 
= 7.0 Hz, H3-27), 0.75 (3H, s, H3-19). HRESI MS m/z 429.4084 (calcd for C30H53O 429.4096). 
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(24S)-24-Ethyl-4-methyl-5α-cholest-3-ene (75). To a solution of 74 (30 mg, 0.070 mmol) in dry 
pyridine (5 mL), a solution of tosyl chloride (66 mg, 0.35 mmol) in dry pyridine (5 mL) was 
added. The solution was stirred at room temperature for 2 h and then concentrated in vacuo. The 
precipitate was re-dissolved in CH2Cl2, washed with NaHCO3 saturated solution and water, dried 
with Na2SO4, and then evaporated to dryness to give the 3β-tosylate, which was subjected to the 
next step without any purification. A solution of 3β-tosylate and CH3COOK (7.5 mg, 0.077 mmol) 
dissolved in DMF (3.5 mL) and water (0.5 mL) was refluxed for 2 h. The solution was cooled at 
room temperature and then ethyl acetate and water were added. The separated aqueous phase was 
extracted with ethyl acetate (3 × 30 mL). The combined organic phases were washed with water, 
dried (Na2SO4) and evaporated to dryness. Purification by HPLC on a Nucleodur Isis 100-5 C18 (5 
µm; 4.5 mm internal diameter × 250 mm) with MeOH:H2O (999.5:0.5) as eluent (flow rate 1 
mL/min) gave 75 (21 mg, 75% over two steps) as an amorphous solid. [α]25D = +43 (c 0.01, 
CH3OH); selected 1H NMR (400 MHz C6D6): δ 5.44 (1H, br s, H-3), 1.64 (3H, s, H3-30), 1.06 
(3H, d, J = 6.4 Hz, H3-21), 0.96 (3H, s, H3-18), 0.94 (3H, t, J = 7.5 Hz, H3-29), 0.91 (3H, d, J = 6.8 
Hz, H3-26), 0.90 (3H, d, J = 6.8 Hz, H3-27), 0.81 (3H, s, H3-19); HRESI MS m/z 411.3985 (calcd 
for C30H51 411.3991). 
(24S)-24-Ethyl-3β-hydroxyl-5α-cholest-4-one (76). A stream of O3 was bubbled into CH2Cl2 (5 
mL) at −78 °C until a blue-colored solution resulted. A portion of this solution (4 mL) was added 
to a solution of 38 (10 mg, 0.023 mmol) in CH2Cl2 kept under argon at −78 °C. After stirring for 1 
h, excess of ozone was removed upon bubbling with N2 and the solution was treated with excess 
dimethylsulfide (2 mL). After 5 h, the solution was concentrated in vacuo to remove the solvent 
and the mixture was purified by HPLC on a Nucleodur Isis 100-5 C18 (5 µm; 4.5 mm internal 
diameter × 250 mm) with MeOH:H2O (999.5:0.5) as eluent (flow rate 1 mL/min) to give 8.4 mg 
(84%) of 76 (tR = 27.5 min) as an amorphous solid. [α]25D = +3.2 (c 0.37, CH3OH); selected 1H 
NMR (400 MHz C6D6): δ 3.80 (1H, m, H-3), 1.06 (3H, d, J = 6.4 Hz, H3-21), 0.94 (3H, t, J = 7.4 
Hz, H3-29), 0.91 (3H, d, J = 7.0 Hz, H3-26), 0.90 (3H, d, J = 7.0 Hz, H3-27), 0.83 (3H, s, H3-18), 
0.45 (3H, s, H3-19); 13C NMR (100 MHz C6D6): δ 212.1 (C-4), 144.3 (C-14), 125.3 (C-8), 75.2 (C-
3), 57.6 (C-17), 56.6 (C-9), 49.6 (C-5), 47.0 (C-24), 44.3 (C-10), 43.4 (C-13), 38.0 (C-1), 35.7 (C-
20), 35.1 (C-12), 34.5 (C-22), 33.4 (C-2), 29.8 (C-25), 28.8 (C-7), 27.8 (C-15), 27.1 (C-23), 26.6 
(C-16), 23.8 (C-28), 21.5 (C-6), 20.9 (C-11), 20.1 (C-27), 19.9 (C-26), 19.6 (C-21), 18.8 (C-18), 
14.4 (C-19), 12.9 (C-29); HRESI MS m/z 429.3741 (calcd for C29H49O2 429.3733). 
(24S)-24-Ethyl-5α-cholestan-3β,4β-diol (77). A stream of O3 was bubbled into CH2Cl2 (5 mL) at 
−78°C until a blue-colored solution resulted. A portion of this solution (4 mL) was added to a 
solution of theonellasterol (10 mg, 0.023 mmol) in CH2Cl2 kept under argon at −78 °C. After 
stirring for 1 h, excess O3 was removed upon bubbling with N2. To the solution was added 
methanol (2 mL) and then treated with an excess of NaBH4. The solution was stirred at room 
temperature for 3 h and then concentrated in vacuo. The precipitate was re-dissolved in ethyl 
acetate, washed with water, dried with Na2SO4 and then evaporated to dryness. The mixture was 
purified by HPLC on a Nucleodur Isis 100-5 C18 (5 µm; 4.5 mm internal diameter × 250 mm) 
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with MeOH:H2O (999.5:0.5) as eluent (flow rate 1 mL/min) to give 9.2 mg (93%) of 77 (tR = 31.5 
min) as a amorphous solid. [α]25D = +6.9 (c 0.5, CH3OH); selected 1H NMR (400 MHz, C6D6): δ 
3.52 (1H, br s, H-4), 3.28 (1H, dd, J = 5.2, 10.6 Hz, H-3), 1.12 (3H, s, H-19), 1.05 (3H, d, J = 6.8 
Hz, H-21), 0.94 (3H, s, H-18), 0.93 (3H, t, J = 7.5 Hz, H-29), 0.90 (3H, d, J = 7.2 Hz, H-26), 0.89 
(3H, d, J = 7.2 Hz, H-27); 13C NMR (100 MHz C6D6): δ 143.1 (C-14), 127.3 (C-8), 74.8 (C-3), 
72.7 (C-4), 57.6 (C-17), 51.0 (C-9), 49.0 (C-5), 46.9 (C-24), 43.6 (C-13), 38.3 (C-10), 38.2 (C-12), 
37.2 (C-1), 35.8 (C-20), 34.6 (C-22), 30.6 (C-6), 29.7 (C-25), 27.9 (C-7), 27.0 (C-23), 26.6 (3C, C-
2, C-15 and C-16), 23.8 (C-28), 20.1 (C-11), 20.0 (C-27), 19.9 (C-21), 19.6 (C-26), 19.0 (C-18), 
15.4 (C-19), 13.0 (C-29); HRESI MS m/z 431.3883 (calcd for C29H51O2 431.3889). 
Spectroscopic Data 
1H NMR spectrum of Conicasterol E  (60) in C6D6 at 500 MHz. 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 63 in CDCl3 at 400 MHz. 
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13C NMR spectrum of Compound 63 in CDCl3 at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 64 in CDCl3 at 400 MHz. 
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13C NMR spectrum of Compound 64 in CDCl3 at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 65 in CDCl3 at 400 MHz. 
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13C NMR spectrum of Compound 65 in CDCl3 at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of Compound 66 in CDCl3 at 400 MHz. 
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13C NMR spectrum of Compound 66 in CDCl3 at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 6-ECDCA (61) in CD3OD at 400 MHz. 
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13C NMR spectrum of 6-ECDCA (61) in CD3OD at 100 MHz. 
 
 
 
13C NMR spectrum of 6-ECDCA 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR of Theonellasterol (38) in C6D6 at  at 500 MHz. 
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13
 C NMR of Theonellasterol (38) in C6D6 at  at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR of Compound (67) in C6D6 at  at 400 MHz. 
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13C NMR of Compound (67) in C6D6 at  at 100 MHz. 
 
 
 
 
 
 
1H NMR of Compound (68) in C6D6 at  at 400 MHz. 
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13C NMR of Compound (68) in C6D6 at  at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR of Compound (69) in C6D6 at  at 400 MHz. 
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13C NMR of Compound (69) in C6D6 at  at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR of Compound (70) in C6D6 at  at 400 MHz. 
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13C NMR of Compound (70) in C6D6 at  at 100 MHz. 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
1H NMR of Compound (71) in C6D6 at  at 400 MHz. 
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1H NMR of Compound (72) in C6D6 at  at 400 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR of Compound (72) in C6D6 at  at 100 MHz. 
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1H NMR of Compound (73) in C6D6 at  at 400 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR of Compound (74) in C6D6 at  at 400 MHz. 
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1H NMR of Compound (75) in C6D6 at  at 400 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR of Compound (76) in C6D6 at  at 400 MHz. 
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13C NMR of Compound (76) in C6D6 at  at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR of Compound (77) in C6D6 at  at 400 MHz. 
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13C NMR of Compound (77) in C6D6 at  at 100 MHz. 
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V. Experimental section of stereochemical studies of perthamide C 
General experimental procedures.  
Specific rotations were measured on a Jasco P-2000 polarimeter. High-resolution ESI-MS spectra 
were performed with a Micromass Q-TOF mass spectrometer. ESI-MS experiments were 
performed on a Applied Biosystem API 2000 triple-quadrupole mass spectrometer. HPLC was 
performed using a Waters Model 6000-A pump equipped with U6 K injector and a differential 
refractometer, model 401. NMR spectra were obtained on a Varian Mercury-400 and Inova-500 
NMR spectrometers, δ in parts per million, J in hertz, spectra referred to CD2HOD or CHCl3 as 
internal standards (δH=3.31 and 7.26, respectively). For an accurate measurement of the coupling 
constants, NMR spectra were recorded on Varian 700 MHz and Bruker DRX-600 spectrometers, 
equipped with cryo-probe. All spectra were acquired in the phase-sensitive mode and the TPPI 
method was used for quadrature detection in the ω1 dimension. NMR sample was obtained 
dissolving 20 mg of perthamide C in DMSO-d6. 3JH-H values were extracted from 1D 1H NMR and 
2D E.COSY spectra. For the E.COSY spectrum 32 scans for t1 value were acquired with a t1max of 
65 ms. 2,3JC-H values were obtained from phasesensitive PFG-PS-HMBC spectra and 13C coupled 
and decoupled HSQC-TOCSYaccording the following conditions. The PFG-PS-HMBC spectrum 
was recorded using 2 K points in ω2, setting the delay for long-range coupling evolution (∆) at 50 
ms, with 32 scans/t1 (t1max 15.2 ms). Zero-filling (8x1 K) was carried out in ω2 and ω1, 
respectively, to obtain a digital resolution of 0.9 Hz in ω2. The 13C coupled and decoupled HSQC-
TOCSY were recorded using 2 K points in ω2, setting the mixing time 80 ms and 1JCH of 140 Hz, 
with 120 scans/t1 (t1max 9.7 ms). Zero-filling (8Kx1K) was carried out in ω2 and ω1, respectively, 
to obtain a digital resolution of 0.5 Hz in ω2; the protone-carbon 2,3J coupling were extracted 
through a computer-aided analysis of the heteronuclear coupled and decoupled multiplets acquired 
in two separate experiments. The reverse single-quantum heteronuclear correlation (HSQC) 
spectra were recorded by using a pulse sequence with a Wurst pulse 0.15 s before each scan to 
suppress the signal originating from protons not directly bound to 15N; the interpulse delays were 
adjusted for an average 1JNH of 90 Hz. For the phase-sensitive PFG-HETLOC spectrum, a total of 
160 scans/t1 were acquired using 4 K points in ω2, with a spin lock of 50 ms and a t1max of 41.7 ms. 
The data matrices were zero-filled to 4Kx1k affording a digital resolution of 0.4 Hz in ω2. 
Through-space 1H connectivities were evidenced using a ROESY experiment with mixing times of 
400, 100 and 50 ms, respectively, and NOESYexperiment acquired with 200 and 100 ms mixing 
times.  
Computational details.  
Molecular mechanics (MM) calculations were performed using the MacroModel 8.5 software 
package and the MMFFs force fields. MonteCarlo Multiple Minimum (MCMM) method (10,000 
steps) of the MacroModel package was used in order to allow a full exploration of the 
conformational space. All the structures, so obtained, were optimised using the PolakeRibier 
Coniugated Gradient algorithm (PRCG, 1000 steps, maximum derivative less than 0.05 kcal/mol). 
The initial geometries of the minimum energy conformers were optimised at the hybrid DFT 
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MPW1PW91 level using the 6-31G(d) basis set (Gaussian 03 software package). GIAO J-coupling 
calculations were performed using the MPW1PW91 functional and the 6-31G(d) basis set, using 
as the input the geometry previously optimised at MPW1PW91/6-31G(d) level. 
Synthetic procedures.  
(E)-Ethyl 6-methylhept-2-enoate (83). DMSO (4.18 mL, 58.8 mmol) was added dropwise for 15 
min to a solution of oxalyl chloride (14.7 mL, 29.4 mmol) in dry dichloromethane (50 mL) at -78 
°C under argon atmosphere. After 30 min a solution of the alcohol 82 (1.00 g, 9.80 mmol) in dry 
CH2Cl2 was added via cannula and the mixture was stirred at -78 °C for 1 h. Et3N (6.83 mL, 49.0 
mmol) was added dropwise and the mixture was allowed to warm to room temperature. The 
reaction was quenched by addition of aqueous NaHSO4 (1 M, 50 mL). The layers were separated 
and the aqueous phase was extracted with CH2Cl2 (3x50 mL). The combined organic layers were 
washed with saturated aqueous NaHSO4, saturated aqueous NaHCO3 and brine. The organic phase 
was then dried over Na2SO4 and concentrated to give the corresponding aldehyde 81 (0.951 g, 
97%) as a colourless oil, which was used without any further purification. δH (400 MHz, CDCl3) 
9.70 (1H, s, CHO), 2.44 (2H, m, CH2CHO), 1.59 (1H, m, CHMe2), 1.25 (2H, m, CH2), 0.92 (3H, 
d, J 6.6 Hz, Me), 0.91 (3H, d, J 6.6 Hz, Me); δC (100 MHz CDCl3) 203.5, 40.2, 31.1, 27.9, 22.7, 
22.5. To a solution of compound 81 (0.950 g, 9.50 mmol) and LiOH (250 mg, 10.5 mmol) in THF 
(10 mL) was added TEPA (triethyl phosphonoacetate, 2.07 mL, 10.5 mmol). The reaction mixture 
was stirred for 24 h at room temperature and then quenched withwater (10 mL). The mixture was 
then extracted with EtOAc (3x30 mL), and the organic phase was concentrated in vacuo. Flash 
chromatography (hexane/EtOAc, 99:1) afforded pure 83 (1.21 g, 75%). δH (400 MHz, CDCl3) 
6.95 (1H, dt, J 15.4, 6.6, CH=CHCO), 5.80 (1H, d, J 15.4 Hz, CH=CHCO), 4.17 (2H, q, J 7.4, 
OCH2), 2.20 (2H, m, CH2CH=), 1.56 (1H, m, CHMe2), 1.32 (2H, m, CH2), 1.24 (3H, t, J 7.4, 
OCH2Me), 0.88 (3H, d, J 6.6 Hz, Me), 0.89 (3H, d, J 6.6 Hz, Me); δC (100 MHz CDCl3) 165.4, 
150.8, 121.0, 60.4, 37.2, 30.4, 27.8, 22.5 (2C), 14.5; HRMS (ESI): calcd for C10H19O2: 171.1382; 
found 171.1389 [M+H]+. 
(E)-6-Methylhept-2-en-1-ol (80). To a solution of compound 83 (1.10 g, 6.47 mmol) in toluene (35 
mL) at -78 °C, under a nitrogen atmosphere and with stirring, was slowly added DIBAL-H (7.59 
mL of a 1.7 M solution in toluene, 12.9 mmol). After 1 h (TLC monitoring), the reaction was 
quenched with saturated NH4C1 (25 mL) and the mixture was extracted with Et2O (50 mL). 
Organic layer was dried over Na2SO4, concentrated in vacuo and purified on SiO2 chromatography 
(hexane/EtOAc, 90:10) affording pure compound 80 (787 mg, 95%). δH (400 MHz, CDCl3) 5.67 
(2H, m, CH=CH), 4.09 (2H, d, J 5.2 Hz, CH2OH), 2.05 (2H, m, CH2CH=),1.63 (1H, m, CHMe2), 
1.27 (2H, m, CH2), 0.82 (3H, d, J 6.6 Hz, Me), 0.81 (3H, d, J 6.6 Hz, Me); δC (100 MHz CDCl3) 
133.8., 128.6, 63.8, 38.3, 30.1, 27.5, 22.4 (2C); HRMS (ESI): calcd for C8H17O: 129.1279; found 
129.1274 [M+H]+. 
(2S,3S)-2,3-Epoxy-6-methylheptan-1-ol (84). To a 100 mL round bottom flask under argon 
equipped with a magnetic stirrer were added molecular sieves (4A°, 164 mg) in CH2Cl2 (50mL). 
At -23 °C were then added Ti(Oi-Pr)4 (77.7 mg, 0.273mmol) and L-(+)-DET (67.7mg, 
Experimental section 
232 
 
0.328mmol). The solution was allowed to stir for 5 min, then compound 80 (0.700 g, 5.47mmol) 
and TBHP (1.98mL of a 5.5 M solution in decane, 10.9mmol) were added successively. After 24 h 
a solution of tartaric acid (492 mg, 3.28mmol) and FeSO4 (1.8 g, 6.56mmol) in 20mL of water was 
added and was stirred at -23 °C. After 30min, the cooling bath was removed and stirring was 
continued at room temperature for 1 h until the aqueous layer become clear. After separation of the 
aqueous layer, the organic layer was washed once with water, dried over Na2SO4 and concentrated. 
This oil was diluted with Et2O (50mL) and cooled in a ice bath, and then NaOH (25mL of 1 N 
solution in brine) was added; the two phase mixture was stirred at 0 °C for 0.5 h, and then the ether 
phase was washed with brine, dried over Na2SO4 and concentrated. SiO2 chromatography 
(hexane/EtOAc, 90:10) afforded pure compound 84 (709mg, 90%). [α]D20 -10.7 (c 0.3, CHCl3); δH 
(400 MHz, CDCl3) 3.89 (1H, br d, J 12.6 Hz, O-CHCH2OH), 3.60 (1H, br d, J 12.6 Hz, CH-O), 
2.92 (2H, m, CH2OH), 1.58 (1H, m, CHMe2), 1.32 (2H, m, CH2CH-O), 1.25 (2H, m, CH2CH2CH-
O), 0.88 (3H, d, J 6.4 Hz, Me), 0.87 (3H, d, J 6.4 Hz, Me); δC (100 MHz CDCl3) 61.9, 58.8, 53.7, 
35.1, 29.6, 28.0, 22.7, 22.6; HRMS (ESI): calcd for C8H17O2: 145.1229; found 145.1224 [M+H]+. 
Compound 84 (0.5-1.0 mg) was dissolved in freshly distilled CH2Cl2 and treated with 
triethylamine (10 mL) and (+)-α-methoxy-α-(trifluoromethyl)phenylacetyl chloride [(S)-MTPA-
Cl] and a catalytic amount of 4-(dimethylamino)pyridine. The mixturewas left to stand at room 
temperature for 2 h. After this period, the mixture was concentrated in vacuo affording pure (R)-
MTPA ester in quantitative yield. δH (400 MHz, CDCl3) 7.47 (2H, m, ArH), 7.36 (3H, m, ArH), 
4.47 (1H, dd, J 12.0, 3.0 Hz CH2O), 4.16 (1H, dd, J 12.0, 6.0 Hz CH2O), 3.50 (3H, s, -OMe), 2.94 
(1H, m, CHO), 2.76 (1H, m, CHO) 1.47 (4H, m, CH2CH2CH-O), 1.22 (1H, m, CHMe2), 0.81 (3H, 
d, J 6.6 Hz, Me), 0.80 (3H, d, J 6.6 Hz, Me); HRMS (ESI): calcd for C18H24F3O4: 361.1627; found 
361.1632 [M+H]+. 
(2R,3S)-2,3-Epoxy-6-methylheptanoic acid (79). To a vigorously stirred mixture of compound 84 
(0.700 g, 4.86 mmol) were added NaIO4 (4.25 g, 19.9 mmol) in CCl4 (18.5 mL), CH3CN (18.5 
mL), H2O (27.8 mL) and RuCl3.H2O (26.2 mg, 0.0972 mmol). The mixture was stirred at 20 °C for 
2 h; then the acidic material was carefully extracted at 0 °C into ether, dried briefly over Na2SO4 
and evaporated in vacuo to give a crude residue 79 (750 mg), that was subjected to next steps 
without further purification. δH (400 MHz, CDCl3) 3.50 (1H, m, O-CHCOOH), 3.19 (1H, m, CH-
O), 1.62 (1H, m, CHMe2), 1.36 (2H, m, CH2CH-O), 1.26 (2H, m, CH2CH2CH-O), 0.91 (3H, d, J 
6.3 Hz, Me), 0.90 (3H, d, J 6.3 Hz, Me); δC (100 MHz CDCl3) 173.0, 59.4, 52.8, 34.7, 29.6, 27.9, 
22.6 (2C); HRMS (ESI): calcd for C8H13O3: 157.0865; found 157.0861 [M+H]+. 
(2R,3S)-Methyl 2,3-epoxy-6-methylheptanoate (85). To an aliquot of 79 (200 mg) in CH2Cl2 was 
added an ethereal solution of diazomethane until the solution become yellow. Evaporation and 
silica gel chromatography (hexane/EtOAc, 99:1) afforded pure 85 (196 mg, 82% over two steps 
from 84). [α]D 20 +27.0 (c 1.1, CHCl3); δH (400 MHz, CDCl3) 3.76 (3H, s,OMe), 3.50 (1H, m, O-
CHCOOMe), 3.13 (1H, m, CH-O),1.63 (1H, m, CHMe2),1.36 (2H, m, CH2CH-O),1.26 (2H, m, 
CH2CH2CH-O), 0.88 (3H, d, J 6.3 Hz, Me), 0.87 (3H, d, J 6.3 Hz, Me); δC (100 MHz CDCl3) 
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170.8, 58.9, 53.2, 52.6, 34.7, 29.5, 27.9, 22.5, 22.6; HRMS (ESI): calcd for C9H17O3: 173.1178; 
found 173.1172 [M+H]+. 
(2S,3R)-3-Bromo-2-hydroxy-6-methylheptanoate (86). To a solution of compound 85 (160 mg, 
0.930 mmol) in Et2O (6 mL) was added MgBr2.Et2O (361 mg, 1.40 mmol). The solutionwas stirred 
at room temperature for 1 h and then washed with brine, and the organic layers were evaporated in 
vacuo. The crude mixture was purified by SiO2 chromatography (hexane/EtOAc, 99:1), affording 
pure 86 (230 mg, 98%). [α]D 20 -6.4 (c 0.3, CHCl3); δH (400 MHz, CDCl3) 4.40 (1H, d, J 3.3 Hz, 
CHOH), 4.16 (1H, m, CH-Br), 3.81 (3H, s, OMe), 1.90 (1H, m, CHaHbCHBr), 1.79 (1H, m, 
CHaHbCHBr), 1.55 (1H, m, CHMe2), 1.44 (1H, m, CHaHbCH2CHBr),1.29 (1H, m, 
CHaHbCH2CHBr), 0.88 (3H, d, J 6.3 Hz; Me), 0.86 (3H, d, J 6.3 Hz, Me); δC (100 MHz CDCl3) 
171.5, 74.7, 53.0, 37.0, 32.0, 27.7, 23.0, 22.4, 21.2; HRMS (ESI): calcd for C9H1879BrO3: 
253.0434; found 253.0439 [M+H]+. 
(2R,3S)-3-Azido-2-hydroxy-6-methylheptanoate (87). A mixture of 86 (189 mg, 0.750 mmol) and 
NaN3 (195 mg, 3.00 mmol) in DMF (5.0 mL) was stirred at 65 °C for 24 h. The mixture was then 
diluted with EtOAc (10.0 mL), washed with water (10.0 mL), and concentrated in vacuo. Silica gel 
chromatography (hexane/ether, 99:1) afforded pure 87 (148 mg, 92%). [α]D 20 +1.5 (c 0.1, CHCl3); 
δH (400 MHz, CDCl3) 4.25 (1H, d, J 5.6 Hz, CHOH), 3.82 (3H, s, OMe), 3.47 (1H, t, J 7.0, CH-
N3), 3.03 (1H, d, J 5.6 Hz, CHOH), 1.83 (1H, m, CHaHbCHN3), 1.81 (1H, m, CHaHbCHN3), 1.61 
(1H, m, CHMe2), 1.34 (2H, m, CH2CH2CHN3), 0.93 (3H, d, J 6.3 Hz, Me), 0.91 (3H, d, J 6.3 Hz, 
Me); δC (100 MHz CDCl3) 172.6, 68.4, 59.0, 53.7, 30.6, 29.2, 24.0, 23.2 (2C); HRMS (ESI): 
calcd for C9H18N3O3: 216.1348; found 216.1352 [M+H]+. 
(2R,3S)-3-Amino-2-hydroxy-6-methylheptanoic acid (78b). A solution of 87 (130 mg, 0.604 
mmol) in ethyl acetate was hydrogenated in the presence of Pd/C catalyst (2 mg) for 24 h at room 
temperature. The mixture was filtered through Celite and concentrated in vacuo to give a 125 mg 
residue that was subjected to under vacuum vapour-phase hydrolysis (HCl 6 N, 110 °C for 18 h). 
HPLC purification on the reversed-phase Phenomenex Hydro (4 m, 250x4.6 mm) column eluting 
with 85% H2O/MeOH (0.1% TFA) furnished compound 78b (79.3 mg, rt=19.5 min) in 75% yield 
over two steps. [α]D 20 +3.3 (c 0.3, MeOH); δH (400 MHz, CD3OD) see Table 8 in the text; 13C 
NMR (100 MHz, CD3OD) δC: see Table 8 in the text; HRMS (ESI): calcd for C8H18NO3: 
176.1286; found 176.1293 [M+H]+. 
(2R,3R)-3-Amino-2-hydroxy-6-methylheptanoic acid (78a). Compound 79 (200 mg, 1.27 mmol) 
was dissolved in water (2 mL). Powdered NaN3 (124 mg, 1.91 mmol) and 1.3 mL of an aqueous 
solution 0.1 M of Cu(NO3)2 were added under stirring (resulting pH 4.3e4.5), and the mixture was 
warmed to 65 °C. After 1.5 h (ca. pH 5.5) the reaction mixture was cooled to 0 °C, and NaBH4 
was added portion-wise (96.1 mg, 2.54 mmol). After 30 min at 0 °C the reaction mixture was 
filtered and concentrated in vacuo to give a residue that, subjected to HPLC purification on the 
reversedphase Phenomenex Hydro (4 m, 250x4.6 mm) column eluting with 85% H2O/MeOH 
(0.1% TFA), furnished compound 78a (167 mg, rt=21 min) in 75% yield over two steps. [α]D 20 
+8.6 (c 0.5, MeOH); δH (400 MHz, CD3OD) see Table 8 in the text; 13C NMR (100 MHz, 
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CD3OD) δ: see Table 8 in the text; HRMS (ESI): calcd for C8H18NO3: 176.1286; found 176.1291 
[M+H]+. 
Determination of the absolute configuration 
Peptide hydrolysis and AHMHA isolation. A 30 mg sample of perthamide C was dissolved in 6 N 
HCl (3 mL) and heated in vacuo at 130 °C for 12 h. The crude residue was fractionated by HPLC 
on the reversed-phase Phenomenex Hydro (4 m, 250x4.6 mm) column eluting with 85% 
H2O/MeOH (0.1% TFA) (flow rate 0.5 mL/min) to give 3 mg of pure ADMHA (rt=21 min). [α]D 
20 +8.8 (c 0.55, MeOH); δH (400 MHz, CD3OD) see Table 8 in the text; 13C NMR (100 MHz, 
CD3OD) δ: see Table 8 in the text. 
LC-MS analysis of Marfey’s (FDAA) derivatives. A portion of pure AHMHA or the amino acid 
standards 78a and 78b (500 mg) was dissolved in 80 mL of a 2:3 solution of TEA/MeCN and this 
solution was then treated with 75 mL of 1% 1-fluoro-2,4-dinitrophenyl-5- alaninamide (L- or D-
FDAA) in 1:2 MeCN/acetone. The vials were heated at 70 °C for 1 h, and the contents were 
neutralised with 0.2 N HCl (50 mL) after cooling to room temperature. An aliquot of the FDAA 
derivative was dried under vacuum, diluted with 50% aqueous acetonitrile containing 5% formic 
acid, and separated on a Proteo C18 (25x1.8 mm i.d.) column by means a linear gradient from 10% 
to 50% aqueous acetonitrile containing 5% formic acid and 0.05% trifluoroacetic acid, over 45 min 
at 0.15 mL/min. The RP-HPLC system was connected to the electrospray ion source by inserting a 
splitter valve and the flow going into the mass spectrometer source was set at a value of 100 
mL/min. Mass spectra were acquired in positive ion detection mode (m/z interval of 320e900) and 
the data were analysed using the suite of programs Xcalibur; all masses were reported as average 
values. Capillary temperature was set at 280 °C, capillary voltage at 37 V, tube lens offset at 50 V 
and ion spray voltage at 5 V. Retention times of L-FDAA-3-amino-2-hydroxy-6-methylheptanoic 
acid (min): (2R, 3R)-88a (48.50), (2R, 3S)-88b (39.40), AHMHA-naturale (48.50). Retention times 
of D-FDAA-3-amino-2-hydroxy-6-methylheptanoic acid (min): (2R, 3R)-88c (40.99), (2R, 3S)-
88d (48.30). 
Spectroscopic data  
1H NMR of Compound (81) in CDCl3 at  at 400 MHz. 
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13C NMR of Compound (81) in CDCl3 at  at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR of Compound (83) in CDCl3 at  at 400 MHz. 
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13C NMR of Compound (83) in CDCl3 at  at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR of Compound (80) in CDCl3 at  at 400 MHz. 
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13C NMR of Compound (80) in CDCl3 at  at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR of Compound (84) in CDCl3 at  at 400 MHz. 
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13C NMR of Compound (84) in CDCl3 at  at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR of Compound (79) in CDCl3 at  at 400 MHz. 
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13C NMR of Compound (79) in CDCl3 at  at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR of Compound (85) in CDCl3 at  at 400 MHz. 
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13C NMR of Compound (85) in CDCl3 at  at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR of Compound (86) in CDCl3 at  at 400 MHz. 
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13C NMR of Compound (86) in CDCl3 at  at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR of Compound (87) in CDCl3 at  at 400 MHz. 
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13C NMR of Compound (87) in CDCl3 at  at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR of Compound (78a) in CD3OD at  at 400 MHz. 
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13C spectrum  of Compound (78a) in CD3OD at  at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR of Compound (78b) in CD3OD at  at 400 MHz. 
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HSQC spectrum  of Compound (78b) in CD3OD at  at 100 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
ESI-LC/MS spectrum of  (88a). 
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ESI-LC/MS spectrum of  (88c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ESI-LC/MS spectrum of  (88b). 
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ESI-LC/MS spectrum of  (88d). 
 
 
 
 
 
 
 
 
 
 
 
 
ESI-LC/MS spectrum of  (L)-FDAA derivative of AHMHA. 
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